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c-Myc (hereafter Myc), a transcription factor that regulates a variety of cellular functions 
including growth and differentiation, is deregulated in many different types of cancers. Myc 
regulates the Warburg effect and oncogenic biosynthesis, but also many aspects of metabolism, 
believed to be a pivotal point of transformation. Myc is known to control glycolysis and 
glutaminolysis but little is known about the interplay between glucose, amino acid, and fatty acid 
oxidation. We hypothesize Myc integrates glucose, amino acid, and fatty acid utilization for 
energy, and either loss- or gain-of-function will disrupt metabolic homeostasis. 
 Loss of Myc in rat fibroblasts elicits a severe energy deficit, including diminished 
acetyl-coA levels, to which they respond by enhancing FAO and lipid uptake and storage. Using 
an in vivo model, we found murine hepatocytes respond to Myc ablation with a milder 
phenotype. They display metabolic defects, including reduced respiratory chain capacity and an 
increased metabolic rate when fed a high-fat diet. Additionally, hepatocytes had major lipid 
defects including transcriptional deregulation, lipid accumulation and increased FAO.  
Reduced ATP in Myc KO fibroblasts constitutively activates AMPK, a protein which 
limits anabolism for catabolism, leading us to hypothesize AMPK may play a role in Myc 
deregulated phenotypes. We found AMPK controls mitochondrial structure and function in 
conjunction with Myc over-expression, via redox state, electron transport chain (ETC) capacity, 
and TCA cycle dehydrogenases. Additionally, AMPK KO cells demonstrate transcriptional and 
translational differences and differential responses in regulating glycolysis, which results in 
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metabolite dysfunction, when exposed to Myc over-expression. Thus, AMPK is critical to 
supporting metabolic pathways in response to Myc deregulation.  
 To ascertain if Myc plays a role in hepatic proliferative capacity, we turned to a 
mouse model of hereditary tyrosinemia. We definitively proved that Myc is not required for 
prolonged hepatocyte proliferation, even in direct competition with Myc-replete hepatocytes.  
Proliferating KO hepatocytes were associated with a pro-inflammatory environment that 
correlated with worsening lipid accumulation and lipid oxidation-mediated liver damage, a 
phenotype reminiscent of non-alcoholic fatty liver-like disease. Throughout this work, we reveal 
Myc-regulated metabolism is vital for maintaining lipid homeostasis and energy production, but 
dispensable for sustained hepatic proliferation. 
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1.0  INTRODUCTION 
The MYCC gene is among the most frequently deregulated oncogenes in human tumors. At basal 
expression levels, c-Myc (hereafter Myc) functions as a transcription factor to inhibit 
differentiation and promote proliferation [13]. However, when the protein is amplified or over-
expressed, the resulting deregulated expression can result in cellular transformation [14]. In 
normal cells, Myc has been proposed to control cell cycle progression, differentiation, apoptosis, 
and mitochondrial biogenesis and function [4, 15-17]. It has been suggested that deregulated 
Myc merely amplifies global expression of already-transcribed genes, contingent on estimates 
that Myc can regulate 10-15% of the genome [14]. However, this appears to be an 
oversimplification, based on the abundance of specific genes involved in cell cycle, growth, 
metabolism, protein and ribosomal biogenesis, and mitochondrial function [18]. Myc 
deregulation in tumorigenesis affects many metabolic pathways, but its direct role in tumor cell 
metabolism is poorly understood. A fuller understanding of Myc’s regulation of metabolism may 
provide key weaknesses, which can be exploited by novel therapies.  
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Figure 1: Schematic of Metabolic Pathways. Yellow box indicates glycolysis and potential 
biosynthetic offshoots. Green box illustrates FAO and de novo fatty acid synthesis pathway. Red box is an 
example of oncogenic manipulation of the TCA cycle and production of the oncometabolite 2HG. IDH3 is the 
isoform responsible for TCA cycle reduction of NAD+ to NADH, while IDH1 (cytoplasmic) and IDH2 
(mitochondrial) reduce NADP+ to NADPH. Abbreviations: Phosphoenol Pyruvate (PEP), Pyruvate Kinase 
(PK), Pyruvate Dehydrogenase (PDH), ATP Citrate Lyase (ACLY), Citrate Synthase (CS), Malate 
Dehydrogenase (MDH), Fumarate Hydrolase (FH), Succinate Dehydrogenase (SDH), α-Ketogluterate 
Dehydrogenase (α-KGDH), Isocitrate Dehydrogenase (IDH), 2-Hydroxyglutarate (2HG).  
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1.1 TUMOR METABOLISM 
It was once believed the deregulated metabolism of tumors was merely a byproduct of their rapid 
proliferation, but it is now considered to be one of the hallmarks of cancer [19]. Otto Warburg 
introduced the idea of altered cancer metabolism when he discovered that tumor cells accumulate 
lactate in the process of breaking down glucose (glycolysis), despite an ample supply of oxygen 
to reduce glucose down to TCA cycle substrates (Figure 1, yellow box) [20]. Many tumors 
preferentially use aerobic glycolysis at the cost of reduced ATP production because it confers the 
proliferative advantage of providing the necessary anabolic precursors needed to proliferate [21]. 
Canonical biochemical pathways used to generate energy in normal tissues are re-routed to 
synthetic intermediates for nucleic acids, amino acids, and lipids production [21, 22]. The 
described glutamine addiction of Myc-expressing tumors results because Warburg respiration 
depletes the TCA cycle of intermediates, which can be restored by glutamine conversion to α-
ketoglutarate [23-25]. The oncogenic environment is rich in substrates to be broken down for 
oxidative phosphorylation, but cannot provide the anabolic intermediates or reducing equivalents 
for biosynthetic reactions [26]. This is strong motivation for proliferative pathways to regulate 
cellular metabolism, and also why many cancer-driving mutations usurp this control. 
If neoplastic transformation depends in part on altering the metabolic microenvironment, 
it is increasingly understood that many oncogenes and tumor suppressors must play a vital role in 
regulating metabolism. For example, p53, a well-known tumor suppressor, activates metabolic 
arrest in the setting of glucose depletion; however, when p53 is lost or mutated, proliferation can 
proceed unchecked despite lack of available nutrients [27]. p53 mutations also increase the 
expression of genes involved in cholesterol biosynthesis (mevalonate) pathways [28], suggesting 
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that successful oncogenic transformation alters cellular metabolism on many fronts. Many other 
cancer-associated mutations can reprogram metabolism, such as loss-of-function mutations in 
fumarate dehydrogenase (FH) and succinate dehydrogenase (SDH) or gain-of-function mutations 
in isocitrate dehydrogenase (IDH), that produce aberrant metabolites (“oncometabolites”) [21, 
29-31]. Mutations in FH and SDH cause abnormal accumulation of fumarate and succinate, 
while mutations in IDH reverse the normal flow of the TCA cycle and switch production of 
NADH to consumption of NADPH, with the consequences being a high level of 2-
hydroxyglutarate [32, 33]. These metabolites can cause transformation by obstructing normal 
regulation of α-ketoglutarate dioxygenases, causing deregulation in fatty acid metabolism, 
oxygen sensing, and epigenetic modifications (as reviewed in [34]). Another example is the 
canonical breakdown of acetyl CoA through the TCA cycle, which is not normally re-
synthesized into lipids in a starved state. Acetyl CoA is converted to citrate and then α-
ketoglutarate (Figure 1, red box) to generate ATP producing intermediates. Tumor metabolism 
can reverse the TCA cycle to convert glutamine to citrate, and then increase activity of ATP 
Citrate Lyase (ACLY) to utilize acetyl CoA for lipid synthesis [19, 35]. Far from being a mere 
coincidence, the deregulation of metabolism is a necessary and directed step for oncogenic 
transformation and proliferation. 
1.2 MYC AND METABOLIC REPROGRAMMING 
 Myc is directly responsible for a variety of changes in transformed and non-transformed cells, 
though the response is tissue- and context-specific [25, 36]. Myc is a major regulator of the 
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Warburg effect and will increase glucose uptake and lactate production [21, 22]. Myc drives a 
rapid switch from fatty acid oxidation (FAO) and pyruvate oxidation via the TCA cycle to 
aerobic glycolysis, the pentose phosphate shunt, and glutamine oxidation [1, 37, 38]. Myc 
overexpression also modulates the alternative splicing from pyruvate kinase isoform 1 to 2 
(PKM1/2), which results in less carbon flow from glucose to acetyl CoA [38, 39]. PKM2 has a 
higher activation energy (km) and lower activity level (kcat), allowing upstream intermediates to 
build up and be re-directed into the above-mentioned anabolic pathways. The Warburg effect can 
further negatively regulate PKM through tyrosine phosphorylation and reactive oxygen species 
(ROS) which destabilize it from the tetrameric (active) to dimeric (inactive) form [21]. Myc 
tumorigenesis requires MondoA, a transcription factor that works by sensing nutrients, 
specifically glycolytic intermediates that accumulate due to reduced PKM activity [40, 41]. As 
Myc stimulates Warburg metabolism, the anabolic products feed back on and reinforce Myc-
driven tumorigenesis in a targeted and essential part of transformation.  
1.3 MYC AND FATTY ACID METABOLISM 
Lipid metabolism can also be disrupted by cancer metabolism, potentially through Myc (Figure 
1, green box). Each cell type, transformed or un-transformed, has a unique metabolic profile 
based on its individual needs. Fatty acid oxidation can be preferred over glucose breakdown 
because one molecule of palmitate, a long-chain fatty acid, yields 129 molecules of ATP while 
glucose yields only 38. While fatty acids are a rich energy source, they tend to induce lipid 
peroxidation and result in cellular damage, and are used by tissues which can respond by 
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repairing damage or replacing the cell [42]. On the other hand, tissues which require a constant, 
reliable source of energy tend to use glucose, which can be supplied throughout the body by the 
liver [42]. To further complicate the matter, bioavailability plays a major role in how a tissue 
fulfils its unique energy needs.   
Mitochondrial fatty acid β-oxidation (FAO) is the main pathway for breakdown of most 
fatty acids, though some oxidation can occur in peroxisomes [43]. Peroxisomal β-oxidation of 
fatty acids is uncoupled to any respiratory chain and results in H2O2 production and heat [44]. 
Because loss of Myc results in lipid accumulation, peroxisome oxidation of this lipid may result 
in increased ROS in Myc knockout models and in human diseases like non-alcoholic fatty liver 
disease (NAFLD) and non-alcoholic steatohepatitis (NASH) [45, 46]. While shorter chain fatty 
acids can diffuse through the mitochondrial membrane to be used for fatty acid oxidation [47], 
longer chain fatty acids require more active processing and facilitated transport into the 
mitochondria, specifically by the rate-limiting enzyme carnitine palmitoyltransferase 1 (CPT1) 
[48, 49]. Fatty acyl chains are joined to CoA in the mitochondrial matrix and are broken down to 
yield NADH, FADH2, and acetyl CoA by iterative cycles of oxidation/hydration [50]. Both 
prostate [51] and pancreatic [52] cancers rely on FAO as the major energy producing pathway 
and inhibition of FAO in leukemia [53] and glioblastomas [54] will induce apoptosis. Prostate 
tumors are particularly dependent on FAO because of a decreased ability to utilize glucose [55, 
56], which results in an increased uptake of fatty acids [57] and an over-expression of β-
oxidation enzymes [58]. 
Rather than oxidized for ATP, fatty acids can be directly incorporated into new lipids to 
provide membranes for rapidly growing normal or cancer cells [59].  Typically, there exists an 
equilibrium between oxidation and de novo fatty acid synthesis, but safeguards are in place to 
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keep both from occurring simultaneously. Mechanistically, CPT1 is inhibited by malonyl CoA, a 
product of synthesizing acetyl CoA into long chain fatty acids by Acetyl CoA Carboxylase 
(ACCα/β) (Figure 1, green box) [50]. The energy state of the cell dictates whether CPT1 or 
ACCα/β is active and AMPK controls this through phosphorylation of ACCα/β. Phosphorylation 
inhibits ACCα/β, resulting in FAO up-regulation and inhibition of fatty acid synthesis [60]. 
Though FAO is stimulated in some types of cancer, CPT1 is more often down-regulated in 
cancers, tipping the balance in favor of increased fatty acid synthesis [61, 62]. Enhanced lipid 
synthesis is more often associated with different types of cancers, such as breast and ovarian 
tumors, and is driven by the expression of ACLY and fatty acid synthase (FASN) [63-68]. In 
instances of cancers where fatty acid oxidation (FAO) is favored over fatty acid synthesis, the 
Warburg effect might dictate the fate of all other available substrates, leaving the transformed 
cells reliant on fatty acids as a source of ATP. 
While much is known regarding Myc regulation of glucose and glutamine metabolism, 
Myc control over lipid metabolism is still an emerging field. In chapters 2 and 4, we attempt to 
distinguish lipid profiles of cells driven by oncogenic Myc signaling, compared to normal cells, 
and cells removed from Myc signaling. The removal of Myc may initiate a switch from 
glycolysis to FAO, so we studied each of these situations to determine how the cell transports, 
directs, and breaks down fatty acids. On one hand, Myc signaling necessitates de novo synthesis 
for a large supply of macromolecular precursors.  Previous studies have shown pharmacologic 
inhibition of Myc by the drug 10058-F4 results in diminished fatty acid synthesis [69] and Myc 
directly contributes glucose-derived acetyl coA to lipid biosynthesis [70]. On the other hand, the 
proliferating cell also requires ATP and other studies show that induction of Myc increases fatty 
acid oxidation [71].  Since oxidation and de novo synthesis do not occur simultaneously under 
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normal circumstances, this could be an issue of cell type or bioavailability, or this could be a 
Myc-specific phenomenon.  Another novel, Myc-specific occurrence is the lipid accumulation 
that occurs with genetic or pharmacological inhibition of Myc [69, 72]. In this work, we begin to 
determine the cause and effect of Myc-deplete induced lipid accumulation. 
1.4 AMPK AND MYC 
A primary regulator of cellular metabolism in most eukaryotic cells is AMP-activated protein 
kinase, or AMPK, which is activated in response to energetic stress (i.e. high AMP:ATP ratios) 
to promote survival [73].  This involves the stimulation pathways to increase ATP production, 
such as glucose and fatty acid uptake and oxidation and mitochondrial biogenesis (Figure 2 and 
[74, 75]).  Along with that comes concurrent inhibition of anabolic processes such as protein and 
glycogen synthesis [74]. As an important regulator of metabolism, it seems an obvious target for 
controlling the tumor microenvironment and AMPK acts as an energy sensor at the intersection 
of several tumor suppressor pathways. However, mutations in AMPK are relatively rare events 
in cancer, suggesting that metabolic elasticity is important for tumor survival. Upstream or 
downstream regulators can be modified so proliferation continues in spite of AMPK activation. 
For example, the tumor suppressor LKB1 directly regulates AMPK activity upstream [76], while 
TSC2 [77] and p53 [27] are downstream. Mutations in these proteins are more common and 
control certain aspects of AMPK function to promote proliferation, while allowing AMPK 
otherwise autonomic function.  
 9 
 
AMPK can be activated, and thereby controlled, in a variety of ways (Figure 2). The 
classical pathway is in response to the ratio of AMP and ADP:ATP, but it can also be activated 
by less well-characterized modes such as calcium or magnesium, by the drugs resveratrol and 
metformin, and by oxidative (H2O2) and genotoxic stress [74]. Non-canonical activation of 
AMPK may be another way to promote survival while oncogenic drivers are subverting 
metabolism but maintaining a normal AMP:ATP ratio.  
 
Figure 2: Regulation of AMPK. Activation of AMPK via phosphorylation of Thr172 can occur 
through canonical (thick arrow) or non-canonical (thin arrows) means. AMPK activation then stimulates 
catabolic pathways (green dashed lines) and inhibits anabolic pathways (red dashed lines). 
 
Myc positively regulates cell growth and a number of synthetic pathways, in direct 
opposition of AMPK action in an energy crisis. But both Myc and AMPK enhance glucose and 
fatty acid oxidation. So though the two proteins control metabolism differently, AMPK may 
interact with Myc-driven metabolism to maintain metabolic homeostasis. For instance, the loss 
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of Myc results in activation of AMPK [78]. This may be purely circumstantial as loss of Myc 
reduces ATP and AMPK is conceivably activated to restore depleted ATP. In other 
circumstances, AMPK can inhibit Myc biosynthetic pathways and suppress tumor growth, in 
effect counteracting Myc activation [79]. Faubert et al. used a Myc-driven model of B-cell 
lymphoma to show deletion of AMPK cooperated with Myc to enhance lymphogenesis [79]. Yet 
there must also be some yet-undiscovered adaptability to the response between AMPK and Myc, 
because in of Myc-driven osteosarcoma, loss of AMPK resulted in increased cell death [80]. 
Given the conflicting roles for these two proteins controlling metabolism, it seems clear the end 
result is tissue- and context-dependent. The flexibility conferred by AMPK may be necessary for 
later stage tumors, but loss of AMPK may be beneficial in the early stages of tumorigenesis.  
By promoting survival, AMPK could cooperate with oncogenic drivers and is thus 
advantageous for cellular survival. What coordination exists and how it is regulated remains 
largely unknown. In chapter 3, we study the interaction between AMPK and Myc.  To determine 
if AMPK is necessary for Myc-driven proliferation, murine embryonic fibroblast line with 
ablated AMPK activity was used to study the initiation of Myc deregulation. Because Myc 
stimulates both energy production and energy utilization at a high cost to the cell, AMPK may 
dampen the true Myc response.  When AMPK is absent, we can evaluate how this crosstalk 
affects Myc-directed metabolism.  
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1.5 MYC AND PROLIFERATION 
While Myc has long been implicated in the regulation of cellular proliferation, apoptosis, and 
cell growth [81, 82], the actual role in normal tissue physiology remains elusive and at times 
contradictory. The simple explanation that regulation by Myc seems to be tissue- and situation-
specific includes exceptions based on age and experimental model. The loss of Myc in bone 
marrow severely disrupts normal hematopoietic proliferation and homeostasis [83]. Trumpp et 
al. determined that when mice were lacking a single Myc allele (heterozygous null), they had 
overall reduced organ size [84]. They found cell number was reduced in spleen, lymph nodes, 
and bone marrow, but no differences in cell size, indicating that loss of even a single copy of 
Myc causes some reduction in proliferation and a smaller total number of cells in these organs 
[84]. On the other hand, genetic ablation of Myc in villi and intestinal crypts by Bettess et al. 
showed no difference in small intestine development of adults [85]. Soucek et al. used a 
dominant negative Myc mutant to cause global inhibition of Myc transcription, which caused 
only minor proliferative damage in high-turnover tissues like skin, testes, and gut epithelia, 
which resolved when Myc was restored [86]. The remaining tissues, including moderately 
proliferating tissue like lung, pancreas, liver and kidney, all exhibited no structural or 
proliferative changes [86]. 
Several groups have studied liver or hepatocyte specific proliferation when Myc is 
reduced or completely ablated. Even these studies on single organs produce considerably 
dissimilar results (Table 1). Sanders et al. used a model similar to that employed in chapter 4, 
namely an albumin-driven Cre recombinase which excised the endogenous myc gene, flanked by 
LoxP sites (“floxed”), in a hepatocyte-specific manner. They found there to be no difference in 
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liver size, weight, architecture or hepatocyte proliferation [87]. Li et al. deleted floxed myc 
alleles from the liver in 6 week old mice with adenovirus-driven Cre introduced through tail vein 
injection, and found deceased proliferation after a partial hepatectomy, but otherwise complete 
regeneration 7 days [88]. Baena et al. used an Mx-Cre deletion induced though pI:pC injections 
in newborns and in 6 week old mice, resulting in mycFLOX/FLOX excision throughout the liver [89]. 
They found increased liver:body weight and apoptosis, decreased liver function, and pyknotic 
nuclei [89]. While Baena et al. observed a decrease in hepatocyte size, Li et al. reported an 
increase and Sanders et al. found no change. All of these models do have some things in 
common: 1) none found any compensation by Myc family members N-Myc or L-Myc; and 2) 
they all made use of 2/3rd partial hepatectomy, to drive proliferation and increase stress in the 
liver. However, in order to replace the lost tissue (typically ~70% of the entire hepatic mass), the 
remaining hepatocytes need undergo only ~1.5 cell divisions, which is not very stringent 
proliferative stress.  
Table 1: Summary of papers published on Myc's role in liver regeneration 
  Baena (2005) - c-Myc 
regulates cell size and 
ploidy but is not essential 
for postnatal proliferation 
in liver 
Li (2006) - Conditional 
Deletion of c-myc Does Not 
Impair Liver Regeneration 
Sanders (2012) - Postnatal 
liver growth and 
regeneration are 
independent of c-myc in a 
mouse model of conditional 
hepatic c-myc deletion. 
Method of Myc 
deletion 
endogenous myc gene with 
loxP sites 
endogenous myc gene with 
loxP sites  
endogenous myc gene with 
loxP sites 
crossed with mx-cre mice adenovirus-driven Cre 
recombinase  
albumin-driven Cre 
recombinase 
Four polyinosinic: 
polycytidylic acid i.p. 
injections 
tail vein injections hepatocyte specific 
deletion induced 2 days after 
birth or at 6 weeks for PH      
 All experiments were 
performed on mice ~6 weeks 
 8-10 week old mice were 
used for regeneration 
experiments                            
Liver weight     No difference 
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Body weight decreased (10wk)     
Liver/body 
weight 
Increased no difference No difference 
PH- liver/carcass 
weight ratio 
  no difference (2 and 7 days), 
difference at 5 days post 
No difference 
Liver 
architecture 
disorganized parenchyma disorganized No difference 
Cell size - 
Hepatocyte 
decreased - 10day and 10wk enlarged, also enlarged post 
HP 
  
Hepatocytes/field Increased decreased (7days post HP), 
no difference (2days post 
HP) 
  
Proliferation of 
hepatocytes 
BrdU increased-6wk, 
however no major difference  
no difference   
PH - hepatocyte 
proliferation 
decreased (PCNA - 48h) decreased - day 7 slight decrease (48h post; Ki-
67 +ve), not significant  
Nuclei Pyknotic enlarged   
Polyploidy decreased - 10 wk increase - 4N hepatocytes, 
decrease - 2N, no change in 
8N 
  
Binucleated cells Decreased     
Apoptosis increased- 10day and 10wk 
(TUNEL) 
    
Levels of Myc/ 
Myc-related 
proteins 
No difference (n-myc, l-myc, 
b-myc, max, mad, mxi, 
mad3, mad4, mnt) 
no change (l-myc, n-myc) no change (L-myc, b-Myc, 
Max; n-myc below detection 
level) 
Oxidaive Status 
of hepatocytes 
increased 10day and 10wk 
(DCFH-DA) 
    
Conclusions Liver regeneration is 
compromised 2 days post PH 
Liver regeneration after PH 
within 7 days 
  
  
c-Myc not required for 
hepatocyte proliferation and 
protein synthesis in liver 
  
  
  c-Myc required for  
polyploidy in hepatocytes 
  C-myc regulates cell size and 
number in liver 
 
Our goal in chapter 4 is to clarify Myc’s necessity in adult hepatocyte proliferation using 
a much more demanding model of repopulation – a mouse model of hereditary tyrosinemia 
where the recipient fah-deficient cells slowly die while Myc WT or KO donor hepatocytes 
repopulate the existing liver architecture. To further characterize the proliferating hepatocyte, we 
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examine Oxphos and biosynthetic capacity, which may be reduced in the absence of Myc 
signaling. Additionally, the consequences of proliferative stress are evaluated in terms of lipid 
accumulation and oxidative or inflammatory stress, which was briefly characterized in chapter 2.  
In vivo, the large accumulation of lipids in the liver may result in a disease similar to non-
alcoholic fatty liver disease, which is characterized by steatosis, increased inflammation and 
fibrosis[90].  
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2.0  C-MYC PROGRAMS FATTY ACID METABOLISM AND DICTATES ACETYL 
COA ABUNDANCE AND FATE 
2.1 INTRODUCTION 
Cells dividing rapidly in response to normal or oncogenic signals have metabolic profiles distinct 
from those of their quiescent counterparts. Because they must coordinate mass accretion and 
division, they devote considerable resources to generating macromolecular precursors [19, 26]. 
To support these processes, they must also be equipped to generate large amounts of ATP, 
usually by increasing glucose and glutamine utilization by the TCA cycle [91]. Given this 
increased demand for energy and the fact that many of the macromolecular precursors originate 
from glycolytic and TCA cycle intermediates [19, 26], dividing cells undergo a process of 
metabolic re-programming whereby the shunting of these intermediates into anabolic pathways 
assumes a more prominent role than during quiescence. An example of this occurs with the 
Warburg effect whereby glycolysis, normally utilized by resting cells to generate ATP 
anaerobically, continues to function aerobically to supply certain essential amino acids, 
nucleotides and pentose sugars for macromolecular bio-synthesis [19, 91, 92].  
The dependence of dividing cells on the Warburg effect has occasionally been 
misconstrued as indicating that they minimize energy production via oxidative phosphorylation 
(Oxphos). In fact, provided sufficient oxygen, both glycolysis and Oxphos are often concurrently 
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increased in tumor cells [93, 94]. A particularly instructive example of this occurs with Myc 
oncoprotein de-regulation which, in addition to stimulating glycolysis, also increases 
mitochondrial mass, Oxphos and electron transport chain (ETC) function [4, 95]. Although basal 
ATP levels do not change, its half-life is shortened [4] and likely reflects its increased utilization 
for anabolic processes. In contrast, Myc-deficient cells, such as myc-/- rat fibroblasts (KO cells) 
[95], have dramatically lower ATP levels and turnover that correlate with reduced glycolysis, 
Oxphos, replication and cell mass relative to their myc+/+ wild-type (WT) counterparts or to KO 
cells whose Myc expression is restored (KO-Myc cells) [4]. The mitochondrial changes 
documented in KO cells include an overall paucity of these organelles, atrophy of those which 
remain and structural and functional ETC defects [4, 95].  
The enhanced utilization of glucose and glutamine that accompanies Myc over-
expression correlates with increased uptake of these substrates and their consumption in the 
glycolytic pathway and TCA cycle, respectively. Myc positively regulates a majority of 
glycolytic enzymes and increases glutamine’s conversion to glutamate and α-ketoglutarate by 
both transcriptional and post-transcriptional mechanisms [37, 91, 92].  
Another highly efficient energy source derives from mitochondrial fatty acid β-oxidation 
(FAO), which, like glycolysis, yields acetyl CoA, the entry-level TCA cycle substrate. During 
proliferation, acetyl CoA’s immediate downstream product, citrate, can also be converted back to 
acetyl CoA in the cytoplasm where, in ATP-consuming processes, it can be used for de novo 
lipid or steroid bio-synthesis [68, 96]. While considerable effort has been devoted to delineating 
the means by which glucose and glutamine metabolism are regulated by Myc [37, 91, 92], our 
understanding of how Myc supervises the transport, directionality and metabolism of fatty acids 
and their catabolites remains incomplete. In the current work, we have studied how WT, KO and 
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KO-Myc rat fibroblasts differ in this regard. Our studies indicate that, in an apparent effort to 
compensate for their ATP deficit and poor utilization of glucose and glutamine as energy-
generating substrates, KO cells preferentially transport and oxidize long chain fatty acids 
(LCFAs) such as palmitate. The channeling of LCFAs into the TCA cycle is facilitated not only 
by the up-regulation of enzymes involved in their transport and β-oxidation but also by a 
concurrent down-regulation of acetyl CoA consumption for anabolic purposes. Because KO cells 
oxidize LCFAs more rapidly, their rate of incorporation into neutral lipids is lower than that of 
WT or KO-Myc cells. These latter cells utilize their neutral lipid stores for anabolic purposes to a 
greater extent, while KO cells eventually accumulate a higher stored neutral lipid content. 
Similar studies, which traced the fate of the freely diffusible medium chain fatty acid (MCFA) 
octanoate and the two carbon molecule acetate indicated that their metabolism was also altered to 
maximize their conversion to acetyl CoA. The importance of acetyl CoA as a critical metabolic 
intermediate that links these opposing functions was further underscored by demonstrating that 
its supply is also regulated by additional Myc-dependent enzymes including pyruvate 
dehydrogenase (PDH), which converts pyruvate to acetyl CoA; acetyl CoA acetyltransferase 
(Acat1/2), which participates in FAO and directs the catabolism of certain amino acids into 
acetyl CoA, and acetyl CoA synthase 2 (AceCS2) and cytoplasmic acetyl CoA hydrolase 
(cACH), which regulate the balance between acetate and acetyl CoA. Despite these 
compensatory changes, KO cells remained profoundly depleted of acetyl CoA. Collectively, 
these studies identify adaptive pathways through which exogenous fatty acid substrates, ranging 
from LCFAs to simple two carbon units, can be converted to acetyl CoA, which in KO cells is 
then preferentially directed toward replenishing ATP. KO cells resort to multiple strategies to 
correct their acetyl CoA and ATP deficits. These include generating acetyl CoA from multiple 
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sources, redirecting it into an otherwise compromised TCA cycle, and minimizing its use for 
purposes other than ATP generation.  
2.2 RESULTS 
2.2.1 Uptake and oxidation of fatty acids by KO cells 
To quantify fatty acid utilization among WT, KO and KO-Myc cells, we exposed them to 14C-
radio-labeled palmitate or 14C-octanoate as representative long- and short-medium chain fatty 
acids, respectively [97, 98]. In each case, the 14C tag resided on the carboxylic acid moiety, 
which allowed us to test the integrity and interdependence of at least seven distinct enzymatic 
steps in the β-oxidation pathway. These include the placement of the trans-double bond between 
C2 and C3 by very long- or medium-chain acyl CoA dehydrogenase , the production of L-B-
hydroxyacyl CoA by enoyl CoA hydratase, the conversion of L-B-hydroxyacyl CoA to B-
ketoacyl CoA by B-hydroxyacyl CoA dehydrogenase and thiolysis between C2 and C3 of B-
ketoacyl CoA to produce acetyl CoA. Upon entry into the TCA cycle, 14C-tagged acetyl CoA 
would need to be conjugated with oxaloacetate before eventually surrendering its tag as CO2 
during the conversion of isocitrate to α-ketoglutarate. Importantly, LCFA oxidation is also 
dependent on the rate at which the substrate is actively transported across the plasma and 
mitochondrial membranes and into the mitochondrial matrix [99]. These steps may not 
necessarily parallel CO2 production given that LCFAs can also be stored cytoplasmically as 
neutral lipids or utilized for anabolic rather than catabolic purposes. MCFAs can be utilized 
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similarly although they enter mitochondria passively without contributing to neutral lipid pools 
[47, 99]. Thus, differences in MCFA uptake should better reflect the rate of β-oxidation. As seen 
in Fig. 3A, the rate of 14C-palmitate oxidation was similar in WT and KO-Myc cells after 
adjusting for differences in mitochondrial mass (p=0.58), but was nearly 25-fold higher in KO 
cells (p<0.0001). Similar studies performed with 14C-octanoate (Fig. 3B) also showed a >5-fold 
higher rate of β-oxidation in KO cells. Thus, despite their markedly slower proliferation and their 
reduced mitochondrial function, KO cells actually utilize a larger amount of LCFAs and MCFAs 
for energy generation than do their Myc-replete counterparts.  
We next asked whether the observed differences in FAO among the above three cell lines 
were associated with differences in their fatty acid uptake rates. As seen in Fig. 3C, 14C-palmitate 
uptake was highest in KO cells, in keeping with their overall greater utilization of this substrate 
for FAO. A higher rate of 14C-octanoate uptake by KO-Myc cells was also consistent with their 
preferential utilization of this substrate for processes other than FAO (Fig. 3C). Interestingly, 
WT and KO-Myc cells showed distinct preferences for LCFAs and MCFAs, with the former 
cells demonstrating a greater uptake of palmitate than octanoate whereas the reverse was true for 
KO-Myc cells. Thus, KO cells have a selective uptake for both LCFAs and MCFAs and utilize 
them more efficiently as FAO substrates. However, each cell line possesses a distinct pattern of 
LCFA and MCFA uptake that presumably reflects differential usage for processes other than 
FAO. 
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2.2.2 Differential utilization of fatty acids 
The initial stage of FAO involves the iterative insertion of a trans double bond between the C2 
and C3 carbon atoms of the acyl CoA thioester substrate in a reaction that, for palmitate, is 
catalyzed by very long-chain acyl CoA dehydrogenase (ACADVL) and, for octanoate, by 
medium-chain acyl CoA dehydrogenases (ACADM) [100]. To determine whether the 
preferential utilization of palmitate and octanoate for FAO by KO cells could be explained by 
Figure 3: Differential utilization and uptake of LCFAs and MCFAs by WT, KO and KO-Myc cells. 
(A) β-oxidation of 14C-palmitate. (B) β-oxidation of 14C-octanoate. (C) Uptake of 14C-palmitate. (D) Uptake 
of 14C-octanoate. Each point represents the mean of triplicate determinations +/- 1 S.E.M. p values are 
expressed relative to WT cells (*=p<0.05, **=p<0.001) 
 21 
 
differences in these enzymes, we measured their activities [101]. As seen in Fig. 4A and B, both 
ACADVL and ACADM activities were increased significantly in KO cells after adjusting to 
mitochondrial mass, thus providing an explanation for their more efficient utilization of these 
substrates. 
The foregoing studies were designed to evaluate the fate of fatty acids as energy-
generating catabolic substrates but did not explain how the acetyl CoA generated from their 
catabolism was utilized for anabolic purposes. To address this, we labeled the cell lines with 3H-
palmitate and followed the incorporation of its tag into both phospho- and neutral lipid pools 
[98]. Because octanoate is not incorporated into neutral lipids, we measured the transfer of its 
14C-tag into phospholipids only. The rate of incorporation of the 3H tag of palmitate into both 
neutral lipids (Fig. 4C) and phospholipids (Fig. 4D) and the 14C-octanoate tag into phospholipids 
(Fig. 4E) was significantly lower in KO cells.  
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2.2.3 Neutral Lipid Accumulation in KO cells 
Previous studies have shown that N-Myc inhibition in neuroblastoma cells increases their neutral 
lipid content [69]. We therefore next asked whether fatty acid uptake and utilization were 
balanced by assessing differences in basal neutral lipid content. Each cell line was stained with 
the neutral lipid-specific probe BODIPY-493/503 and visualized by fluorescence microscopy to 
Figure 4: ETF assays for ACADVL and ACADM activities and incorporation of LCFAs and MCFAs 
into neutral and phospholipids in WT, KO and KO-Myc cells. (A) ACADVL enzymatic activity. Mean values 
are depicted +/- 1 S.E.M. Results were normalized to account for differences in mitochondrial mass among 
the three cell types[4]. (B) ACADM activity. Results are presented as described for A. (C) Incorporation of 
3H-palmitate into neutral lipids. (D) Incorporation 3H-palmitate of into phospholipids. (E) Incorporation of 
14C-octanoate into phospholipids.    
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assess its neutral lipid content. WT and KO-Myc cells demonstrated low-level accumulation of 
BODIPY-493/503 in contrast to KO cells in which considerable amounts of the dye could be 
detected (Fig. 5A and B). In other experiments, we confirmed the presence of excess neutral lipid 
staining in KO cells by Oil Red O staining (Fig. 5C). Using two different approaches, we 
confirmed that the accumulation of neutral lipids was a direct and rapid consequence of Myc 
inactivation. First, treatment of WT cells with the Myc inhibitor 10058-F4 [102] significantly 
increased BODIPY-493/503 uptake (Fig. 5D). Additionally, reduction of Myc protein levels in 
A549 human lung cancer cells using tetracycline-dependent conditional expression of a Myc 
shRNA produced a similar result (Fig. 5E and F). Collectively, these findings support the idea 
that neutral lipid accumulation in KO cells is a direct consequence of Myc depletion and 
mitochondrial dysfunction.  
 To better define the relationship between fatty acid transport and metabolism and the 
generation and utilization of acetyl CoA, we utilized real-time qRT-PCR to quantify transcripts 
encoding the enzymes described above plus select others to allow an overview of the activity of 
relevant pathways (Fig. 6A). Transcripts were grouped into six functional categories representing 
fatty acid transport and FAO, de novo lipid and steroid biosynthesis, neutral lipid storage and the 
generation of acetyl CoA from acetate and pyruvate. This last category included transcripts for 
the pyruvate dehydrogenase (PDH) E1 subunit and its regulators, pyruvate dehydrogenase kinase 
1 (PDK1) and pyruvate dehydrogenase phosphatase 2 (PDP2), which are responsible for the 
phosphorylation-dependent inactivation and activation, respectively, of E1 [103]. Also included 
were transcripts for pyruvate carboxylase (PC) which catalyzes an anaplerotic reaction important 
for gluconeogenesis and lipid biosynthesis and irreversibly re-directs pyruvate to oxaloacetate to 
 24 
 
limit the former’s conversion to acetyl CoA [104]. We also examined transcripts for the pyruvate 
kinase isoforms PKM1 and PKM2, which catalyze the irreversible conversion of 
phosphoenolpyruvate (PEP) to pyruvate during glycolysis. PKM2 is typically more abundant in 
rapidly proliferating cells and has a significantly higher Km for PEP [105, 106]. This may better 
allow for the accumulation of upstream glycolytic intermediates, thus facilitating their 
channeling into collateral, anabolic pathways in support of proliferation-associated mass 
accretion [106, 107]. Consistent with this idea, the activity of PKM2 is subject to negative 
regulatory control by ATP and possibly by acetyl CoA as well [21, 26, 105].  
 The results of transcriptional profiling (Fig. 6B) were largely consistent with our 
foregoing studies. First, they indicated that KO cells up-regulate transcripts encoding enzymes 
involved in the production of acetyl CoA for energy generation while down-regulating those 
involved in anabolism such as de novo lipid and steroid biosynthesis (Fig. 6A). One example of 
the potential precision of this re-programming in KO cells was seen in the case of the 5-fold 
change in the relative ratio of acetyl CoA carboxylase 1 and 2 isoforms (ACC1 and ACC2), 
which function in fatty acid synthesis and β-oxidation, respectively [108]. Also notably up-
regulated in KO cells were several transcripts such as phosphatidic acid phosphatase types 2b 
and c (Ppap2b and Ppap2c) and diacylglycerol acyltransferase 1 (Dgat1), which encode key 
enzymes involved in the shunting of fatty acids into neutral lipid storage pools [109, 110]. 
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Figure 5: Neutral Lipid Accumulation in KO cells. (A) Staining of cells for neutral lipids. WT, KO 
and KO-Myc cells were plated onto glass microscope slides and allowed to grow to sub-confluency before 
being fixed and stained with BODIPY-493/503 and counter-stained with Texas red-labeled phalloidin and 
DAPI. Representative fields are shown. (B) Quantification of neutral lipid staining. Each of the indicated cell 
types was stained with BODIPY-493/503 and assessed by flow cytometry. (C) Oil Red O staining. Each of the 
indicated cell types were plated as in (A), and stained with Oil Red O. (D) 10058-F4-mediated inhibition of 
endogenous Myc leads to the accumulation of neutral lipids. WT cells in log-phase growth were exposed to 50 
µM 10058-F4 (22) for 48 hr before being stained with BIODIPY-493/503 and assessed by flow cytometry. The 
number in the upper left corner is the ratio of the mean intensity of staining of cells with (red) and without 
(green) 10058-F4 exposure. (E) Induction of shMyc in A549 cells leads to neutral lipid accumulation. A549 
cells (ca. 10% confluency) were allowed to grow for an additional 3 days in the absence (green) or presence 
(red) of 2.5 µg/ml Doxycline (Dox) before being stained with BODIPY-493/503 as described for (B). (F) 
Immunoblots demonstrating a reduction in endogenous Myc protein levels following a 3 day exposure to 
Doxycline. 
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2.2.4 AMPK is Myc-responsive 
Some of the above-discussed enzymes are regulated post-translationally by AMP-dependent 
protein kinase (AMPK), a serine/threonine kinase that is itself activated by phosphorylation in 
response to low ATP/(AMP+ADP) ratios [74]. A role for AMPK in maintaining adenosine 
nucleotide homeostasis stems from its inhibition of ATP-consuming processes such as 
macromolecular synthesis and cell proliferation along with its stimulation of ATP-generating 
reactions such as glycolysis and Oxphos [111]. Among the enzymes depicted in Fig. 6 whose 
activities are down-regulated by AMPK-mediated phosphorylation are ACC1, which catalyzes 
the conversion of acetyl CoA to malonyl CoA in the initial step of fatty acid synthesis; fatty acid 
synthase (FASN), which converts malonyl CoA into palmitate; and HMG-CoA reductase 
(HMGCR), the rate-limiting step in the biosynthesis of cholesterol and other steroids [111]. 
AMPK-mediated phosphoryl-ation of the palmitate cell surface receptor CD36 has also been 
reported to increase its rate of cycling between the cell membrane and intracellular 
compartments thereby affecting the normal balance between FAO and lipid accumulation in 
favor of the latter [112, 113]. Finally, although not known to be a direct AMPK target, carnitine 
palmitoyltransferase I (CPT1) is suppressed by malonyl CoA, such that ACC1 inhibition by 
AMPK would likely increase FAO [114]. 
To determine whether the altered metabolic pathways of KO cells might be susceptible to 
post-translational modulation by AMPK, we compared the levels of total and active (Thr172-
phosphorylated) forms of AMPK in WT, KO and KO-Myc cells. KO cells showed marked 
constitutive Thr172 phosphorylation as well as increased total AMPK levels (Fig. 6C). These 
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findings are in keeping with the profound ATP deficit of KO cells [4] and suggest that, despite 
AMPK’s constitutive activation, it is unable to correct the energy deficit. 
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Figure 6: Alteration of metabolic pathways in KO cells. (A) Pathways depicting the generation and 
utilization of acetyl CoA in KO cells. The major sources of mitochondrial acetyl CoA include the glycolytic 
intermediate pyruvate; long and medium chain fatty acids such as palmitate and octanoate; acetate and a 
subset of amino acids that includes tryptophan, lysine, phenylalanine, tyrosine, leucine and isoleucine. 
Cytoplasmic acetyl CoA can also be generated from the mitochondrial TCA substrate citrate in a reaction 
involving ACLY and from acetate by AceCS2. Acetyl CoA’s fate in pathways other than the TCA cycle 
primarily include its conversion to malonyl CoA during fatty acid synthesis. In addition, pyruvate, the direct 
glycolytic precursor of acetyl CoA, can be diverted from this pathway by an anaplerotic reaction involving its 
conversion to oxaloacetate that is catalyzed by pyruvate carboxylase (PC) and palmitate can be diverted into 
neutral lipids. The activity of pyruvate dehydrogenase (PDH), which catalyzes the conversion of pyruvate to 
acetyl CoA is also negatively regulated by pyruvate dehydrogenase kinase1 (PDK1) and positively regulated 
by pyruvate dehydrogenase phosphatase 2 (PDP2). Based on transcriptional profiling shown in (B), enzymes 
whose transcripts are up-regulated in KO cells are depicted in green and those which are down-regulated are 
depicted in red. (B) Transcript expression. For simplicity, transcripts and proteins are designated by common 
acronyms.  Transcripts that were significantly up-regulated in KO cells are indicated in green and those that 
are down-regulated are depicted in red. The values of transcripts in WT cells were arbitrarily set at 1 (black). 
Transcripts are arranged according to the functional categories of their representative enzymes. Each value 
represents the mean of triplicate determinations for each transcript.  (C) AMPK is up-regulated in KO cells. 
Immunoblots of total cell lysates from WT, KO and KO-Myc cells were probed with antibodies for total 
AMPK or phospho-AMPK (pThr172). 
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2.2.5 KO cells maximize their accumulation of acetyl CoA by increasing its production 
and decreasing its utilization for purposes other than TCA cycle utilization  
The E1 subunit of the mitochondrial PDH complex catalyzes pyruvate decarboxylation, which is 
the first and rate-limiting step in its irreversible conversion to acetyl CoA (Fig. 7A) [115]. In 
addition to its regulation by PDK1 and PDP2 [103, 116, 117], PDHE1 is under additional 
negative feedback control by acetyl CoA and positive control by ATP by virtue of the latter’s 
inhibitory effect on PDP2 [118]. Furthermore, ATP and ADP exert positive and negative control, 
respectively, over PDK1 (Fig. 7A). Although the transcripts encoding these proteins were 
modestly down-regulated in KO cells (Fig. 7B), the complexity of PDHE1 post-translational 
regulation demanded that we actually measure its activity and thereby gauge the overall extent to 
which it was subject to control by these various and often opposing regulatory factors. As shown 
in Fig. 7B, KO cells contained ca. 8 times as much PDH activity as WT and KO-Myc cells. 
Although immunoblotting showed modest differences in PDHE1 protein levels among the three 
cell lines (Fig. 7C), it demonstrated more dramatically, in both KO and KO-Myc cells, the 
relative under-phosphorylation of PDHE1 on Ser293, the site whose modification by PDK1 and 
PDP2 most affects its activity [74]. Further consistent with the increased PDH activity in KO 
cells was their higher levels of PDP2 relative to WT cells. In contrast, no differences in the levels 
of PDK1 were observed between WT and KO cells. Although KO-Myc cells contained nearly 5-
fold lower levels of PDP2 transcripts than WT cells and 60-fold higher levels of PDK1 
transcripts (Fig. 6B), this was not reflected in PDH activity (Fig. 7B).  
 30 
 
 Another source of acetyl CoA is acetate, which, in the whole animal, is typically supplied 
by bacterial fermentation in the colon, by the metabolic breakdown of acetaldehyde and by the 
action of enzymes such as sirtuins and histone deacetylases [119]. Like octanoate, acetate is both 
freely diffusible and readily available for metabolism in both the cytosol and mitochondria. 
Consistent with the notion that KO cells attempt unsuccessfully to normalize acetyl CoA levels, 
we note that AceCS2 transcript levels were elevated by nearly 40-fold in KO cells whereas those 
for AceCS1 were modestly decreased (Fig. 6B). AceCS2, a mitochondrial enzyme, converts 
acetate to acetyl CoA for utilization by the TCA cycle whereas AceCS1, which is cytoplasmic, is 
more important for fatty acid synthesis [120]. Thus, the >60-fold changes in the 
AceCS1:AceCS2 ratio described above would be expected to greatly favor acetate conversion 
into acetyl CoA in the mitochondria. Further consistent with, and perhaps contributing to, the 
reduced utilization of acetate for fatty acid synthetic pathways was the finding that transcripts for 
cACH, which converts acetyl CoA back to acetate in the cytoplasm [121], were increased 4.5-
fold in KO cells. Indeed, when cells were incubated with 14C-acetate, KO cells incorporated the 
least amount of 14C-tag, particularly into phospholipids (Fig. 7D and E).  
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Figure 7: Myc-regulated control of acetyl CoA generation from pyruvate. (A) Outline of the reaction 
and its regulatory network. The E1 subunit of the mitochondrial PDH complex is subject to negative 
feedback inhibition by acetyl CoA and to enzymatic regulation by the inhibitory kinase PDK1 and the 
stimulatory phosphatase PDP2 via Ser293 phosphorylation on the E1 subunit of PDH. PDK1 is subject to 
additional positive control by ATP and to negative control by ADP, whereas PDP2 is subject to negative 
control by ATP. In addition, the PKM2 isoform, which is less efficient at converting PEP to pyruvate, is 
under positive regulatory control by ADP and negative regulatory control by ATP and acetyl CoA. (B) PDH 
activity in WT, KO and KO-Myc cells after adjusting for differences in mitochondrial mass. (C) Immunoblots 
for PDHE1, phospho(Ser293)-PDHE1 (pPDHE1), PDK1 and PDP2. A β-actin blot was included as a protein 
loading control. (D) and (E), Acetate incorporation in neutral lipids and phospholipids, respectively. (F) Total 
acetyl CoA levels in WT, KO and KO-Myc cells. Each point represents the mean of quadruplicate 
determinations +/- 1 S.E.M. 
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Finally, we measured steady-state levels of acetyl CoA. As seen in Fig. 7F, both KO and 
KO-Myc cells contained reduced levels of acetyl CoA relative to WT cells, although the latter 
did not reach statistical significance. Together with the previous results (Fig. 6B), these findings 
are most compatible with the idea that KO cell metabolism is directed primarily at maximizing 
the generation of acetyl CoA for use by the TCA cycle and minimizing its utilization for anabolic 
reactions. Despite maximal efforts to produce more acetyl CoA, KO cells remain unable to 
maintain normal levels of this substrate.  
2.3 DISCUSSION 
Numerous studies support the idea that Myc’s importance in promoting cell proliferation derives 
in part from its ability to ensure the provision of adequate supplies of anabolic substrates and 
ATP to support macromolecular syntheses [19, 24, 37, 91, 92]. Myc’s silencing is associated 
with numerous metabolic and proliferative consequences that ultimately can be traced to defects 
in glycolysis and mitochondrial structure and function [4, 17, 122]. That these factors are rate-
limiting for proliferation is supported by findings shown here and elsewhere that, even when 
provided with adequate energy-generating substrates such as glucose, glutamine and fatty acids, 
KO cells remain chronically ATP-depleted and respond by activating AMPK in a futile attempt 
to remedy this energy deficit (Fig. 6C). However, because two of the major responses to AMPK 
activation include the up-regulation of glycolysis and Oxphos, both of which are Myc-dependent 
[4, 74, 91, 92], the AMPK response is ultimately abortive despite its chronicity.  
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  KO cells respond to their ATP deficit by up-regulating FAO and many of the transcripts 
associated with LCFA uptake, transport and metabolism (Fig. 6A and B). Palmitate oxidation, 
which begins with ACADVL, is further enabled by the high activity of this enzyme in KO cell 
mitochondria. Thus, despite their reduced overall mass, atrophic structure and relatively poor 
utilization of substrates such as glucose and glutamine [4, 17], KO cell mitochondria 
disproportionately oxidize LCFAs. They also contain higher ACADM activity and preferentially 
oxidize octanoate whose transport into cells and mitochondria, unlike that of palmitate, is 
passive.  
Importantly, the transcriptional profiles depicted in Fig. 6B represent steady state levels 
in otherwise isogenic cells that have adapted to long-term differences in Myc expression and 
have distinct metabolic behaviors [95]. While these differences may not necessarily reflect 
“direct” Myc targets [123, 124], they are nonetheless useful in that they reveal long-term 
strategies employed by Myc-compromised cells to compensate for their inherent metabolic 
disadvantages. In this regard AMPK, whose level of activation is clearly inversely related to Myc 
levels (Fig. 7C), is a well-known regulator of many of the same process controlled by Myc such 
as FAO, fatty acid synthesis, glycolysis and Oxphos [74]. However, since the ultimate metabolic 
function of Myc is to increase ATP synthesis in support of anabolism and proliferation [4] 
whereas AMPK’s function is to conserve energy until the ATP:ADP/AMP balance is restored, 
the integrated effects we observe based on steady state transcripts may reflect a metabolic 
compromise between these opposing actions [79].  
 In a seemingly paradoxical finding, KO cells were found to possess the highest stores of 
neutral lipids (Fig. 5A-C) despite incorporating the least amount of 3H-palmitate into this 
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compartment (Fig. 4C). This latter finding is likely attributable to the fact that a large proportion 
of palmitate entering KO cells is immediately utilized for FAO (Fig. 3A) whereas in Myc-replete 
cells, larger amounts of the fatty acid are directed into neutral lipid pools (Fig. 4C). The 
extremely slow rate of KO cell proliferation [95] minimizes the need for these neutral lipid pools 
to serve as sources for phospholipid synthesis. Reduced demand for neutral lipid mobilization 
thus permits KO cells to accumulate higher neutral lipid stores despite their lower rates of 
accumulation. In contrast, WT and KO-Myc cells synthesize phospholipids at higher rates (Fig. 
4C) and thus mobilize neutral lipids much more rapidly for this purpose (Fig. 4D) thus 
preventing their accumulation. The highly dynamic nature of neutral lipid stores is further 
evidenced by the rapidity with which they accumulate following Myc inhibition (Fig. 5D and E 
and [69]). 
 A major finding of the current study is that KO cells, in addition to deriving a 
considerable fraction of their acetyl CoA from FAO, also maximize its production from other 
sources and minimize its utilization for purposes other than energy production. For example, 
reduced levels of transcripts involved in fatty acid synthesis such as those for ATP citrate lyase 
(ACLY), ACC1 and FASN support the notion that KO cells minimize their incorporation of 
acetyl CoA into lipids. That this down-regulation occurs throughout the pathway and involves its 
most proximal enzyme (ACLY) would seem to favor the retention of citrate within the TCA 
cycle to ensure its utilization for Oxphos. Further consistent with this was the finding that ACC2, 
proposed to be more important than ACC1 for FAO [108], was up-regulated in KO cells, 
whereas ACC1 was down-regulated. High levels of palmitate within KO cells might further 
inhibit fatty acid synthesis by virtue of the well-known tendency of the substrate to suppress 
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ACC1 [125]. A similar attempt to direct acetyl CoA away from synthetic pathways was observed 
with the down-regulation in KO cells of transcripts for HMGCR, the rate-limiting enzyme of the 
mevalonate pathway [126]. Both ACC1 and HMGCR are also further suppressed by AMPK 
[74]. The down-regulation of PC also serves indirectly to maximize the availability of pyruvate 
for conversion into acetyl CoA by diverting it away from the anaplerotic pathway that furnishes 
oxaloacetate. Other pathways through which acetyl CoA production is maximized are up-
regulated in KO cells and include those involving its AceCS2-mediated synthesis directly from 
acetate and the catabolism of selected amino acids by Acat 1 and 2. 
 The PDH-mediated conversion of pyruvate to acetyl CoA provides yet another example 
of how KO cells attempt to selectively utilize acetyl CoA for ATP generation (Fig. 7A). This 
reaction is particularly noteworthy as it illustrates the complex and interdependent regulation that 
Myc and adenine nucleotides may exert over acetyl CoA levels as well as the negative feedback 
control that acetyl CoA itself provides. PDH activity, which is increased in KO cells (Fig. 7B) is 
positively controlled by the PDP2 phosphatase and negatively controlled by the PDK1 kinase 
[103, 115-117]. The net result is PDHE1 de-phosphorylation and activation (Fig. 7C). Non-
enzymatic control is exerted by the repressive action of acetyl CoA; by ATP, which inhibits 
PDP2 and stimulates PDK1; and by ADP, which represses PDK1 (Fig.7A) [103, 115-117]. Given 
that the intracellular milieu of KO cells is one in which both acetyl CoA and ATP levels are low, 
these small molecules likely exert significant additional influence on PDH activity. The 
relatively normal PDH activity in KO-Myc cells, despite its hypo-phosphorylation, suggests that 
factors other than those examined here may play additional roles in its regulation [103].  
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 Another factor that might also influence acetyl CoA levels in KO cells is PKM2, whose 
ability to catalyze the conversion of phosphoenolpyruvate (PEP) to pyruvate is accelerated by 
ADP and inhibited by ATP and acetyl CoA (Fig. 7A) [105, 106, 127]. Because this reaction is 
one of only three in the entire glycolytic pathway that is irreversible, it provides a relatively 
stable source of the substrate. It is noteworthy that both PKM2 and PKM1 are equally up-
regulated in KO cells in contrast to KO-Myc cells where they are coordinately down-regulated. 
In the latter case, where ATP generated by Oxphos is already abundant, this may permit PEP and 
its upstream precursors to accumulate and be diverted into anabolic pathways.  
Although both KO and KO-Myc cells have lower levels of acetyl CoA (Fig. 7F), the 
origins and consequences of these deficits are likely quite different. In KO cells, we believe this 
arises primarily from reduced ability to produce acetyl CoA within atrophic and dysfunctional 
mitochondrial that reduces the overall acetyl CoA supply, despite an increased in PDH activity 
as discussed above. In contrast, the acetyl CoA deficiency of KO-Myc cells likely reflects the 
proliferative strain imposed upon them as they attempt to keep pace with high levels of fatty acid 
synthesis and high rates of ATP turnover [4]. Thus, the reduced level of acetyl CoA in KO-Myc 
cells more likely represents the accelerated rate at which this substrate is utilized in contrast to 
KO cells in which acetyl CoA production is compromised. This suggests that the supply of acetyl 
CoA may represent a potential proliferative and metabolic bottleneck that might be exploited in a 
therapeutic setting, particularly in cancers that are Oxphos-dependent. 
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2.4 EXPERIMENTAL PROCEDURES 
2.4.1 Cell culture 
All cell lines were routinely maintained as previously described [4]. KO-Myc cells were 
generated through the use of stable transduction with a lentiviral vector encoding a full-length 
human Myc cDNA [4]. A549-shMyc cells were generated by infecting A549 human alveolar 
lung cancer cells with a pTRIPZ lentiviral vector encoding red fluorescent protein and a shRNA 
directed against human Myc, both of which were tetracycline-inducible (Thermo Fisher, 
Waltham, MA). All lentiviral packaging and infections were performed as previously described 
[122] under BSL2+ conditions and were approved by the University of Pittsburgh Biosafety 
Committee. Stable transfectants were selected and maintained in puromcycin-containing medium 
(1 µg/ml) as described above.  
2.4.2 14C-palmitate and 14C-octanoate uptake and β-oxidation studies 
FAO was quantified as previously described [98]. Briefly, 2x104 WT and KO-Myc cells and 
4x104 KO cells (all >90% viable) were seeded into 24-well tissue culture plates and allowed to 
attach overnight. The following day, medium was removed and the cells were incubated at 37C 
for 30 min. in PBS. 200 µL of fresh PBS containing 1 mM carnitine (Santa Cruz Biotechnology, 
Santa Cruz, CA) and 0.2 µCi BSA-bound [1-14C]-palmitate (sp. act. = 32 mCi/mmol), (Perkin-
Elmer, Waltham, MA) or 0.1 µCi 14C-octanoate (sp. act. = 55 mCi/mmol), (American 
Radiolabelled Chemicals, St. Louis, MO) was then added. 14CO2 was collected onto filters 
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soaked in 0.6N KOH which were placed in a collection apparatus made from a 0.4 ml Eppendorf 
tube and maintained under air-tight seal at 37C for 2 hr [97]. The medium was then acidified by 
adding 20 µL 6M perchloric acid to release additional dissolved CO2. Filters were removed after 
60 min and released 14CO2 was quantified from quadruplicate samples on a Beckman LS6500 
scintillation counter. Counts were adjusted so as to normalize for any differences in total protein 
content among the three groups of cells (generally <10%). p values were calculated using 1-way 
ANOVA followed by Bonferroni's post-hoc comparisons test. To measure 14C-palmitate and 14C-
octanoate uptake, cells were plated as described above the day prior to labeling. Monolayers 
were washed twice with PBS and then incubated in fresh PBS (200 µL) for 30 min. Fatty acid-
free BSA-bound 14C palmitate (0.2 µCi/well) with 1 mM carnitine was incubated for the 
appropriate time periods. After thorough washing, the cells were lysed in 160 µL 5% SDS and 
subjected to scintillation counting as described above. Results from triplicate samples were 
normalized to protein content. All experiments were repeated two additional times with 
comparable results. 
2.4.3 Incorporation of 3H-palmitate, 14C-octanoate and 14C-acetate into lipids 
Cells were plated as described for oxidation studies except that tritiated palmitate was utilized 
[98]. The next day, they were starved for 1 hr in PBS and then labeled for 1 hr in 200 µL of fresh 
PBS containing 0.5 µCi BSA-bound [9,10-3H(N)]palmitate (sp. act. = 32 mCi/mmol) (Perkin-
Elmer, Waltham, MA), 14C-octanoate (0.1 μCi) containing 1 mM carnitine or 0.2 μCi 14C-Na 
acetate (Perkin-Elmer, sp. act. = 54.3 mCi/mmol). The cells were then washed twice in warm 
PBS, and fresh PBS with 1 mM carnitine was added for 2 hr. Cells were then lysed with 25 µl 
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6N KOH and an organic extraction was performed in 1 ml of methanol: chloroform (1:1), which 
was then removed and dried under nitrogen. After adding ice-cold acetone to the dried lipid film 
and incubating at -20 C overnight, the phospholipid pellet was separated by centrifugation 
(14,000 x g, 30 mins at 4C). Both neutral and phospholipids were re-dissolved in 50 µL of 
chloroform for quantification. The labeled fractions were quantified by scintillation counting as 
described above. Each assay was performed in triplicate and p values were calculated using 2 
way ANOVA followed by Bonferroni’s post-hoc comparison. 
2.4.4 Enzyme assays 
Measurements of very-long and medium chain acyl CoA dehydrogenase activities (ACADVL 
and ACADM, respectively) in cell-free extracts were performed using the anaerobic electron 
transfer flavoprotein (ETF) fluorescence reduction assay as previously described [101]. 
Measurements were performed with a LS50B fluorescence spectrophotometer (Perkin-Elmer, 
Waltham, MA) with a heated cuvette block set to 32C. One unit of activity was defined as the 
amount of enzyme necessary to completely reduce 1 μmol of ETF in 1 min. Each assay was 
performed in duplicate and one-way ANOVA followed by Bonferroni's post-hoc comparisons 
tests were performed in all statistical analyses. Assay results were adjusted to account for 
previously determined differences in mitochondrial mass based on staining with 10-n-nonyl-
acridine orange (NAO) [4]. 
 PDH activity was quantified using an enzyme activity microplate assay kit 
(MitoSciences, Eugene, OR). 5 nearly confluent 100 mm plates of cells were harvested by 
trypsinization, washed twice in PBS, flash frozen in liquid nitrogen and stored at -80 C until 
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ready to assay. Each assay utilized 1 mg of total cellular protein in 200 μl of the buffer provided 
by the supplier. The remainder of the assay was completed according to the supplier’s protocol. 
2.4.5 Visualization and quantification of neutral lipids 
Cells were plated in 12 well dishes containing sterile glass coverslips and cultured overnight. 
They were then washed once in PBS and stained with Bodipy-493/503 Neutral Lipid stain 
(Molecular Probes/Thermo-Fisher: final concentration = 10 µg/ml) in complete D-MEM for 30 
minutes at 37 C. After washing in PBS the cells were fixed for 30 minutes at room temperature 
in PBS-2% paraformaldehyde, and permeabilized in PBS-0.1% Triton-X 100 for 5 min. After 3 
additional washes in PBS, the coverslips were blocked in 1% BSA for 30 min and co-stained 
with 0.165 mg/ml Texas Red Phallodin (Life Technologies, Grand island, NY) and 0.1 mg/ml 
4′,6-diamidino-2-phenylindole (DAPI) Nuclear Stain (Sigma-Aldrich, St. Louis, MO) final and 
mounted. Representative fields were imaged on an Olympus IX81 Motorized Inverted Confocal 
Microscope using Olympus Fluoview software (Ver.2.1c).  
 Neutral lipid content was quantified using a modification of a previously described 
protocol [128]. Briefly, 106 cells were trypsinized, collected in PBS and stained at 25C for 30 
min in the dark using Bodipy-493/503 (final concentration = 10 µg/ml in complete D-MEM). 
Flow cytometry was performed using a FACStar flow cytometer (Becton-Dickinson Biosciences, 
San Jose, CA). Each experiment was performed in triplicate with similar outcomes. 
 Oil Red O staining was performed using standard histologic techniques following growth 
of cells on coverslips, which were air-dried and stained with both Oil Red O and H&E.  
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2.4.6 Immunoblotting 
 Western blots were performed as previously described [4]. Antibodies used included 
those for total AMPK (Rabbit polyclonal IgG, 1:1,000, Cell Signaling Technology, Beverly, 
MA, cat. no. 2532) or phospho-AMPK (pThr172) (Rabbit monoclonal IgG, 1:2,000 Cell 
Signaling, cat. no. 4188), PDHE1 (Mouse monoclonal IgG, 1:1,000, Santa Cruz Biotechnology, 
Santa Cruz, CA. cat. no. SC-377092) or phospho-PDH (pSer293) (Rabbit monoclonal IgG, 
1:10,000, EMD Millipore, Billerica, MA, cat. no. ap1062) PDK1 (Rabbit monoclonal IgG, 
1:1,000, Cell Signaling, cat. no. 3820) and PDP2 (Rabbit polyclonal IgG, 1:500, Biovision, Inc., 
Milpitas, CA cat. no. 3944). Endogenous Myc protein was assessed with the mouse monoclonal 
antibody 9E10 (Santa Cruz) as previous described [4]. Protein loading was confirmed using a β-
actin mAb (1:2,000, Santa Cruz cat. no. 3700). Blots were developed using a SuperSignal™ 
West Pico Chemiluminescent Substrate kit (Thermo Fisher). 
2.4.7 RNA isolation and real time qRT-PCR 
RNA was isolated from 80-90% confluent cell culture wells using a Qiagen RNAeasy Mini Kit, 
according to manufacturer’s instruction (Qiagen, Inc. Chatsworth, CA). Residual DNA was 
removed using a TURBO DNA-free™ DNase Treatment and Removal Kit (Life Technologies). 
PCR reactions were conducted with Power SYBR® Green RNA-to-CT™ 1-Step Kit (Life 
Technologies), using a StepOnePlus™ Real-Time PCR System (Applied Biosystems, Inc. 
Carlsbad, CA). qRT-PCR primers were designed using Primer3web software 
(http://bioinfo.ut.ee/primer3/) and were synthesized by International DNA Technologies, Inc. 
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(Coralville, IA). Reactions were optimized such that only single bands of the predicted size were 
visualized upon gel electrophoresis (primer sequences and conditions are found in Table 2 and 
3). Each qRT-PCR reaction was performed in triplicate with variations among samples seldom 
exceeding 5%. Statistical analysis was performed using Student’s t-test.  
Table 2: Transcripts evaluated by qRT-PCR and the functions of their encoded proteins 
 
Symbol: Description (mRNA): Accession ID: Pathway
CD36 CD36 molecule (thrombospondin receptor) NM_031561 FA Transport
CPT1 carnitine palmitoyltransferase 1a, liver NM_031559 FA Transport
FABP4 fatty acid binding protein 4, adipocyte NM_053580 FA Transport
FATP1 (Scl271a) solute carrier family 27 (fatty acid transporter) 1 NM_053580 FA Transport
Acat1 acetyl-CoA acetyltransferase 1 NM_017075.2 FA Oxidation
HADHa hydroxyacyl-CoA dehydrogenase (trifunctional protein), alpha subunit NM_130826.2 FA Oxidation
HADHb hydroxyacyl-CoA dehydrogenase (trifunctional protein), beta subunit NM_133618.2 FA Oxidation
ACADL acyl-CoA dehydrogenase, long chain NM_012819 FA Oxidation
ACADM acyl-CoA dehydrogenase, C-4 to C-12 straight chain NM_016986.2 FA Oxidation
ACADVL acyl-CoA dehydrogenase, very long chain NM_012891 FA Oxidation
ACC1 acetyl-CoA carboxylase alpha NM_022193 FA Synthesis
ACC2 acetyl-CoA carboxylase beta NM_053922 FA Synthesis
ACLY ATP citrate lyase NM_016987 FA Synthesis
FASN fatty acid synthase NM_017332 FA Synthesis
Agpat1 1-acylglycerol-3-phosphate O-acyltransferase 1 NM_212458 Lipid/ cholesterol  Synthesis
Dgat1 diacylglycerol O-acyltransferase 1 NM_053437 Lipid/ cholesterol  Synthesis
Gpat1 (Gpam) glycerol-3-phosphate acyltransferase, mitochondrial NM_017274 Lipid/ cholesterol  Synthesis
Ppap2a phosphatidic acid phosphatase type 2A Nm_022538 Lipid/ cholesterol  Synthesis
Ppap2b phosphatidic acid phosphatase type 2b Nm_138905 Lipid/ cholesterol  Synthesis
Ppap2c phosphatidic acid phosphatase type 2c Nm_139252 Lipid/ cholesterol  Synthesis
HMGCR 3-hydroxy-3-methylglutaryl -CoA reductase NM_013134.2 Lipid/ cholesterol  Synthesis
PC pyruvate carboxylase NM_012744.2 Pyruvate → Acetyl CoA  Conv.
PDH (Pdha1) pyruvate dehydrogenase (lipoamide) alpha 1 NM_001004072 Pyruvate → Acetyl CoA  Conv.
PDK1 pyruvate dehydrogenase kinase, isozyme 1 BC089783 Pyruvate → Acetyl CoA  Conv.
PDP2 pyruvate dehydrogenase phosphatase isoenzyme 2 AF062741.1 Pyruvate → Acetyl CoA  Conv.
PKM1 pyruvate kinase, muscle, isoform 1 NM_053297 Pyruvate → Acetyl CoA  Conv.
PKM2 pyruvate kinase, muscle, isoform 2 NM_053297 Pyruvate → Acetyl CoA  Conv.
AceCS1 acyl-CoA synthetase short-chain family member 2 (cytoplasmic) NM_001107793 Acetate → AcCoA Conv.
AceCS2 acyl-CoA synthetase short-chain family member 1 (mitochondrial) NM_001106524 Acetate → AcCoA Conv.
cACH (Acot12) acyl-CoA thioesterase 12 NM_130747 Acetate → AcCoA Conv.
 43 
 
Table 3: Sequences and annealing temperatures for all PCR primers used for Fig. 4B. 
Symbol: Forward Primer Sequence (5' → 3') Reverse Primer Sequence (5' → 3')
Product 
Length 
(bps)
Annealing 
Temp.
CD36 ATTGGGAAAGTTATTGCGACATG AACC1GCATAGATGGACCTG 124 62
CPT1 AACACCATCCACGCCATAC GAAGTATTGAAGAGTCGCTCCC 125 62
FABP4 GATTTCCTTCAAACTGGGCG ACTTTCCATCCCACTTCTGC 119 62
FATP1 (Scl271a) GGACCCTAACTCAATGTACCAG TCAAAGCCTTCACGCTGTAG 141 62
Acat1 TGCTACACGAACTCCCATTG ATGACGTTGCCCATGTAGAC 147 62
HADHa AGGCACTCACATCCTTCGAA GAGAGCAGATGTGTTGCTGG 194 58
HADHb GCCTTTGCTGTTTCTCGAATG TGCTAACTGTGTCTTTTCCTGG 133 62
ACADL CCTGCTTGGCATCAACATTG TCTGAATGGAGGCTGAAACC 126 62
ACADM CAAGAGAGCCTGGGAACTTG CCCCAAAGAATTTGCTTCAA 154 60
ACADVL GGCTCGGATGGCTATTCTG CACTCATCTGTCACTTTCCAGG 150 58
ACC1 AAGGCTATGTGAAGGATGTGG GAGGTTAGGGAAGTCATCTGC 137 62
ACC2 TTTGAGACCCCTTTGAGCC AGTAACCCCACACGTTCTTG 148 62
ACLY TTACGAGTGATGGGAGAAGTTG AGGAAGTTGGCAGTGTGAG 149 62
FASN GGCGTACACCCAGAGCTACC GATGAGGTCCACAGCAGCAG 178 62
Agpat1 GTTCCCTCGACCTGCTTG AATGAAGATGACTCCTGCCAG 125 62
Dgat1 GACAGCGGTTTCAGCAATTAC GGGTCCTTCAGAAACAGAGAC 149 62
Gpat1 (Gpam) CTGCTCACCTTCATCCTCTTC CGTCAAGCCTCCGTCTTATG 133 62
Ppap2a GAACAGAAGGTCAGGGAAGG AACTGTAGCATGGGTCGTAAG 143 62
Ppap2b ACTACAAACACCATCCTAGCG CTTGAAGAGGTCAGACACGAAG 95 62
Ppap2c CCCTGCTAATGTCACCGAG AAGAACTGAACGGTGGGC 147 62
HMGCR GCCTCGACCTAATGAAGAGTG AGTTTGTAGGCTGGGATGTG 120 62
PC TCATCCCCAACATCCCATTC GTTAAGGGAGTCAAAGATCCGG 146 62
PDH (Pdha1) TCTGGCCTGCAAGTATAATGG CCATAGCGGTTATTCTCACAGATG 150 62
PDK1 TCGAAAACC1TTGGAAGCA ATGGGACGGAACATAAACCA 181 60
PDP2 GTTCTCCACATGGTGGCTTT ACACCTTGTCGGTCTTCCAC 226 60
PKM1 AGCATGATCAAGAAGCCACG TCTCGAGCTATCAGGTGCTG 155 58
PKM2 CTCCTTCAAGTGCTGCAGTG CATGGCCAAGTTCACACGAA 502 58
AceCS1 CCAAGAGTACCAAGGGCCAG GCAGGCCCAAGGTAAGAACT 279 58
AceCS2 GTGGCAACCGGTGAAAACTC CCTCCCATGCTTAGCCACAA 247 60
cACH (Acot12) CCACCACCTTGGAGAAGATAAA CACCGAGCAGGTGATGTAAT 215 62
 
2.4.8 Acetyl CoA assays 
Acetyl CoA was assayed using an Acetyl-Coenzyme A Assay Kit (Sigma-Aldrich cat. # 
MAK039) according to manufacturer’s instruction. Samples were isolated from fresh cell pellets, 
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lysed, and protein was quantified using a Pierce™ BCA Protein Assay Kit (Thermo-Fisher). 
Samples were deproteinized by adding 2 μl 1N perchloric acid/mg protein, and the resulting 
supernatant was neutralized by adding 3M KHCO3. Standards were quantified on a 0-1 nmol 
scale, and 50 μl of sample was added to each well. The plate was read on a SpectraMax M2 
Fluorescence Plate Reader and normalized to protein content. Analysis was performed using a 
one-way ANOVA and a post-hoc Bonferroni test of comparisons. Similar results were obtained 
when cells were simultaneously lysed and de-proteinated or when lysates were incubated on ice 
for prolonged periods. Thus results were not influenced by exogenous reactions that 
differentially depleted cells of AcCoA. 
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3.0  C-MYC AND AMPK CONTROL CELLULAR ENERGY LEVELS BY 
COOPERATIVELY REGULATING MITOCHONDRIAL STRUCTURE AND 
FUNCTION 
3.1 INTRODUCTION 
c-Myc (Myc) oncoprotein de-regulation occurs in a substantial fraction of human cancers and 
alters numerous transformation-associated phenotypes [14, 129-131]. Myc over-expression 
exerts marked effects on proliferation, survival, differentiation and biomass accumulation as a 
result of global changes in the expression of RNAs regulated by all 3 RNA polymerases [14, 23, 
36, 132, 133]. Together, these changes reflect Myc’s role as a general transcription factor that 
broadly modulates the levels of most, if not all, genes [134-137]. The molecular mechanisms by 
which Myc mediates these effects on transcription are varied and highly dependent upon the 
degree of Myc over-expression, the identity of various co-factors and the type of cell in which 
Myc de-regulation occurs [36, 136, 138, 139]. 
Metabolic changes are among the most universal consequences of aberrant Myc 
expression [140]. Myc induces the majority of genes encoding glycolytic enzymes and thus is 
important for promoting the Warburg effect, defined as the persistence of glycolysis under 
aerobic conditions [19, 23]. Rather than being a result of defective mitochondrial function and 
confined to tumor cells as originally proposed [20] , the Warburg effect also occurs in rapidly 
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proliferating normal cells [19, 141]. It thus seems likely that the major purpose of the Warburg 
effect is to supply anabolic precursors such as ribose sugars, nucleotides and select amino acids 
whose production must be increased and carefully coordinated with the doubling of biomass that 
accompanies replication [19, 21]. 
In addition to enhancing glycolysis, Myc re-programs oxidative phosphorylation 
(Oxphos) and supports the structural and functional integrity of mitochondria and the electron 
transport chain (ETC) via the direct up-regulation of certain mitochondrial-specific transcription 
factors [4, 17]. This has the effect of increasing the production of ATP needed to support 
macromolecular synthesis during proliferation [4, 37, 140]. Concurrently, Myc promotes the 
uptake and β-oxidation of exogenous fatty acids, which serve as an alternate source of acetyl 
CoA that is otherwise provided in lower yield by the re-programmed glycolytic pathway [11, 
142, 143]. The transport of glutamine and its conversion to glutamate and α-ketoglutarate are 
also under stringent positive Myc control and provide yet another source of TCA cycle 
intermediates [23, 140, 144]. In support of all the above findings, myc-/- fibroblasts show severe 
structural and functional ETC defects, low rates of glycolysis and Oxphos and profound ATP 
depletion [4].  
The regulation of both anabolic and catabolic processes is also a property of AMP-
activated protein kinase (AMPK), a Ser/Thr kinase that is activated in response to a decrease in 
the ATP: AMP ratio [73, 145, 146]. AMPK is a trimeric enzyme whose γ-regulatory subunit 
undergoes a conformational change upon binding AMP that allows phosphorylation of the α 
catalytic subunit’s Thr172 residue by the upstream kinase and putative tumor suppressor LKB [73, 
147, 148]. The consequences of this activating phosphorylation event include a general inhibition 
of energy-consuming processes such as protein and fatty acid synthesis and proliferation [73] 
 47 
 
and an increase in energy-generating process such as glycolysis and Oxphos [73, 149, 150]. 
Collectively, these cooperate to ensure the timely restoration of a positive ATP: AMP balance 
and allow the resumption of proliferation. Thus AMPK and Myc appear to enhance energy-
generating processes while simultaneously exerting opposing effects on energy-consuming 
processes. How these are regulated and coordinated remain largely unexplored.  
We have recently observed that the ATP-depleted state of myc-/- fibroblasts is associated 
with chronic phosphorylation-dependent AMPK activation whereas Myc re-expression restores 
normal ATP levels and suppresses AMPK [11]. These observations suggest that Myc and AMPK 
engage in a form of cross-talk, the purpose of which is to optimize proliferation and energy 
production while balancing Oxphos and the Warburg effect. In the current work, we have 
investigated how and the extent to which such communication occurs as well as how 
compromising AMPK function affects Myc’s metabolic phenotype.  
3.2 RESULTS 
3.2.1 AMPK is necessary for Myc-stimulated mitochondrial biogenesis and function 
To investigate the role for AMPK in mediating mitochondrial structure and function in the basal 
state and in response to Myc activation, we stably expressed the MycER fusion protein [151]. In 
both cases, the cells were of identical size and grew at similar rates (not shown). In response to 
the estrogen analog 4-hydroxytamoxifen (4HT), both cell types increased their rates of glycolysis 
although basal levels were higher in KO cells (Fig.8A and Suppl. Fig. 25A and B). Cells had very 
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little glycolytic reserve when simulated by oligomycin (Suppl. Fig. 25A and B.), implying that all 
lines were operating at near maximal glycolytic capacity. In contrast, KO cells failed to up-
regulate Oxphos in response to MycER activation (Fig. 8B and Suppl. Fig. 25C and D). Thus, at 
least in MEFs, basal levels of glycolysis and Myc’s up-regulation of Oxphos are AMPK-
dependent. Very little oxygen was consumed for non-mitochondrial respiration in any of the cell 
lines (Suppl. Fig. 25C and D), indicating that no respiration was occurring as a result of side 
reactions attributable to factors such as peroxisomal oxidation. The trends of Oxphos and 
glycolysis recorded for basal respiration (Fig. 8A and B) continued throughout the mitochondrial 
stress test (Suppl. Fig. 25). 
To determine whether KO cells’ failure to increase Oxphos in response to MycER 
activation was indicative of a more global degree of mitochondrial unresponsiveness, we 
quantified changes in mitochondrial mass and production of reactive oxygen species (ROS), both 
of which are normally increased by Myc over-expression [4, 17, 152]. MycER activation in WT 
cells was accompanied by a reproducible 20-30% increase in mitochondrial mass as evidenced 
by staining with both MitoTracker Green and Acridine orange 10-nonyl bromide (NAO) as well 
as by an increase in ROS [4, 11] (Fig. 8C). The likely mitochondrial origin of ROS was also 
confirmed by MitoSox staining, which detects superoxide (O2
-). The marked attenuation or 
absence of these responses in KO cells indicated that, in addition to Oxphos, other Myc-
regulated mitochondrial responses are also AMPK-dependent.  
We assessed the bio-energetic consequences of the above differences by measuring ATP 
levels in WT and KO MEFs during the course of MycER activation and subsequent inactivation. 
Basal (day 0) ATP levels in KO MEFs were routinely 30-40% lower than those in WT MEFs 
(Suppl. Fig. 24B.). In both cases, ATP levels declined within 24 hr. of MycER activation, 
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remained low throughout the ensuing 4 days and then normalized within 48 hr. of 4HT removal. 
However, the degree of ATP depletion in KO MEFs was greater than in WT MEFs, particularly 
after accounting for the lower basal levels in the former cells (Fig. 8D and Suppl. Fig. 24B.). 
Concurrent immuno-blotting performed on WT cells showed an inverse relationship between 
AMPK activation and ATP levels (Fig. 8E) as well as the persistence of AMPK activation for at 
least 4 additional days beyond the time at which ATP levels had returned to pre-treatment levels. 
This suggested that factors other than adenosine nucleotide levels might also be contributing to 
AMPK activation. Because ROS can also activate AMPK [153-156], we repeated the above 
experiment in the presence of the anti-oxidant N-acetylcysteine (NAC) at a concentration that 
reduced ROS in 4HT treated cells (Fig. 8F). Under these conditions, AMPK phosphorylation 
was markedly attenuated (Fig. 8G). AMPK’s activation beyond the point of ATP normalization 
also correlated with the persistence of high ROS following 4HT removal (Fig. 8H). Thus, in the 
face of Myc deregulation in WT cells, the prolonged activation of AMPK is likely to be a 
consequence of both ATP depletion and the persistence of ROS.  
ETC structure and function are highly Myc-responsive in myc-/- rat fibroblasts [4]. To 
determine whether these properties were also AMPK-dependent in MEFs, we used blue native 
gel electrophoresis (BNGE) to evaluate the integrity of each of the 4 multi-protein components 
of the ETC (Complexes I-IV) along with the monomeric and dimeric forms of Complex V (ATP 
synthase) termed Vm and Vd, respectively. BNGE can also resolve ETC “supercomplexes” (SCs), 
which are comprised primarily of higher order associations of Complexes I, III and IV in varying 
stoichiometries and are believed to promote more efficient ETC function [157, 158]. Individual 
BNGE components of Complexes I-V from WT and KO MEFs were similar in appearance and 
 50 
 
did not change appreciably following Myc induction (Fig. 9A). In contrast, at least 5 SCs (SCa-
SCe) and Complex Vd, readily seen in WT MEFs, were reduced or absent in KO cells (Fig. 9A). 
Activity assays for individual complexes better emphasized the differences between WT 
and KO MEFs both prior to and following MycER activation (Fig. 9B and C & Suppl. Fig. 26). 
For example, neither Complex I nor Complex Vm activity was significantly altered under either 
condition whereas Complex Vd was virtually absent in KO cells regardless of MycER status. In 
contrast, Complex III activity was decreased in KO cells regardless of MycER status whereas 
Complex IV decreased only in response to MycER activation. Consistent differences were also 
observed in the enzymatic activities of several SC components (Fig. 9B and Suppl. Fig. 26). 
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ETC structure and function are highly Myc-responsive in myc-/- rat fibroblasts [4]. To 
determine whether these properties were also AMPK-dependent in MEFs, we used blue native 
gel electrophoresis (BNGE) to evaluate the integrity of each of the 4 multi-protein components 
of the ETC (Complexes I-IV) along with the monomeric and dimeric forms of Complex V (ATP 
synthase) termed Vm and Vd, respectively. BNGE can also resolve ETC “supercomplexes” (SCs), 
which are comprised primarily of higher order associations of Complexes I, III and IV in varying  
Figure 8: Energy-generating pathway responses to MycER activation. (A) Baseline glycolysis 
measurements normalized to cell number at conclusion of the experiment. WT and KO MEFs were either 
untreated or exposed to 4HT for 7 days to activate MycER (+Myc). Glycolysis was quantified by measuring 
extracellular acidification rates (ECAR). Bars represent the mean of quadruplicate measurements ± 1 
standard error of the mean (SEM). (A) Baseline Oxphos measurements. Oxygen consumption rates (OCR) 
were simultaneously quantified on the same samples described in (A). See Suppl. Fig. 25 for additional details 
regarding the glycolytic and Oxphos responses of these cells. (C) Changes in mitochondrial mass and ROS 
production. Untreated or 4HT-treated (7 days) WT and KO cells were stained with MitoTracker Green or 
NAO to independently assess mitochondrial mass. In parallel experiments, cells were also stained with CM-
H2-DCFDA to quantify total ROS production or with MitoSOX to specifically quantify the production of 
mitochondrial-derived superoxide. In all cases, typical flow diagrams are depicted. The numbers in the upper 
left portion of each panel indicate the mean ratios of fluorescence intensities between 4HT-treated and 
control, untreated cells from at least 4 independent experiments ± 1 SEM (D) ATP levels in response to 
MycER activation and inactivation. ATP levels were measured at baseline (Suppl. Fig. 24), after the indicated 
periods of exposure to 4HT (+) and its subsequent removal (-). Each value shown depicts the mean of 
quadruplicate samples ± 1 SEM. Basal (day 0) ATP levels in untreated KO cells were routinely found to be 
30-40% lower than those of their WT counterparts (Suppl. Fig. 24) but are normalized here to 100% in both 
cell types for easier comparison. After taking the day 0 differences into account, KO MEFs also showed 
significantly lower ATP levels on days +1-4 compared to their WT counterparts (P < 0.02) (Suppl. Fig. 24). 
(E) AMPK response to MycER activation/inactivation in WT MEFs. WT cells were exposed to 4HT for the 
indicated times. On day 4, 4HT was remov d (-4HT) and cell  c tinued to be cultured in its ab ence for an 
additional 6 days. Total AMPK and pAMPK were assessed by immunoblotting at the time points shown. (F) 
MitoSox staining as described in Fig. 1C after 2 days of 4HT treatment. In the concurrent presence of 1 mM 
NAC, no significant change in ROS was observed. (G) AMPK activation is suppressed by NAC. WT cells 
were exposed to 4HT in the absence or presence of 1 mM NAC. Total and phospho-AMPK were assessed by 
immuno-blotting as described for panel (E). (H) Persistence of ROS following MycER inactivation. WT cells 
ere exposed to 4HT for 4 days at which point ROS were quantified using MitoSox as described i  (C). 4HT 
was then removed with ROS levels again being determined 2 and 4 days later (days 6 and 8). Numbers in 
upper left corner indicate the ratio of mean fluorescence intensity of 4HT-treated (red curves) to non-4HT-
treated MEFs (black curves).  
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Specifically, SCa activity was lower in KO cells, irrespective of Myc’s activation status, 
whereas changes in the remaining SCs were detected only in KO cells following MycER 
activation (Suppl. Fig. 26.). Complex II activity was slightly higher in KO cells but increased 
significantly following MycER activation whereas no change was evident in WT cells (Fig. 9C). 
Thus, while MycER activation had little to no discernible effect on the ETC enzymatic activity 
of WT cells, it had a pronounced effect in KO cells. This provided further evidence that AMPK 
is needed to maintain normal mitochondrial function both in the basal state and in response to 
Myc deregulation. 
3.2.2  Transcriptional and enzymatic profiling reveals co-operativity between Myc and 
AMPK in modulating metabolic function 
Given AMPK’s influence on both basal and Myc-dependent mitochondrial functions, we 
performed a small-scale gene expression survey of WT and KO cells. We examined 30 
transcripts whose encoded proteins comprise key elements of glycolysis, the TCA cycle and 
other pathways relevant to energy regulation and mitochondrial function. Significant differences 
were noted between WT and KO MEFs with 19 transcripts being relatively under-expressed in 
the latter cells, 3 over-expressed and 8 unchanged (Fig. 10A and Suppl. Fig. 27.). Following 
MycER activation, WT cells showed significant up-regulation of 19 transcripts and down-
regulation of 9, in a pattern that generally correlated with the increased rates of glycolysis and 
Oxphos (Fig. 8A and B). In contrast, the transcriptional response to MycER activation in KO 
cells was markedly different with only 12 transcripts demonstrating any significant change 
(Fisher’s Exact test, P < 0.0001). Moreover, 19 of the 28 Myc-responsive transcripts in WT cells 
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were expressed discordantly in KO cells. Particularly noteworthy examples included transcripts 
for glucose 6-phophatase (G6P); the M2 isoform of pyruvate kinase (PKM2); isocitrate 
dehydrogenase 2 (IDH2) and each of the 4 subunits of succinate dehydrogenase (SDHa-d), 
which comprise Complex II of the ETC. Collectively, these studies indicate that AMPK 
functions to coordinate the transcriptional activity of the majority of transcripts examined herein. 
both in their basal state and in response to MycER activation. 
The actual enzymatic activities of several mitochondrial oxidoreductases encoded by the 
above transcripts were also discordant (Fig. 10B). For example, basal activity of NADH-
dependent isocitrate dehydrogenase (IDH) was higher in WT cells and increased in response to 
Myc activation whereas it declined in KO cells. A different pattern was observed in the case of 
glycerol 3-phosphate dehydrogenase (G3PDH), which was lower in basal-state KO cells than in 
WT cells; it also failed to respond to Myc over-expression in contrast to WT cells where its 
activity declined. That not all enzymatic activities were altered as a consequence of the loss of 
AMPK was evidenced by malate dehydrogenase (MDH) levels, which were identical in basal-
state WT and KO cells and decreased commensurately in response to Myc over-expression. As is 
commonly the case for many transcripts and their encoded proteins and for individual subunits of 
multi-protein complexes [159-165] the measured enzyme activities did not closely correlate with 
the relevant transcript levels shown in Fig. 10A. Collectively, these findings are consistent with 
those depicted in Fig. 9 and Suppl. Fig. 26 and support the notion that some TCA cycle enzymes 
rely upon AMPK either for their basal function or their proper response to Myc over-expression.  
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Figure 9: Structural and functional properties of ETCs complexes in WT and KO cells. (A) Analysis 
of ETC complexes by non-denaturing BNGE. Mitochondria were purified from triplicate cultures of the 
indicated cell types and resolved by BNGE. At least 5 individual supercomplexes (SCa-e) could be resolved. 
Note that Complex V (ATP synthase) is composed of both monomers (Vm) and dimers (Vd). (B) In situ 
enzymatic assays for Complex I (NADH ubiquinone oxidoreductase) plus supercomplexes, Complex Vm and 
Vd (ATPase), Complex III (decylubiquinol cytochrome c oxidoreductase) and Complex IV (Cytochrome c 
oxidase). Each assay was performed in triplicate on at least 2 occasions, with representative results being 
shown here (also see Suppl. Fig.26.). (C) Complex II (succinate dehydrogenase) activity was quantified on 
lysates prepared from purified mitochondria as its in situ assessment was found to be unreliable. The results 
shown in the histogram represent the mean of triplicate enzymatic determinations ± 1 SEM. See Suppl. Fig. 
26 for quantification of all enzymatic measurements. 
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The above studies suggested that both AMPK and Myc might be controlling more 
proximal determinants of Oxphos. We therefore conducted a qRT-PCR-based survey for 20 
known regulators of mitochondrial structure and function including those involved in DNA 
replication and transcriptional maintenance [166-169]. 13 of the tested transcripts were found to 
be differentially expressed between WT and KO cells, with 10 up-regulated in KO cells and 3 
down-regulated (Fig. 10C and Suppl. Fig. 28). Following MycER activation, significant 
additional differences were noted. For example, in contrast to the up-regulation of 6 transcripts 
and the down regulation of 2 transcripts in WT cells in response to MycER activation, KO cells 
responded anomalously, with only 3 transcripts up-regulated and 9 down-regulated. Within these 
subsets of Myc-responsive transcripts, the largest differences in WT cells included a 2.4-fold 
increase in NSUN4 and a 4.6-fold increase in UCP2 whereas in KO cells, Mterf1 and UCP2 
transcripts were reduced by 3.4- and 3.9-fold, respectively. These results indicate that AMPK 
and Myc cooperate to ensure the proper coordination of numerous factors that supervise 
mitochondrial-specific DNA replication and transcription.  
Aiming to identify changes in the relative abundance of mitochondrial proteins between 
WT and KO MEFS both prior to and in response to de-regulated Myc over-expression, we 
applied a differential mass spectrometry (dMS) workflow to a set of enriched mitochondrial 
samples isolated from WT and KO cells either prior to or following an 8 day period of Myc 
activation [170, 171]. We reliably identified and quantified the relative abundance of 345 
mitochondrial proteins as annotated in the DAVID Bioinformatic Database and/or the Mouse 
MitoCarta Inventory of Mammalian Mitochondrial Genes. High-resolution liquid-
chromatography Fourier transformed mass spectrometry was used to detect these proteins by 
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comparing the relative intensity of individual high-resolution isotope distributions across each of 
the analyzed samples (S6 Fig.). We observed a 24% higher average intensity of all mitochondrial 
peptides in KO samples both with and without Myc over-expression 2-way analysis of variance 
(ANOVA) p value of 0.002 compared to WT samples, despite the overall abundance of non-
mitochondrial proteins being otherwise identical. This may be caused by a slightly higher purity 
of mitochondria in the former samples.  
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It could also be due to a slightly greater overall mitochondrial mass in KO cells, although this 
was not observed by staining with NAO or MitoTracker dyes (Fig. 8C).  
3.2.3 Differences in mitochondrial proteomes of WT and KO MEFs 
Using a conservative q-value cutoff of 0.05, we determined the abundance of 28 proteins 
to be significantly different between WT and KO MEFs prior to MycER activation with 22 being 
more abundant in WT cells and 6 more abundant in KO cells (Fig. 11A and C, red circle). 
Following 8 days of MycER activation, 31 mitochondrial proteins were altered in WT cells, with 
17 up-regulated and 14 down-regulated (Fig. 11B and C, green circle). 8 of these (26%) were 
also members of the group depicted in Fig. 11A that were thus also AMPK-responsive (Fig. 11C, 
yellow). In contrast, only 6 proteins were found to be Myc-responsive in KO MEFS (Fig. 11D 
and C, blue circle). Of these, Tamm41, Aldh1l2, and Clic4 were also influenced by Myc in WT 
cells (Fig. 11C, cyan). The response of 8 proteins to Myc over-expression was also found to be 
Figure 10: Transcriptional and enzymatic differences between WT and KO MEFs. (A) 
Transcriptional profiling. Real-time qRT-PCR was performed in triplicate for each of the indicated 
transcripts. The levels of each transcript determined in WT cells were arbitrarily set to 1 as indicated by the 
white boxes. See Suppl. Fig. 27. for the actual numerical values and p values for individual determinations. 
(B) Functional assays for oxidoreductases. Each bar represents the mean of biological triplicate 
determinations ± 1 SEM performed on purified mitochondrial lysates. Note that the results for SDH are the 
same as those presented in Fig. 9C. (C) qRT-PCR profiling of transcripts involved in the regulation of 
mitochondrial DNA replication and maintenance, transcription and function. Analyses were performed as 
described for (A). See Suppl. Fig. 28 for the actual numerical differences and p values for individual 
determinations. 
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discordant and having a significant “interaction effect” (Fig. 11E), with 5 of them (Prdx4, Sqrdl, 
Slc16a1, Clic4 and Ptrf) changing their abundance in opposite directions in WT vs. KO cells, and 
the other 3 (Cyb5a, Echs1, and Slc25a13) only being affected by Myc over-expression in WT 
cells. Together, these findings indicate that approximately 15% of evaluable mitochondrial 
proteins (i.e. 51 of 345) can be conservatively described as being regulated by AMPK and/or 
Myc and that much of the long-term mitochondrial proteomic adaptation to Myc deregulation is 
AMPK-dependent.  
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3.2.4 Differential redox states of WT and KO cells 
The differential activities of the ETC, mitochondrial dehydrogenases and the glycerol 
phosphate shunt (represented by G3PDH), as well as altered ROS production, might be expected 
to exert distinct effects on the redox states of WT and KO cells [172-175]. We tested this directly 
by stably targeting a redox-sensitive form of green fluorescent protein (roGFP2) [176, 177] to 
either the cytoplasm or mitochondrial matrix of WT or KO cells (Fig. 12A). In control 
experiments, exposure of roGFP-expressing WT or KO cells to H2O2 markedly increased the 
ratio of oxidized:reduced roGFP, irrespective of its subcellular location (i.e. roGFP-cyto versus 
roGFP-mito) whereas treatment of the same cells with DTT alone or with H2O2 followed by DTT 
shifted the ratio to that of a more reduced state (Fig. 12B and C and data not shown). The 
Figure 11: Mitochondrial proteomic profiling. LC-MS/MS reliably identified and quantified 
345 proteins with mitochondrial localization from representative peptides in each of the 4 
experimental groups. (A) Differential protein expression between WT and KO MEFs prior to 
MycER activation. (B) Differential protein expression in WT MEFs prior to or following an 8 day 
period of MycER activation. (C) Venn diagram of protein overlap between WT and KO MEFs, WT 
vs. WT+Myc and KO versus KO+Myc. Each of the protein subsets within these 3 groups are 
enclosed by red, green and blue circles and correspond to the proteins denoted in panels (A), (B), and 
(D), respectively. All proteins were selected by a conservative q-value of <0.05 by 2-way analysis of 
variance (two way ANOVA). (D) Differential protein expression in KO MEFs prior to or following 8 
days of Myc over-expression. (E) Quantification of 8 proteins that showed a significant interaction 
effect by both AMPK and Myc overexpression. 
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responses of WT and KO cells to these extreme stresses were indistinguishable (not shown) and 
defined the limits within which supra-physiologic changes in the redox state can occur.  
Quantification of oxidized and reduced roGFP2 in the mitochondrial and cytoplasm of 
WT and KO cells prior to or following MycER activation for 24 hr. showed both compartments 
to be relatively reduced (Fig. 12C) and in agreement with previous findings in other cell types 
[176, 178-180] However, in the basal state, KO cells showed a 28% greater degree of 
cytoplasmic oxidation (p<0.001) and a 6% greater degree of mitochondrial oxidation than WT 
cells (p<0.001). MycER activation in WT cells led to a further 9% increase in cytoplasmic 
oxidation (p=0.0004) and an 8% increase in mitochondrial reduction (p<0.0001). Finally, 
although an identical 9% increase in oxidation occurred in the cytoplasm of KO cells following 
MycER activation (p=0.002), no change occurred in their mitochondrial redox state (p=0.2). 
These results are consistent with those of our preceding studies indicating that AMPK and Myc 
cooperate to promote mitochondrial biogenesis and function. They further indicate that 
mitochondrial structural and functional alterations mediated by Myc de-regulation are associated 
with significant differences in the redox state of the mitochondrial matrix.  
3.2.5 AMPK influences Myc-mediated re-programming of steady-state metabolites 
We used high performance liquid chromatography-electrospray ionization tandem mass 
spectrometry (HPLC-ESI-MS/MS) to quantify steady state levels of a select group of metabolites 
in WT and KO cells prior to or following MycER activation. The metabolites were chosen to 
reflect relevant glycolytic and TCA cycle intermediates, anabolic substrates and determinants of 
cellular redox and energy status. Significant differences were seen between WT and KO cells 
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prior to MycER activation with the most striking being the generally lower levels of glycolytic 
substrates and higher levels of TCA cycle substrates in KO cells (Fig. 13A). This suggested that 
the higher glycolytic rate of KO cells (Fig. 5A) might be responsible for depleting some of the 
intermediates in this pathway whereas defects in the ETC might allow a buildup of TCA 
intermediates. Higher levels of nucleosides and deoxynucleosides in KO cells were consistent 
with the previously report of AMPK being a negative regulator of the Warburg effect [79], which 
could also explain the relative depletion of glycolytic substrates if they were being shunted into 
Warburg-related pathways. The modestly higher levels of AMP and ADP in WT cells in 
response to MycER activation, together with reduced ATP levels (Fig. 8D and Suppl. Fig. 24B), 
is likely sufficient to account for any activation of AMPK that is not otherwise attributable to 
ROS (Fig. 8E). In contrast, the even higher levels of AMP in KO cells, both prior to and 
following MycER activation, can likely be explained by the inability to normalize ATP and 
AMP in AMPK’s absence.  
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MycER activation was also associated with other distinct metabolite re-distribution 
patterns. Most notably WT cells showed an overall reduction of TCA cycle intermediates that 
most likely reflected their rapid consumption in response to increased mitochondrial mass and 
metabolic activity (Figs. 8B and C) and/or a reduction of acetyl CoA entering the TCA pathway, 
perhaps as a result of the Warburg effect as noted above. In contrast, changes in TCA cycle 
intermediate levels were less pronounced in KO cells following MycER activation, which was 
again consistent with their generalized mitochondrial unresponsiveness (Figs. 8A and C). Despite 
differences in the basal glycolytic intermediate content of WT and KO cells, the redistribution of 
these molecules was somewhat similar in response to MycER activation, with the exception of 
fructose-1,6-bisphospate. For example, both cell types showed significant increases in 
intracellular glucose content, likely reflecting the known propensity for Myc to increase glucose 
transport [19, 23]. Phosphoenolpyruvate (PEP) was also markedly increased in both cell lines 
Figure 12: Redox states in cytoplasmic and mitochondrial compartments of WT and KO MEFs. (A) 
Live cell confocal images of WT MEFs stably expressing roGFP-mito and roGFP-cyto demonstrating specific 
mitochondrial and cytoplasmic localization, respectively. Nuclear counter-staining was with Hoechst 3334. 
(B) Live cell confocal microscopy of KO MEFs expressing roGFP-mito. Cells were untreated or exposed to 1 
mM H2O2 or 10 mM DTT for 30 min prior to obtaining images. (C) Quantification of redox differences 
between WT and KO MEFs. Monolayer cultures were grown for 24 hr. in the absence or presence of 4HT. 
Flow cytometry was then used to quantify the mean fluorescence ratios of oxidized and reduced roGFP. Each 
bar represents the average ± 1 SEM of mean fluorescence intensities obtained from 3 independent plates of 
cells. *= P<0.001. Similar results were independently obtained in 2 repeat experiments as well as in 2 
experiments performed following a longer period of MycER activation (7 days, not shown). The 4 bars on the 
right represent control experiments in which WT cells expressing roGFP-cyto were exposed under the 
conditions described in (B). These values define the maximal possible degree of oxidation or reduction 
capable of being achieved under the most extreme conditions. 
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(Fig. 13A). Other notable differences included a generalized decrease in the free amino acid 
content of WT cells in contrast to either no change or an increase in KO cells. Both cell types 
also up-regulated nucleoside and deoxynucleoside pools in response to MycER activation. 
Finally, and consistent with their more highly oxidized cytoplasm (Fig. 12C), KO cells contained 
higher levels of glutathione disulfide (GSSG), which is the oxidized form of glutathione (GSH) 
[181]. Moreover, both cell types increased their GSSG:GSH ratio in response to Myc activation 
in a manner that closely mirrored the accompanying changes in cytoplasmic roGFP fluorescence 
(Fig. 13C). 
To investigate potential mechanism(s) underlying some of the differences in metabolite 
distribution between WT and KO cells, we next examined pyruvate dehydrogenase (PDH) and 
pyruvate kinase (PK). These enzymes are notable for catalyzing 2 of the 3 irreversible steps in 
glycolysis (∆G = -7.5kcal each) and are subject to complex and multi-factorial positive and 
negative regulation (Fig. 13B) [26, 182, 183]. For example, in addition to modifications such as 
acetylation and oxidation and feedback regulation by adenosine nucleotides, PDH is also tightly 
controlled post-translationally by the inhibitory Ser/Thr kinase pyruvate dehydrogenase 1 
(PDK1) and the stimulatory phosphatase pyruvate dehydrogenase phosphatase 2 (PDP2) both of 
which regulate the level of Ser293 phosphorylation of the PDH E1 subunit (PDHE) [116, 184]. 
PK activity is typically regulated by changes in the abundance of its PKM1 and PKM2 isoforms, 
with the expression of the latter tending to correlate with high rates of proliferation [26, 182]. 
This, together with the significantly higher Km of PKM2 is believed to account for the 
accumulation of substrates upstream of PEP that drive the Warburg effect and limit the 
availability of glycolytically-derived acetyl CoA for usage by the TCA cycle [26, 185]. 
Additionally, both PK isoforms are also subject to multiple and non-mutually exclusive types of   
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Figure 13: Metabolite profiling of WT and KO MEFs. (A) HPLC-ESI-MS/MS quantification of select 
metabolites in MEFs prior to or following MycER activation for 8 days. Each box represents the average of 
biological quadruplicate samples. Levels of each depicted metabolite were arbitrarily set to 1 in WT cells 
(white boxes). (B) Enzymatic and metabolite feedback control of PDH and PK. Note the control of the former 
by the stimulatory phosphatase PDP2 and the inhibitory kinase PDK1 as well as additional indirect and 
direct control of PDH and PK, respectively by ATP and ADP. PDH and PK enzyme activities (C and D, 
respectively) and acetyl CoA assays (E) were performed on whole cell extracts as previously described in 
Chapter 2. 
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post-translational modification; allosteric feedback by metabolites such as ATP, ADP and 
fructose-1,6,-bi-phosphate; and changes in enzyme dimer: tetramer ratios [29, 186]. 
Immunoblotting of WT and KO cell extracts both prior to and after MycER activation 
showed minimal changes in protein levels of PDHE, PKM1 and PKM2 (Suppl. Fig. 30.). A 
reduced amount of pPDHE1 was observed in KO cells although it did not change appreciably in 
response to MycER activation. Decreases in PDK1 and increases in PDP2 occurred in WT and 
KO cells following MycER activation. 
Changes in the enzymatic activities of PDH and PK were more revealing. As seen in Fig. 
13C, PDH activity was significantly higher in KO cells but only in the basal state. PK activity 
was also higher in KO cells, and increased even further in in KO cells in response to MycER 
activation, but decreased in WT cells after MycER activation (Fig. 13D). Together, these results 
are consistent with the idea that Myc and AMPK cooperatively regulate the switch between 
glycolysis and Oxphos by coordinating the activities of two critical and irreversible glycolytic 
steps that are important for determining the availability of acetyl CoA and its use by the TCA 
cycle. Interestingly, despite the above-noted differences in PDH and PK activities between WT 
and KO cells, the absolute abundance of acetyl CoA, either in the basal state or in response to 
MycER activation was quite similar in WT and KO cells (Fig. 13E).  
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3.3 DISCUSSION 
3.3.1 Mitochondrial responses to Myc over-expression are AMPK-dependent 
Considerable evidence supports the idea that Myc and AMPK influence similar cellular and 
biochemical functions although via different pathways and often for different purposes (Fig. 14). 
For example, both promote glucose uptake, glycolysis, mitochondrial biogenesis and Oxphos [4, 
17, 23, 73, 145, 146, 149, 150]. In response to Myc over-expression, these activities are believed 
to provide the crucial anabolic precursors and ATP needed to support the highly energy-
consuming process of biomass accumulation [19, 21]. In fact, much of the increased glycolytic 
flux mediated by Myc over-expression is currently viewed as being directed towards promoting 
the Warburg effect and anabolism while being diverted away from mitochondrial consumption 
(Fig. 14 and [23, 38, 141]). Similarly, TCA cycle intermediates, some of which originate from 
extra-glycolytic sources such as glutaminolysis and fatty acid β-oxidation, may also be directed 
into non-mitochondrial biosynthetic pathways in a Myc-dependent manner [11, 23, 37]. 
Moreover, Myc’s enhancement of ETC activity increases ATP production and its rate of turnover 
to support anabolism and proliferation [4]. In contrast, AMPK activation occurs in response to 
critical energy shortages, which suppress energy-consuming processes while activating energy-
generating ones [73]. Thus AMPK activation opposes the Warburg effect thereby reducing the 
flow of glycolytic substrates into anabolic pathways and maximizing their eventual conversion 
into acetyl CoA for utilization by the TCA cycle [73, 79]. The cross talk between Myc and 
AMPK is readily apparent in myc-/- fibroblasts, which constitutively express high levels of 
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phosphorylated AMPK as a consequence of their being unable to restore their ATP deficit by up-
regulating glycolysis or Oxphos [11].  
 
 
The failure of KO cells to increase Oxphos in response to MycER activation, while 
retaining a relatively normal glycolytic response (Figs. 1A and B), appears to be the result of a 
Figure 14: Model depicting the relationship between Myc and AMPK (yellow boxes) demonstrating 
their influence over common metabolic functions, although sometimes in opposite ways and for different 
purposes. Communication between Myc and AMPK may occur via at least 2 distinct and semi-autonomous 
routes with different initiating events and consequences. The first involves the activation of AMPK via Myc-
mediated depletion of cellular ATP stores arising as a consequence of energy-consuming anabolic processes 
such as proliferation (-ATP, blue box) (Fig. 8D and Chapter 2). The second involves AMPK activation via 
ROS generated from increases in mitochondrial metabolism or cytoplasmic signaling pathways. It is notable 
that, in the first case, AMPK activation is dependent upon ATP depletion whereas, in the second case, AMPK 
activation occurs regardless of ATP status. AMPK activation via ROS can thus anticipate impending ATP 
depletion and prevent or limit this by down-regulating ATP dependent processes. In the face of a pre-existing 
ATP deficit, other functions of AMPK such as the promotion of proliferative arrest might tend to override 
the effects of Myc over-expression. In contrast, activation of AMPK by ROS might reinforce an already 
highly proliferative and ATP-replete state by promoting pro-anabolic functions such as glycolysis and 
Oxphos without necessarily compromising proliferation. 
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more generalized mitochondrial dysfunction that includes an inability to accrete mass, to 
generate ROS, to maintain normal levels of TCA cycle intermediates and to properly regulate 
ETC function (Figs. 1C, 2 and 3). Perhaps not surprisingly, these abnormalities were collectively 
associated with lower levels of ATP and higher levels of AMP, both in the basal state and in 
response to MycER activation (Fig. 8D and 13A, & Suppl. Fig. 24). The increased basal 
glycolytic rate of KO cells (Fig. 8A), may therefore only reflect a partially effective 
compensatory mechanism aimed at correcting their relative energy deficit (Fig. 8D and Suppl. 
Fig. 24B). Because Myc’s promotion of the pro-anabolic and proliferative states is tightly  
coupled to increased mitochondrial mass and function [4], it seems possible that the previously 
reported transformation-resistance of AMPK-deficient cells is a consequence of their ATP deficit 
and/or their mitochondrial unresponsiveness, despite their ability to up-regulate aerobic 
glycolysis (Fig. 8A) [79, 187-189]. This idea has particular appeal given that numerous 
proliferative signaling pathways converge upon Myc whose uninterrupted expression is critical 
for maintaining tumor cell proliferation in vivo [122, 190, 191]. Thus, the seemingly paradoxical 
finding that AMPK suppression enhances proliferation yet confers transformation-resistance 
[187-189] can perhaps best be explained by postulating that the relative importance of AMPK on 
metabolism and proliferation may vary depending on Myc’s level of expression and/or 
deregulation. Over-expression of Myc might therefore cooperate with AMPK’s tendency to 
enhance glycolysis and Oxphos while simultaneously overriding its suppression of proliferation 
and the Warburg effect. This could be particularly useful under the most highly proliferative 
conditions where high anabolic demands could compromise and perhaps outstrip ATP stores 
(Fig. 8E). AMPK activation might then cooperate with Myc to enhance both glycolysis and 
Oxphos without exerting deleterious effects on proliferation and its reliance on the Warburg 
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effect. The relative resistance of AMPK-depleted cells to transformation could therefore reflect 
the cooperative nature of AMPK and Myc on these metabolic pathways.  
Our transcriptional, proteomic and functional profiling underscores the significant 
differences that distinguish WT and KO cells both in the basal state and in response to Myc de-
regulation (Fig. 10 and 11). Indeed, we note that more genes serving as regulators of 
mitochondrial-specific functions such as DNA replication, maintenance of genomic integrity and 
transcription were found to be AMPK-responsive than Myc-responsive (13 of 20 vs. 8 of 20) 
(Fig. 10C). It seems plausible that the widespread abnormalities in mitochondrial protein 
abundance and function described here are the ultimate consequence of this aberrant 
transcriptional regulation. Both the AMPK α1 and α2 subunits have been noted to localize to the 
nucleus as well as to the cytoplasm and a direct role for AMPK in transcriptional regulation has 
been suggested [192-194]. Moreover, a number of transcription factors, including PGC-1α and 
the carbohydrate response element binding protein, chREBP, which cooperates with Myc to 
regulate certain glucose-responsive genes [195] have been identified as putative AMPK targets 
[196-199]. Thus it is feasible that AMPK also alters many of the genes described here indirectly 
by virtue of its effects on key transcription factors many if not all of which are also direct Myc 
targets. Indeed, we note that several of the mitochondrial-related transcripts studied in Fig. 10C 
such as PPARγ, POLRMT, SIRT3, and UCP2 are completely discordant with respect to their 
Myc responsiveness in WT and KO cells. The unresponsiveness of KO cell mitochondria 
appears to reflect a generalized loss of normal coordination among these various factors that is 
apparent both in their basal state and in response to Myc de-regulation. Obvious targets for 
AMPK-mediated post-translational modification include any of the large number of members 
 70 
 
that comprise the chromatin-modifying and transcriptional-enhancing protein complex that 
assembles in response to DNA binding by Myc [200, 201]. 
3.3.2 Co-operativity between Myc and AMPK in determining cellular redox state 
Maintaining a reduced intracellular environment is believed to protect against excessive 
oxidation of free thiols and other groups, particularly those residing within the catalytic domains 
of critical enzymes [176]. Our finding that both cytoplasmic and mitochondrial compartments, 
particularly the former, were more oxidized in KO cells under basal conditions supports the idea 
that redox regulation is an important, although likely indirect, AMPK function. The additional 
observation that cytoplasmic oxidation increased equivalently in WT and KO cells in response to 
MycER activation suggests that AMPK is less important in this compartment for regulating this 
balance following sudden oxidative stress. That WT mitochondria became more reduced 
following MycER activation further indicates that the cytoplasmic and mitochondrial 
compartments are under distinct forms of redox regulation. Multiple, non-mutually exclusive 
mechanisms could explain these findings including differences in the levels of various factors 
that maintain the reduced state such as thioredoxins, manganese superoxide dismutase, 
peroxiredoxins and the NAD+/NADH ratio [202-204]. The failure of mitochondria to 
significantly alter their redox state following MycER activation likely reflects their general 
unresponsiveness as discussed above.  
The inter-membrane space is one source of ROS, which arise primarily as a consequence 
of electron leakage across Complexes I and III of the ETC [205, 206]. Myc-mediated 
enhancement of Oxphos may increase the absolute amount of this leakage without compromising 
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ETC efficiency or integrity. The mitochondrial matrix is a second source of ROS, which 
originate from qualitative defects in ETC function as occurs in patients with respiratory chain 
mutations [206-208]. The compartmentalization of ROS from these two sources might well have 
different effects on the redox state, with the former source tending to contribute more to 
cytoplasmic oxidation and the latter to mitochondrial. MycER activation likely favors the 
generation of ROS via the first mechanism, and such ROS might be less able to oxidize roGFP 
residing in the matrix.  
3.3.3 Changes in PK and PDH as a potential mechanism for metabolite differences 
between WT and KO MEFs 
In response to MycER activation, WT cells underwent a redistribution of metabolic substrates 
that included the accumulation of selective glycolytic intermediates and a depletion of TCA 
cycle intermediates (Fig. 13A). One explanation for these findings is an increased reliance on the 
Warburg effect, which is often accompanied by a shift from the M1 to the M2 PK isoform. The 
latter possesses a lower affinity for PEP thus slowing its conversion to pyruvate and allowing 
more time for the accumulation of upstream substrates and their diversion into anabolic 
pathways [19, 182, 183, 185, 186]. Although we did not detect significant changes in the 
PKM1:PKM2 ratio upon MycER activation in WT cells (Suppl. Fig. 30), we did observe a 
decrease in total PK activity (Fig. 13D). This by itself could explain the accumulation of 
substrates upstream of PEP thereby limiting the conversion of pyruvate to acetyl CoA. It could 
also account for the observed depletion of TCA cycle intermediates in response to the Myc-
mediated increase in Oxphos (Fig. 13A). A second possibility is that the enhanced glycolysis 
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mediated by MycER activation in WT cells supplies sufficient levels of substrates for both the 
Warburg effect and Oxphos. This could explain the increased production of lactate and 
accompanying extracellular acidification in response to MycER (Fig. 8A). Taken together, 
increased glycolysis, an overall buildup of intermediates due to reduced PK, combined with 
increased mitochondrial activity and a depletion of TCA cycle substrates, could explain many, if 
not all, of the metabolite shifts detected in WT cells in response to Myc activation. However, this 
change is not without its energetic costs as evidenced by the accompanying chronic ATP 
depletion, higher levels of AMP and AMPK-activation (Fig. 8D and E and 13A).  
KO cells in their basal state were relatively depleted of glycolytic substrates and 
oversupplied with TCA cycle intermediates compared to WT cells (Fig. 13A). Although the 
activities of PK and PDH were substantially different between these 2 cell lines (Fig. 13C and 
D), the fact that levels of PEP, pyruvate and AcCoA were actually quite similar  (Fig. 13A and E) 
argues against the idea that significant changes in any of these could account for the differential 
levels and distribution of downstream TCA cycle substrates. Rather, the accumulation of TCA 
cycle intermediates most likely reflects the consequences of the loss of AMPK in these cells as 
manifested by their inability to properly coordinate the mitochondrial response. The ultimate 
result is even lower levels of ATP and higher levels of AMP in KO cells both in the resting state 
and in response to MycER activation (Fig. 8D and 12A & Suppl. Fig. 24).  
3.3.4 Cross-talk between Myc and AMPK 
The wide-ranging differences between WT and KO cells in response to MycER activation 
reported here demonstrate that Myc and AMPK likely engage in a complex cross-talk, the 
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presumed purpose of which is to correctly balance anabolic and proliferative needs with cellular 
energy levels (Fig. 14). The need for maintaining this balance is most dramatically illustrated by 
the rapid and dramatic reduction of ATP levels that follow MycER activation in WT cells and by 
the even steeper decline in KO cells (Fig. 8D and Suppl. Fig. 24). This ATP-mediated cross-talk 
between AMPK and Myc has been previously demonstrated in myc-/- rat fibroblasts in which 
AMPK is constitutively activated as a result of the inability to maintain normal levels of ATP 
due to the overall failure of Myc-dependent glycolysis and Oxphos [4, 11]. Thus, balancing ATP 
production and AMPK activation and with anabolic demands is a process that occurs in response 
to both Myc over- and under-expression. 
Other potential mediators of the cross-talk between Myc and AMPK, that are largely 
independent of but linked to ATP levels, are ROS which, in the examples provided here, 
contribute extensively to AMPK activation (Fig. 8G). ROS are well-known second messengers 
that are rapidly generated in response to many different growth stimuli and the large increase in 
ETC function that accompanies Myc over-expression [4, 152, 209, 210]. Their ability to 
maintain AMPK in an active state, even beyond the point at which ATP levels have normalized 
(Fig. 8E-H) suggests that ROS might serve to limit growth factor-mediated proliferation at a 
point before which ATP levels are compromised and might also serve to more rapidly restore 
ATP levels to normal following a proliferative signal.  
In retrospect, a close relationship between Myc and AMPK might have been anticipated 
given their well-known regulation of a variety of similar processes as noted above. A similar 
relationship has also been previously suggested by Liu et al. [80] who showed that ARK5, an 
upstream regulator of AMPK, could also affect several cellular functions that are relevant to 
Myc. These included the ability of ARK5 to protect against Myc-mediated apoptosis, to increase 
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oxygen consumption, to negatively regulate cell size and to promote cell cycle progression. 
However, many of the consequence of ARK5 suppression in cancer cells were not observed in 
the current study. Perhaps most importantly, and unlike the case with AMPK described here, the 
depletion of ARK5 in transformed cells had little influence on the expression of Myc target 
genes [80]. Taken together, these observations suggest that, while ARK5 and AMPK operate 
within the same pathway, their communication with Myc may occur by distinct mechanisms, 
may be cell-type specific and may serve distinct purposes. 
3.4 EXPERIMENTAL PROCEDURES 
3.4.1 Cell culture 
SV40 T-antigen-immortalized ampk+/+ and ampk-/- MEFs, the latter bearing a double knockout 
of the α1 and α2 subunits of AMPK, were a kind gift from Dr. Benoit Viollet (Institut Cochin, 
Université Paris Descartes) and Dr. Keith Laderoute (Discovery Technologies, SRI International) 
[211, 212] and were generated as described by Laderoute et al. [189]. Both cell lines were 
transduced with a pBabePuro retroviral vector encoding a Myc-estrogen receptor (MycER) 
fusion protein [151]. Stable clones of each AMPK genotype (hereafter referred to as WT or KO) 
were selected in 1 µg/ml of puromycin, pooled, and used for all subsequent experiments. Both 
WT and KO cells expressed equivalent levels of MycER (Suppl. Fig. 24A). All cell lines were 
maintained in puromycin-containing Dulbecco’s-modified Eagle’s minimal essential medium 
(D-MEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), L-glutamine and 
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penicillin/streptomycin as previously described [4]. Unless otherwise stated, MycER was 
activated by adding 4-hydroxytamoxifen (4HT) to cells for 7-9 days at a final concentration of 
250 nM before performing any assessments. All recombinant DNA and retroviral and lentiviral 
work was approved by the University of Pittsburgh Recombinant DNA and Institutional 
Biosafety Committees and, in the latter cases, was performed under BSL2+ conditions. 
3.4.2 Quantification of glycolysis, Oxphos and ATP levels 
All experiments were performed on an XF24 Extracellular Flux Analyzer (Seahorse Bioscience, 
Billirica, MA) as previously described [4, 11]. O2 consumption rate (OCR) and proton 
production, expressed as the extracellular acidification rate (ECAR), were quantified in 
unbuffered D-MEM containing 8.3 g of glucose- and pyruvate-free DMEM (Sigma) 
supplemented with 31 mM NaCl, 2 mM glutamine, 42.3 µM phenol red, and 25 mM glucose, pH 
7.4 to obtain baseline metabolic levels. A mitochondrial stress-test was applied by adding 1 µM 
oligomycin, 0.3 µM FCCP, 100 mM 2-deoxyglucose (2-DG), and 1 µM rotenone. Each 
measurement point was performed in quadruplicate and experiments were repeated at least 3 
times with similar results and normalized to cell number at the conclusion of the experiment. 
Relative effects were expressed as areas under the curve measurements that were generated by 
the manufacturer’s software.  
ATP assays were performed on 20,000–30,000 cells seeded in 96 well plates the day 
before and were performed in quadruplicate wells using the ATPlite Luminescence Assay 
System (Perkin Elmer, Waltham, MA) as instructed by the manufacturer. Results were 
normalized to total protein levels, which were determined on separate sets of identical wells. 
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3.4.3 Measurements of mitochondrial mass and reactive oxygen species (ROS) 
Mitochondrial mass was determined as previously described [4, 11]. Monolayers were stained at 
37C for 45 min in fresh D-MEM containing 20 nM of acridine orange 10-nonyl bromide (NAO), 
0.5 mM of MitoTracker Green, 10 µM of CM-H2-DCFDA or 5 µM of MitoSox (all from 
Invitrogen, Carlsbad, CA)) and then analyzed using a FACStar flow cytometer (Becton-
Dickinson Biosciences, San Jose, CA). Analyses were performed using BD FACSDiva Software 
as previously described [4]. 
3.4.4 Blue native gel electrophoresis (BNGE) and electron transport chain (ETC) enzyme 
assays 
Samples were prepared for BNGE as previously described with some modifications [4]. Cells 
were suspended in 0.5 ml of ice cold HB buffer (50 mM KPO4, pH=7.4; 1mM EDTA; 2.5% 
glycerol; 250 mM sucrose) containing protease inhibitor cocktail (Sigma-Aldrich, St. Louis, 
MO), disrupted on ice with a dounce homogenizer (Isobiotec, Heidelberg, Germany) and 
enriched for mitochondria by differential centrifugation. The pellet was washed twice with HB 
buffer and re-suspended in the same buffer at a final protein concentration of 2-5 mg/ml. To 
achieve optimal solubility of mitochondrial super-complexes/complexes, the digitonin 
concentration was optimized so that 8 mg of digitonin was added per mg of protein in HB buffer 
without EDTA. Following a 20 min incubation on ice, a Coomassie blue solution (5% 
Coomassie blue G250 in 750 mM 6-aminocaproic acid) was added (1:30 v/v). The supernatant 
was then electrophoresed on a 3–12% Native PAGE Novex Bis-Tris gel (Invitrogen) at 80 V for 
 77 
 
4 hours at 4C in the buffer provided by the supplier. 80 µg of protein for each sample was 
electrophoresed to resolve complexes. Following electrophoresis, gels were stained for 30 min 
with Bio-Safe Coomassie G250 (Bio-Rad, Hercules, CA). Gels were scanned and the images 
analyzed for relative band density using AlphaEaseFC 2200 scanner and AlphaEaseFC software. 
In situ gel assays of individual ETC complex activities were performed as previously 
described for Complexes I (NADH ubiquinone oxidoreductase) and V (ATPase) [213]. Complex 
III (CIII) (decylubiquinol cytochrome c oxidoreductase) was assayed by incubating gels with 
CIII assay solution [214] overnight with mild agitation. In a separate reaction, Complex IV 
(CIV) (cytochrome c oxidase) was measured by incubating the gel in a solution containing 1 nM 
catalase, 10 mg cytochrome c and 750 mg sucrose in CIII assay buffer with mild agitation for 30 
min. An optional wash in water at room temperature was employed for 24 hours to further 
sharpen the band patterns. Band intensities were quantified using NIH Image J software and 
were normalized with their corresponding bands on the Coomassie stained gel.  
In situ assays for Complex II (CII) (succinate dehydrogenase) proved to be relatively 
insensitive and irreproducible. We therefore measured this activity on mitochondria purified as 
described above using a method from Munujos et al. [12] modified for a 96 well plate format. As 
a negative control, an inhibitor of CII (0.5 mM thenoyltrifluoro-acetone) was added to a separate 
set of samples. Activity was assessed at 500 nm for 1 hour every minute on a BMG LabTech 
FLUOstar Omega spectrophotometer. The ∆Abs340/min was obtained using the maximum linear 
rate over a period of 20 min. 
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3.4.5 RNA extraction and real-time qRT-PCR analysis 
Total RNA was extracted from logarithmically growing cells and purified using an RNAeasy 
Mini kit (Qiagen, Inc., Chatsworth, CA) as previously described [11]. qRT-PCR reactions were 
performed with a Power SYBR Green RNA-to-CT™ 1-Step Kit (Life Technologies/Thermo-
Fisher, Inc.) with a StepOnePlus Real-Time PCR System (Applied Biosystems, Inc. Carlsbad, 
CA). All primers were synthesized by International DNA Technologies, Inc. (Coralville, IA). 
Reactions were optimized so that single bands of the predicted size were visualized following gel 
electrophoresis. The real-time PCR results were calculated as relative expression after 
normalization to the internal standard β2 microglobulin using ∆∆CƬs compared to WT cells. 
Statistical analyses were performed using Student’s t-test. All primer sequences and 
amplification conditions are listed in Table 4. 
Table 4: qRT-PCR primers used in Chapter 3 
Symbol 
Description (mRNA) 
Gen 
Bank 
Forward Primer 
Sequence 
Reverse Primer 
Sequence 
Anneal 
Product 
Length 
ID (5' → 3') (5' → 3') Temp. (bps) 
ACLY ATP citrate lyase 
BC0563
78.1 
ACCCTTTCACTGG
GGATCACA 
GACAGGGATCAG
GATTTCCTTG 
56 65 
Alt1 Alanine Aminotransferase1 
BK00512
7.1 
TCCAGGCTTCAA
GGAATGGAC 
CAAGGCACGTTG
CACGATG 
55 113 
Cit 
Synth 
citrate synthase 
BC0297
54.1 
GGACAATTTTCCA
ACCAATCTGC 
TCGGTTCATTCCC
TCTGCATA 
55 109 
ERRα estrogen related receptor, alpha 
NM_007
953 
GCCTCCAATGAG
TGTGAGATC 
TTTGTACTTCTGC
CGTCCG 
60 138 
ERRβ estrogen related receptor, beta 
NM_011
934 
CATGAAATGCCTC
AAAGTGGG 
AAATCGGCAGGT
TCAGGTAG 
60 125 
FBP1 fructose 1,6-bisphosphatase 1 
NM_019
395 
GACTGGGGATCA
AGTAAAGAAGC 
AGGTAGCGTAGG
ACGACTTCA 
55 80 
FH1 Fumerate Hydratase 
NM_010
209.2 
GAATGGCAAGCC
AAAATTCCTT 
TCTTACGGTCTGA
GCACCATAA 
55 95 
G3PDH 
(cyto) 
cytosolic glycerol-3-phoshate 
dehydrogenase 1 
NM_010
271 
ATGGCTGGCAAG
AAAGTCTG 
CCTGCATTGCTAC
CCACGAT 
51 80 
G3PDH 
(mito) 
mitochondrial glycerol-3-phoshate 
dehydrogenase 1 
U60987 
ATGGCGTTTCAAA
AGGCAGTG 
ACGGAGGAGGTC
CCAAAACAG 
51 79 
G6P glucose-6-phosphatase (catalytic) 
U00445.
1 
CGACTCGCTATCT
CCAAGTGA 
GGGCGTTGTCCA
AACAGAAT 
60 208 
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GOT1 
asprate aminotransferase isoenzyme, 
glutamine oxaloacetate transaminase 
J02623.1 
GCGCCTCCATCA
GTCTTTG 
ATTCATCTGTGCG
GTACGCTC 
55 133 
IDH1 
(cyto) 
isocitrate dehydrogenase - cytosolic 
NM_001
111320 
ATGCAAGGAGAT
GAAATGACACG 
GCATCACGATTCT
CTATGCCTAA 
55 116 
IDH2 
(mito) 
isocitrate dehydrogenase 1 (NADP+) 
mitochondrial 
U51167 
AAGAGCCCTAAC
GGAACGAT 
TCTTTGGGGTGA
AGACCAAC 
51 202 
IDH3 
(cyto+mi
to) 
isocitrate dehydrogenase3 - mito, 
(NAD+), alpha 
NM_029
573 
TGGGTGTCCAAG
GTCTCTC 
CTCCCACTGAATA
GGTGCTTTG 
55 177 
MDH 
(cyto) 
cytosolic malate dehydrogenase 
NM_008
618 
GAACCAATCAGA
GTCCTTGTGAC 
GGCACAGTCTTG
CAGTTCCA 
51 177 
MDH 
(mito) 
mitochondrial malate dehydrogenase  
NM_008
617 
GCAACCCCTTTCA
CTCCTG 
TCTGGTCTCAATG
TGACTCAGAT 
51 112 
Mterf1 
Mitochondrial transcription termination 
factor 1a 
NM_001
013023.
2 
GTTCCTTTGCTCT
GTTGGATTG 
GAAAGCAGCCTC
TCTCTTATGT 
60 363 
Mterfd1 
(Mterf3) 
MTERF domain containing 1 
NM_025
547.3 
TCATCGTCAAGTT
TCCACAGT 
AGGTTTTGCTGG
GTCATACTG 
60 107 
Mterfd2 
(Mterf4) 
MTERF domain containing 2 
NM_178
051.3 
CAGATGCCCCAC
TGTTTTG 
TGTGTCTCTGCTT
GATCTTGG 
60 146 
NFE2L2 
(NRF2) 
Nuclear factor, erythroid derived 2, like 
2 
NM_010
902.3 
TCCCATTTGTAGA
TGACCATGAG 
CCATGTCCTGCT
CTATGCTG 
60 150 
NRF1 nuclear respiratory factor 1 
NM_010
938 
AATGTCCGCAGT
GATGTCC 
GCCTGAGTTTGT
GTTTGCTG 
60 149 
NSUN4 
NOL1/NOP2/Sun domain family, 
member 4 
NM_028
142.4 
CCAAGTCCGAGT
TACCTCATG 
TCTTCCTTGACCG
CTGAAAG 
60 149 
PC Pyruvate carboxylase 
L09192.
1 
CTGAAGTTCCAAA
CAGTTCGAGG 
CGCACGAAACAC
TCGGATG 
55 162 
PdhE1a 
pyruvate dehydrogenase E1 alpha 1 
(Pdha1), mitochondrial protein 
NM_008
810.2 
GAAATGTGACCTT
CATCGGCT 
TGATCCGCCTTTA
GCTCCATC 
55 123 
PDK1 
Pyruvate dehydrogenase kinase, 
isoenzyme 1, mitochondrial 
NM_172
665 
GGACTTCGGGTC
AGTGAATGC 
TCCTGAGAAGATT
GTCGGGGA 
56 122 
PDP2 
pyruvate dehydrogenase phosphatase 
regulatory subunit 
NM_198
308.1 
AAGACAAAGGAC
TAGCCCAGG 
GATAGGCCACGG
ATGTACCC 
55 146 
PEPCK 
phosphoenolpyruvate carboxykinase 2, 
mitochondrial 
NM_028
994.2 
ATGGCTGCTATGT
ACCTCCC 
GCGCCACAAAGT
CTCGAAC 
55 148 
PGC1α 
peroxisome proliferative activated 
receptor, gamma, coactivator 1 alpha 
NM_008
904 
CACCAAACCCAC
AGAAAACAG 
GGGTCAGAGGAA
GAGATAAAGTTG 
60 125 
PGC1β 
peroxisome proliferative activated 
receptor, gamma, coactivator 1 beta 
NM_133
249 
GGTGTTCGGTGA
GATTGTAGAG 
GTGATAAAACCGT
GCTTCTGG 
60 72 
PKM1 Pyruvate Kinase, Muscle, isoform 1 
NM_012
53883 
TTGTGCGAGCCT
CCAGTC 
ACTCCGTGAGAA
CTATCAAAGC 
55 106 
PKM2 Pyruvate Kinase, Muscle, isoform 2 
NM_011
099 
TTGCAGCTATTCG
AGGAACTCCG 
CACGATAATGGC
CCCACTGC 
55 115 
POLRM
T 
Polymerase (RNA) mitochondrial (DNA 
directed) 
NM_172
551 
AGAAGCCCAACA
CTCTGAAG 
ATGTGTCCAGAA
GCAGTCG 
60 146 
PPARα 
peroxisome proliferator activated 
receptor alpha 
NM_011
144 
CATTTCCCTGTTT
GTGGCTG 
ATCTGGATGGTT
GCTCTGC 
60 133 
PPARβ 
peroxisome proliferator activator 
receptor delta 
NM_011
145 
GGAAAAGTTTTG
GCAGGAGC 
TGTCTTCATCTGT
CAGTGAGC 
61 149 
PPARγ 
peroxisome proliferator activated 
receptor gamma 
NM_011
146 
ATAGGTGTGATCT
TAACTGCCG 
CCAACAGCTTCTC
CTTCTCG 
60 147 
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PRC 
peroxisome proliferative activated 
receptor, gamma, coactivator-related 1 
NM_001
081214 
ACTCAGGCATTG
ACATTCCC 
TTTCGCCAAGAGT
GAGACAG 
61 146 
SDH a Succinate dehydrogenase subunit A 
NM_023
281 
GGAACACTCCAA
AAACAGACCT 
TCCACCACTGGG
TATTGAGTAG 
51 106 
SDH b Succinate dehydrogenase subunit B 
NM_023
374 
ATTTACCGATGG
GACCCAGAC 
GTCCGCACTTATT
CAGATCCAC 
51 79 
SDH c Succinate dehydrogenase subunit C 
NM_025
321 
GCTGCGTTCTTG
CTGAGACACA 
ATCTCCTCCTTAG
CTGTGGTT 
51 110 
SDH d Succinate dehydrogenase subunit D 
NM_025
848 
TGGTCAGACCCG
CTTATGTG 
GAGCAGGGATTC
AAGTACCCA 
51 193 
Ser-
HMT 
Serine Hydromethyltransferase 
AF23770
2.1 
CAGGGCTCTGTC
TGATGCAC 
CGTAACGCGCTC
TTGTCAC 
57 91 
SIRT3 
NAD-dependent deacetylase sirtuin-3, 
mitochondrial 
NM_022
433 
CGGCTCTATACA
CAGAACATCG 
CATCAGCCCATAT
GTCTTCCC 
61 145 
TFAM Transcription factor A, mitochondrial 
NM_009
360 
CACCCAGATGCA
AAACTTTCAG 
CTGCTCTTTATAC
TTGCTCACAG 
58 147 
TFB2M Transcription factor B2, mitochondrial 
NM_008
249 
ACCAAAACCCATC
CCGTC 
TCTGTAAGGGCT
CCAAATGTG 
60 141 
Tha1 Threonine aldolase 
NM_027
919.4 
CTCAGTGGTCTA
GGAATTGGGC 
GTCTTCGCCGTA
ATCATCGTC 
55 137 
UCP2 Mitochondrial Uncoupling Protein 2 
NM_011
671 
GCATTGGCCTCT
ACGACTC 
AAGCGGACCTTT
ACCACATC 
60 145 
YY1 YY1 transcription factor 
NM_009
537 
GATACCTGGCATT
GACCTCTC 
ATAGCAGAGTTAT
CCCTGAACATC 
60 147 
αKGDH 
(DLD) 
dihydrolipoamide dehydrogenase, 
mitochondrial protein 
NM_007
861.4 
GAGCTGGAGTCG
TGTGTACC 
CCTATCACTGTCA
CGTCAGCC 
55 138 
αKGDH 
(DLST) 
dihydrolipoamide S-succinyltransferase 
(E2 component of 2-oxo-glutarate) 
NM_030
225.4 
GGAACTGCCCTC
TAGGGAGA 
GACGCTACCACT
GTTAATGACC 
55 101 
αKGDH 
(OGDH) 
alpha ketogluterate dehydrogenase 
NM_001
252282 
AGGGCATATCAG
ATACGAGGG 
CTGTGGATGAGA
TAATGTCAGCG 
51 106 
 
3.4.6 Immunoblotting 
Blotting were performed as previously described [4, 11]. All relevant antibodies used are listed 
in Table 5.  
Table 5: Antibodies used in Chapter 3 
Name of antibody Description 
Host 
Species 
  Vendor Catalog no. dilution 
AMP-dependent protein kinase alpha (AMPK) Polyclonal Rabbit IgG Cell Signaling  2532S 1:1000 
pAMPK(Thr172) (D79.5E) Monoclonal Rabbit IgG Cell Signaling  4188S 1:1000 
Pyruvate dehydrogenase E1 subunit (PDH)  (D6) Monoclonal Mouse IgG2a Santa Cruz  sc-377092 1:1000 
pPDH E1 (Ser293)  Polyclonal Rabbit IgG EMD AP1062 1:4000 
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Millipore 
Pyruvate dehydrogenase kinase (PDK1) Monoclonal Rabbit IgG Cell Signaling  3820S 1:1000 
Pyruvate dehydrogenase phosphatase 2 (PDP2)  Polyclonal Rabbit IgG Biovision  3944-200 1:500 
Pyruvate kinase M1 isoform (PKM1)  Monoclonal Rabbit IgG Cell Signaling  7067S 1:1000 
Pyruvate kinase M2 isoform (PKM2)  Polyclonal Rabbit IgG Cell Signaling  3198S 1:1000 
β-actin Monoclonal Mouse IgG2b Cell Signaling  3700S 1:10000 
 
3.4.7 Mitochondrial oxidoreductase assays 
The assay for malic dehydrogenase (MDH) relied on the conversion of oxaloacetate (OAA) to 
malate coupled with NADH to NAD+, which was measured using Protocol SPOXAL01 (Sigma-
Aldrich). The ∆Abs340/min was obtained as described above. 
α-ketoglutarate dehydrogenase (α-KGDH) was quantified by measuring the conversion of 
α-ketoglutaric acid (α-KG) to succinyl-CoA coupled to NAD+ conversion to NADH as described 
in Protocol SPKETO03 (Sigma-Aldrich). The ΔA340nm/min was calculated over 15 min using the 
maximum linear rate.  
Isocitrate dehydrogenase (IDH) activity was quantified on 10 µg of mitochondria using 
an IDH Activity Assay Kit according to the directions provided by the supplier (Sigma-Aldrich). 
Absorbance was measured at 37C at OD450nm every 5 minutes over 2 hr. with a final reading 
taken at the plateau stage.  
Glycerol 3-phosphate dehydrogenase (G3PDH) was assayed using a G3PDH Assay Kit 
(Abcam, Inc., Burlingame, CA) with 10 µg of mitochondria and quantified as recommended by 
the manufacturer. End point absorbance (Abs450) was corrected for background controls. All 
enzyme assays were performed on at least triplicate samples 
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3.4.8 Enrichment and Tryptic Digestion of MEF Mitochondrial Proteins 
16 MEF samples (4 each of WT, KO, WT+Myc and KO+Myc) were separately enriched for 
mitochondrial proteins from 107 cells prepared from individual plates as described for BNGE. 
Protein concentrations were determined using a BCA assay (Pierce, Inc., Rockford, IL). A 
pooled control sample was prepared by combining equal volumes of each individual sample and 
was used to monitor sample preparation variation. 22 aliquots (16 samples and 6 controls) 
containing 20 µg of total protein were spiked with 4 µl of 125 nM ovalbumin protein. In-solution 
trypsin digestion was carried out as described [215]. The resulting tryptic peptides were desalted 
with PepClean C-18 Spin Columns (Pierce) according to the manufacturer’s protocol, vacuum-
dried, and resuspended in 20 µl 0.1% formic acid.  
3.4.9 LC-MS/MS Analysis 
Tryptic digests were analyzed using high resolution liquid chromatography tandem accuracy 
mass spectrometer as previously described [216]. In brief, samples were loaded with a 
nanoAcquity autosampler (Waters, Waltham MA) onto a capillary sample trap column, separated 
using a reversed phase gradient on a commercial PicoChip nanospray C18 column (PicoChip) 
and electrospray ionization source (New Objective, Inc. Woburn MA). Mass analysis was 
performed on a hybrid electrosprayed into a LTQ/Orbitrap Velos hybrid mass spectrometer 
(Thermo Fisher). Data dependent acquisition consisted of cycles of a high resolution full scan FT 
mass spectrum followed by 13 MS/MS low resolution tandem mass spectra scans in the linear 
ion trap, with dynamic exclusion setting enabled to minimize redundant selection of precursor 
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ions previously selected for CID. High-resolution liquid chromatography mass spectrometry was 
used to measure the mass-to-charge ratio, retention time, and intensity of the isotopes for each 
identified peptide (for example, see Suppl. Fig.29). Custom differential mass spectrometry 
software (dMS 1.0, University of Pittsburgh and InfoClinika, Seattle WA) was used to align, 
integrate, and link the high resolution peak areas data to the protein identification results from a 
COMET to the tandem MS sequence database search results [217]. In total, detection of 414,655 
isotope distributions, 9,397 peptide sequences, and 1929 protein identifications were obtained 
from this data set (available upon request). 
3.4.10 Selection of Mitochondrial Proteotypic Peptides 
Intensities of a single representative peptide were used as surrogate markers for relative 
abundance of each protein. Proteotypic representative peptides were selected based upon their 
signal intensities and their correlation with other peptides originating from the same protein. 
Proteins with a single identified peptide sequence or with poor concordance among identified 
peptides were excluded from further analysis. For the remaining proteins, peptides with the 
highest signal intensities (average of all samples) among those with good correlation with other 
peptides from the same protein (mean Pearson’s correlation coefficient >0.5) were selected as 
representative peptides. A total of 345 peptides belonging to proteins annotated as having 
evidence of mitochondrial localization in the David (http://david.abcc.ncifcrf.gov/) 
Bioinformatics Database and/or mouse MitoCarta Inventory 
(http://www.broadinstitute.org/pubs/MitoCarta/mouse.mitocarta.html) were selected and their 
high resolution peak area extracted using dMS software were used for statistical analysis. 
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3.4.11 Statistical Analysis 
Two way ANOVA was used to determine the influence of AMPK genotype and Myc over-
expression on the abundance of mitochondrial proteins, and also to determine whether there was 
any significant interaction effect between AMPK genotype and Myc over-expression (i.e. 
whether a protein’s response to Myc was discordant between WT and KO cells). Features were 
selected based on a q value (false discovery rate) cutoff of 0.05. Myc over-expression did not 
affect the overall abundance of mitochondrial proteins (p values for student’s t test comparison 
of WT vs. WT + Myc and KO vs. KO + Myc were 0.870 and 0.761 respectively). However, we 
did observe a 24% higher average intensity of all mitochondrial peptides in KO samples both 
with and without Myc over-expression (two-way analysis of variance [ANOVA] p value of 
0.002) despite the overall intensities of non-mitochondrial proteins being otherwise identical. 
This could be due to a slightly greater overall mitochondrial mass in KO cells although this was 
not confirmed by staining with NAO or MitoTracker dyes (Fig. 8C). To reduce the potential 
effect of bias due to slightly higher amounts of mitochondrial proteins in the KO samples, 
proteins with greater abundance in KO but with fold change less than 2.6 (twice the fold change 
of overall mitochondrial abundance in KO samples) were not considered for the main effect of 
genotype.  
3.4.12 Expression of roGFP2 
roGFP2 was a generous gift from Dr. Michael Palladino (The Univ. of Pittsburgh). Compared to 
GFP, roGFP2 contains several amino acid substitutions, including S147C and Q204C, which 
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allow the molecule to form stable intra-molecular disulfide bonds in reduced environments 
[176]. Oxidation of these residues alters the tertiary structure of the protein as well as the 
intensity of 510 nm light emitted following alternating excitation at 410 nm and 474 nm [180].  
We used standard molecular biology techniques to insert roGFP coding sequences into 
the pDsRed2-Mito vector (Clontech, Inc., Mountain View, CA) from which the DsRed insert had 
been excised. This step placed the roGFP coding sequence downstream from and in-frame with 
the mitochondrial targeting signal peptide from subunit VIII of the human cytochrome c oxidase 
ETC subunit (roGFP-mito). To generate a cytoplasmically-localized roGFP2 vector (roGFP-
cyto), the roGFP-mito vector was digested with NheI and BamHI to excise the mitochondrial 
signal peptide and the subsequently blunt-ended vector was self-ligated. The coding region of 
each vector was then amplified by PCR and cloned directionally into the pLenti6/V5-TOPO 
lentiviral vector (Life Technologies, Inc.). After packaging in 293FT cells, WT and KO MEFs 
were transduced with each vector and selected in 1 µg/ml of blasticidin. Pooled blasticidin-
resistant clones were then further selected by fluorescence-activated cell sorting in order to 
purify the brightest population, which were used for all subsequent experiments.  
3.4.13 Confocal microscopy and flow cytometry of roGFP-mito- and roGFP-cyto-targeted 
cells 
WT and KO cells stably expressing roGFP-cyto and roGFP-mito were grown overnight in glass 
bottom 6 well plates. Fresh medium lacking or containing 4HT was then added for an additional 
24 hr. Confocal images of live cells were obtained with a confocal laser scanning microscope 
(LSM710; Zeiss) using a 20x/0.8 M27 Plan-Apochromat objective and a 31 µm pinhole with the 
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following excitation/emission wavelength (λex/em) settings: λex/em 405/495-575 for oxidized 
roGFP, λex/em 488/495–575 for reduced roGFP. To quantify changes in the cellular redox 
states, analyses were performed by flow cytometry on a BDFACS Aria II SORP using BD 
FACSDiva Software and ratios were calculated using FlowJo software. Spectra were collected 
using a violet laser with 405 nm excitation, emission collected using a 525/50 bandpass filter and 
488 nm excitation was collected using an emission bandpass of 520/50. Control experiments to 
determine maximal responses to oxidized and reduced environments were performed by adding 
H2O2 or DTT to final concentrations of 1 mM or 10 mM, respectively for 30 min prior to flow 
cytometry. A third sample was treated with H2O2 for 30 min followed by the addition of DTT for 
an additional 30 min and then analyzed. In all cases, biological triplicates were assessed for each 
group and each experiment was repeated at least twice. Results were expressed as the mean ratio 
of oxidized: reduced fluorescent roGFP based on changes in emission spectra.  
3.4.14 High performance liquid chromatography-electrospray ionization tandem mass 
spectrometry (HPLC-ESI-MS/MS) 
Analyses were conducted on a Q Exactive mass spectrometer with on-line separation by Dionex 
Ultimate 3000 HPLC (both from Thermo Fisher, San Jose, CA). For untargeted quantification of 
polar metabolites, ~109 cells were extracted in 80% methanol at 0oC and then incubated at -20 °C 
for 1 h. Thermo SIEVE (Thermo Fisher) was used for peak alignment and integration of MS 
results to derive the relative abundance of individual metabolites. For ATP analysis,109 cells 
were extracted at 00 C in 15% trichloroacetic acid (TCA) containing ([13C10,
15N1]ATP) as an 
internal standard. An aliquot of the clarified sample was then directly injected. Quantification 
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was performed by integrating the extracted ion chromatograms of each metabolite, which were 
then compared with a standard curve.  
For the analysis of polar metabolites, lysates from sub-confluent cell cultures were 
prepared as described above, clarified by centrifugation, and the supernatants were placed in 
autosampler vials. HPLC-ESI-MS/MS was performed on a Q Exactive mass spectrometer 
(Thermo Fisher) with on-line separation by Dionex Ultimate 3000 HPLC (Thermo Fisher). 
HPLC was performed as described by Paredes et al. [218], with some modification: column, 
Luna NH2, 3 μm, 2 x 150 mm (Phenomenex, Inc., Torrance, CA); mobile phase A, 5% 
acetonitrile in water with 20 mM ammonium acetate and 20 mM ammonium hydroxide, pH 9.45; 
mobile phase B, acetonitrile; flow rate, 300 μL/min; gradient, 85%-1% B over 10 minutes and 
held at 1% B for 10 minutes. Full scan mass spectra were acquired in the orbitrap using negative 
ion detection over a range of m/z 100 – 800 at 70,000 resolution (m/z 300). Metabolite 
identification was based on the metabolite accurate mass (± 5 ppm), manual interpretation of the 
MS/MS fragment patterns, and agreement with the HPLC retention time of authentic standards. 
Thermo SIEVE was again used to process raw data files in order to quantify metabolites of 
interest. Peak alignment and integration were performed and relative abundances of each 
metabolite were generated among different samples. 
Nucleotides were quantified from cell lysates prepared as described above. Cell pellets 
were extracted at 4o C with 15% TCA containing 13C,15N-ATP as the internal standard, and then 
neutralized with a mixture of trioctylamine and 1,1,2-trichlorotrifluoroethane. LC-MS analyses 
were performed on a Q Exactive mass spectrometer with on-line separation using Dionex 
Ultimate 3000 HPLC (both from Thermo Fisher). HPLC conditions similar to those detailed in 
Zhou et al. [219], with some exceptions: Waters XTerra-MS C18 column (3.5 μm, 2.1 x 
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150mm); mobile phase A, 5 mM hexylamine and 0.5% diethylamine in water, pH10; mobile 
phase B, 50% acetonitrile in water; flow rate, 400 μL/min; gradient, 1%-20% B over 10 minutes 
and followed by 20%-30%B over 5 minutes. Full scan mass spectra were acquired in the orbitrap 
using negative ion detection over a range of m/z 300-800 at 70,000 resolution (m/z 300). 
Identification of metabolites was based on the metabolite accurate mass (± 5 ppm) and 
agreement with HPLC retention times of standards. Quantification was achieved by integrating 
the extracted ion chromatograms of individual metabolites and compared with the appropriate 
standard curves.  
3.4.15 Pyruvate dehydrogenase (PDH), pyruvate kinase (PK) assays, and acetyl CoA 
assays 
PDH activity was quantified using the PDH Enzyme Activity Microplate Assay Kit according to 
the directions provided by the supplier (MitoSciences, Eugene, OR). Triplicate samples were 
loaded at 1 mg/well, measured kinetically over 30 min and the rates were determined as changes 
in OD (∆OD) over time.  
PK activity was determined using a modified protocol from Worthington Biochemical 
Corp (Lakewood, NJ) in which the conversion of phospho(enol)pyruvate (PEP) to pyruvate by 
PK is coupled to the conversion of lactate to pyruvate and the generation of NAD+. 1 plate of 
semi-confluent cells was trypsinized and resuspended in 50 mM imidazole HCl buffer, pH 7.6 
containing 12 mM KCl and 62 mM MgSO4 at 106 cells/ml. 100 µl of cells were dispensed into 
individual wells of a 96 well plate containing a reaction solution whose final components 
consisted of 1.36 mM ADP, 1.36 mM PEP, 0.4 mM NADH and 40-45 U of lactate 
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dehydrogenase in imidazole buffer to a final volume of 200 µl. NADH conversion to NAD+ was 
measured at 340 nm for 15 min and the rate was determined by ∆Abs340/min from quadruplicate 
reactions.  
Acetyl CoA was assayed using an Acetyl Coenzyme A assay kit and was performed as 
recommended by the supplier (Sigma-Aldrich). Samples were prepared as described by Edmunds 
et al. [11]. Triplicate samples were compared to a 1 nmol standard curve using a SpectraMax M2 
fluorescence plate reader and analyzed by Students’s t-test.  
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4.0  ABNORMAL LIPID PROCESSING BUT NORMAL LONG-TERM 
REPOPULATION POTENTIAL OF MYC-/- HEPATOCYTES 
4.1 INTRODUCTION 
A direct role for the c-Myc (Myc) oncoprotein in promoting and/or sustaining neoplastic growth 
was first demonstrated over 35 years ago [220]. This has been subsequently supported by studies 
documenting recurrent MYCC de-regulation in 
 human tumors, from animal models of Myc over-expression and from demonstrations that Myc 
silencing in these models promotes tumor regression [221, 222]. Although Myc supervises many 
of the pathways that are commonly perturbed in cancer such as those regulating differentiation, 
proliferation, survival and metabolism [15, 16], its precise role in these processes and its 
function(s) in normal cells have been somewhat more controversial and, at times, subject to 
conflicting experimental outcomes. 
A requirement for Myc is well-established in the developing mouse where myc-/- 
embryonic lethality occurs at E9.5-10.5 as a result of placental insufficiency and cardiac and 
neural tube defects [223]. Postnatally, Myc silencing is compatible with long-term survival and 
is associated with only mild and reversible toxicities in proliferative tissues such as the bone 
marrow and gastrointestinal track [86]. Moreover, haplo-insufficiency of Myc actually slows the 
onset of numerous age-related pathologies and prolongs life span by approximately 15% [78]. In 
 91 
 
contrast, the in vitro proliferation of primary murine embryonic fibroblasts declines 
progressively as Myc levels are reduced [84]. Thus, the consequences of Myc loss in normal 
cells appear to be more tissue- and context-dependent and variable than in transformed cells [84]. 
Myc’s presumptive role in hepatic regeneration rests in part on the observation that it is 
induced within minutes of partial hepatectomy and is silenced following restoration of normal 
liver mass [224]. However, the actual requirement for Myc in this process has varied among 
different studies which have not always assessed identical parameters [87, 89, 225]. These 
reports also relied exclusively on hepatic regeneration following PH, which occurs over a 
relatively short time frame, requires <2 population doublings by the remaining hepatocytes and 
can also be influenced by the deletion of Myc in cells other than hepatocytes [89]. For these 
reasons, we sought here to assess Myc’s role in hepatocyte proliferation by utilizing a novel 
mouse model of liver regeneration that imposes fewer restrictions on hepatocyte replication. 
Type I hereditary tyrosinemia is a metabolic disorder caused by defective production of 
fumarylacetoacetate hydrolase (FAH), which catalyzes the final step in hepatic tyrosine 
catabolism. In HT, the toxic upstream metabolites fumaryl- and maleyl-acetoacetate accumulate 
and cause liver failure [226]. Deletion of the murine fah gene faithfully mimics the human 
disease [227]. Hepatocyte death in fah-/- animals can be prevented with the drug 2-(2-nitro-4-
trifluoro-methyl-benzoyl)-1,3-cyclo-hexanedione (NTBC), which inhibits p-
hydroxyphenylpyruvate dioxygenase, a more proximal enzyme that catalyzes the second step in 
the tyrosine catabolic pathway [227]. Alternatively, fah-/- animals can be rescued by the 
intrasplenic injection of fah+/+ hepatocytes, which migrate to the recipient liver, expand 50-
100-fold over several weeks-months and partially replace the defective parenchyma [228, 229]. 
 92 
 
Here, we studied livers or purified hepatocytes from mice bearing “floxed” myc alleles 
(hereafter referred to as WT mice) or from littermates expressing albumin promoter-driven Cre 
recombinase in which both myc alleles are deleted perinatally (KO mice). We report heretofore 
unappreciated phenotypes and gene expression differences in KO hepatocytes both prior to and 
following transplant into fah-/- recipients. We also show WT and KO hepatocytes to be equally 
proficient at long-term repopulation of fah-/- livers. The ability of WT and KO hepatocytes to 
proliferate identically under highly demanding conditions may explain why a more global long-
term silencing of Myc is associated with only mild side effects or may even be beneficial [78]. 
Oncogene “addiction”, a frequent feature of Myc-over-expressing cancers [230], may thus 
impose unique cellular changes that are necessary for maintaining transformed but not normal 
states of proliferation. 
4.2 RESULTS 
4.2.1 Characterization of livers and hepatocytes from WT and KO mice 
We first verified excision of mycfl/fl alleles from purified KO hepatocytes (Suppl. Fig. 31A-E). 
RNAseq from the same cell populations further confirmed a >90% reduction in the number of 
reads across exons 2 and 3 relative to those from WT hepatocytes (Suppl. Fig. 31F). 
Although body weights of WT and KO mice were indistinguishable (not shown), 
liver:total body weight ratios differed, being lower in young (<1 month) KO animals and higher 
in older (>3 months) animals (Suppl. Fig. 32A). This was not associated with any differences in 
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liver histology as assessed by hematoxylin and eosin (H&E) staining (Suppl. Fig. 32B). WT and 
KO hepatocyte sizes were also similar (Suppl. Fig. 32C) indicating that, as previously reported, 
KO livers contain fewer rather than smaller hepatocytes to account for their reduced mass [78, 
84]. We discuss below possible reasons for the larger liver:body mass ratio of older KO mice. 
myc-/- rat fibroblasts have dysfunctional mitochondria and a profound energy deficit [4, 
11]. To rectify this, they up-regulate pyruvate dehydrogenase (PDH), presumably to maximize 
pyruvate conversion to acetyl CoA [11]. They also constitutively up-regulate AMP-activated 
protein kinase (AMPK), which responds to reduced ATP:AMP ratios by down-regulating 
energy-consuming processes and up-regulating energy-generating ones as fatty acid -oxidation 
(FAO) [11]. WT and KO livers showed no significant differences in any of these properties 
except for increased rates of FAO (Suppl. Fig. 32D-H). 
Finally, we noted that, while Myc alters the susceptibility to multiple intrinsic and 
environmental pro-apoptotic factors [14, 231] no evidence for an increased level of apoptosis in 
KO livers was observed (Suppl. Fig. 32I). 
4.2.2 Differences in metabolism and mitochondrial function of KO mice 
KO mice have increased oxygen consumption, carbon dioxide production and heat generation 
(Fig. 15) particularly when maintained on a high fat diet. These studies suggested that the 
increased metabolism of KO mice is due to abnormalities in lipid metabolism.  
In addition to altering cellular metabolism, Myc also affects mitochondrial structure and 
function[4, 11, 69]. Blue native gel electrophoresis (BNGE) showed no significant differences in 
electron transport chain (ETC) complexes I-IV and Complex V of WT and KO hepatocytes 
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(Suppl. Fig. 33). However, higher ATPase activity of Complex V (Vm and Vd) was noted in KO 
livers (Suppl. Fig. 33H and I). 
Respirometry measurements showed O2 flux of WT and KO liver mitochondria to be low but 
otherwise equivalent prior to and after priming with the Complex I substrates glutamine, 
pyruvate and malate (G,M,P) (Fig. 16A). However, the magnitude of O2 flux change in response 
to ADP was less pronounced in KO mitochondria (Fig. 16A and B), indicating that they reduced 
molecular oxygen to water via complex IV less efficiently. The provision of succinate resulted in 
additional but similarly unequal increases in O2 flux. This indicated that the ability of Complex II 
(succinate dehydrogenase [SDH]) to drive additional electron flow was unable to compensate for 
the Complex I defect of KO mitochondria (Fig. 16A and C).  
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Figure 15: Increased metabolic activity of KO mice. Mice were maintained in metabolic cages that 
quantified (A) oxygen consumption rate (VO2), (B) carbon dioxide production rate (VCO2), (C) heat 
production, and (D) respiratory exchange ratio (RER). Mice of similar weights were initially maintained on 
an ad lib high-fat diet followed by a period of fasting and subsequent re-feeding with standard chow plus 5% 
glucose-containing water over the course of the experiment. L and D indicates cyclic periods of light and 
dark. Other monitoring showed no differences in the overall activity, food consumption, total fat mass or 
glucose tolerance between groups of WT and KO mice (not shown). 
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We also quantified the activities of several mitochondrial dehydrogenases other than 
Complex II (Suppl. Fig. 33E) which donate electrons to the ETC [232]. WT and KO liver-
derived mitochondria had equal levels of isocitrate dehydrogenases (IDH) 1-3, malate 
dehydrogenase (MDH) and glycerol 3-phosphate dehydrogenase (G3PDH) (Fig. 16D-F). Taken 
together we conclude that, while KO liver mitochondria have defects in Oxphos, they are not 
severe enough to compromise ATP production. 
We next employed a recently described targeted proteomics assay using liquid 
chromatography-tandem mass spectrometry to assess the relative abundance of the 93 known 
subunits of the ETC plus an additional 46 mitochondrial metabolism-related proteins [232]. 
Based on a p-value cut-off of 0.05, none of the quantified proteins exhibited statistically 
significant differences between the two groups (data not shown). 
Next, an unbiased mass spectrometry-based approach was used to compare the relative 
abundance of proteins comprising ~30% of the mitochondrial proteome [232]. In total, 2439 
peptide ions (features) were matched to 377 mitochondrial proteins. Using a Student’s t-test with 
a cut off of p<0.05, we again found there to be no significant differences between WT and KO 
livers with respect to the relative amounts of any of these proteins (data not shown). Together 
with the results shown in Suppl. Fig. 33, we conclude there to be no major quantitative 
differences in the composition of the mitochondrial proteomes of WT and KO hepatocytes. 
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Figure 16: ETC function of WT and KO livers. (A) Typical respirometry profiles from WT and KO 
liver homogenates. Arrowheads indicate the time of addition of glutamine, malate and pyruvate (G,M,P), 
ADP and succinate (Suc). WT and KO liver preparations were simultaneously assayed in parallel. 
Cytochrome c was added to test mitochondrial outer membrane integrity. Note that the large, spike in O2 flux 
seen upon adding G,M,P is an artifact resulting from injecting a large volume of diluted substrates and 
transiently disturbing the O2 concentration. (B) Graphic representation of the ADP responses in 
mitochondria prepared from 7 sets of WT and KO livers assayed as shown in (A). (C) Graphic representation 
of succinate responses. The results in (A)-(C) were adjusted to account for minor differences in total protein 
concentrations. (D-F) Assays of selective TCA cycle dehydrogenases, including: NAD+- and NADP+-
dependent IDHs (IDH3 and IDH1+2) (D); MDH (E) and G3PDH (F) See Suppl. Fig. 33E for similar assays 
performed for SDH (Complex II). 
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4.2.3 RNAseq analysis of WT and KO hepatocytes 
We performed RNAseq on hepatocytes from WT and KO animals of comparable ages (ca. 17-18 
weeks). After adjusting for false discovery rate (FDR), we identified 102 transcript differences, 
35 of which were up-regulated in KO hepatocytes and 67 of which were down-regulated (q 
values <0.05, Fig. 17A). The largest subset was comprised of 12 of the ~103 member 
cytochrome p450 (cyp450) family (Fig. 17B) [233]. Re-evaluation of our data identified 11 
additional members that were initially excluded for not meeting false discovery rate (FDR) 
criteria but which still demonstrated significant differences between the two groups (p<0.05) 
(Fig. 17B). 15 of the 23 differentially expressed cyp450 transcripts (62%) were encoded by the 
CLAN2 family whose 37 members are particularly relevant for the regulation of sterol, bile acid 
and eicosinoid metabolism [233].  
In keeping with Myc’s role in regulating ribosomal biogenesis [234], 12 of the ~80 
known transcripts (~15%) encoding ribosomal proteins were down-regulated in KO hepatocytes 
(Fig. 17C). Thus, Myc maintains normal levels of a subset of ribosomal protein transcripts. 
Ingenuity Pathway Analysis of all differentially expressed transcripts of significance 
(p<0.05) identified specific functional classes of genes that were not necessarily fully 
represented in Fig. 17A. Of 642 pathways queried, 5 of the top 7 involved the regulation of 
cholesterol, sterol or bile acid synthesis (Fig. 17D and E). The remaining 2 related to farnesoid X 
receptor (FXR)- and the liver X receptor (LXR) or their regulation by lipopolysaccharide and/or 
interleukin 1, which are also activated by oxysterols and bile acids [235]. Thus, KO hepatocytes 
also up-regulate multiple pathways involved directly in sterol and bile acid bio-synthesis.  
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WT and KO hepatocytes did not differentially express genes potentially capable of 
complementing the loss of Myc such as N-Myc and L-Myc and non-Myc family-related genes 
such as Myct1, HMG-IY and serine hydroxymethyltransferase [236, 237] (Suppl. Fig. 34A). 
Transcripts encoding the “Mlx family” of bHLH-ZIP transcription factors were also unchanged 
save for a modest (~30%) decrease in those encoding Mlxip1/MondoB/ChREBP in KO cells 
[41], which was not manifested at the protein level (Suppl. Fig. 34B). 
Figure 17: Transcript differences between WT and KO hepatocytes. (A) RNAseq results from 4 individual 
sets each of WT and KO hepatocytes. The 102 differentially expressed transcripts with adjusted FDR q<0.05 
are shown. (B) Differences in cyp450 member transcript expression between WT and KO hepatocytes. Those 
with q<0.05 were taken from A whereas the others represent significant differences at the level of p<0.05 
among other members of the cyp450 family. Those encoding members of the CLAN 2 family  are indicated by 
asterisks. (C) Differentially expressed transcripts encoding ribosomal proteins (p<0.05) are listed. RPL12 is 
from (A). (D) Differential gene expression profiling of genes involved in the top 7 deregulated pathways 
identified by Ingenuity Pathway Analysis. Note that the cyp450 members shown in (B) are not repeated here 
but were included and found to be significant in the pathway analysis of cholesterol metabolism. (E) The top 
7 classifications of all significantly deregulated (p<0.05) transcripts according to their involvement in specific 
pathways based on Ingenuity profiling. The top axis represents the percentage of genes comprising that 
pathway whose transcripts were differentially expressed between WT and KO hepatocytes. Green bars 
indicate transcripts that were up-regulated in KO hepatocytes and red bars indicate down-regulated 
transcripts. Some transcripts are included in more than one pathway. Orange circles indicate the log10 p 
value indicating the probability that the differentially expressed transcripts within a specific pathway would 
have been selected randomly. Numbers on the right indicate the number of transcripts assigned to the 
indicated pathway. 
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4.2.4 Abnormal regulation of triglycerides and sterols in KO livers 
Myc inhibition in vitro increases FAO and neutral lipid storage [11, 69], which is consistent with 
the increased FAO rate in KO livers (Suppl. Fig. 32H). Our RNAseq results and the fact that 
lipid droplets also contain cholesterol suggested that sterol and/or bile acid metabolism might be 
compromised in KO hepatocytes particularly since bile acids derive from sterols and can regulate 
sterol and triglyceride biosynthetic pathways [238]. Indeed, livers of fasted KO mice contained 
higher triglyceride levels as well as more numerous and larger neutral lipid droplets (Suppl. Fig. 
35A and B and 35A and B). A trend toward lower fasting cholesterol levels was also noted and 
increased significantly following re-feeding (Suppl. Fig. 35C). KO hepatocytes also contained 
significantly higher levels of transcripts for squalene epoxidase (SQLE), sterol C-4 
methyloxidase (SC4MOL), 3β-hydroxysteroid dehydrogenase (NSDHL) and sterol C-5 
desaturase (SC5DL) [1.7-fold, 2.0-fold, 1.3-fold and 1.4-fold, respectively (Suppl. Fig. 35D)]. 
However, profiling a series of intermediates in the biosynthetic pathway leading from lanosterol 
to cholesterol and including the bile acid intermediate cholestanol showed no differences 
between WT and KO mice when adjusted either to total protein or total sterol content (Suppl. 
Fig. 35E and F). 
Bile acids consist of conjugates between taurine or glycine and cholic or 
chenodeoxycholic acid [239]. When measured in the livers of non-fasted animals, secondary bile 
acids, which are formed within the small intestine by the action of enteric bacteria, make a larger 
contribution to the total bile acid pool. Therefore, we measured total bile acid levels in the livers 
of fasted WT and KO mice. As seen in Suppl. Fig. 35G, no significant differences were 
observed. 
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4.2.5 WT and KO hepatocytes have equivalent repopulation capacity 
Mice with tyrosinemia can be rescued by the intrasplenic injection of FAH+ donor hepatocytes, 
particularly when performed in immune-compromised fah-/- FRG-NOD recipients [240]. This 
approach therefore provides a superior alternative to PH as the transplanted hepatocytes are 
subject to a more intense and prolonged replicative stress. 
We injected FRG-NOD mice with 3x105 WT or KO hepatocytes and withdrew NTBC 4d post-
transplant to facilitate recipient liver repopulation (Fig. 18A and B). Because NTBC 
discontinuation is associated with weight loss, it was re-initiated whenever body weights 
Figure 18: Rescue of FGR-NOD mice with fah+/+ WT and KO hepatocytes occurs at equivalent 
rates. (A) Schematic for repopulating fah-/- NOD-SCID mice with WT or KO donor fah+/+ hepatocytes (B) 
Pathway of hepatic tyrosine catabolism. FAH’s absence causes accumulation of the toxic upstream 
intermediates maleyl- and fumarylacetoacetate. Animals can be rescued by blocking the more proximal 
enzyme hydroxyphenylpyruvate dioxygenase with NTBC or by transplanting fah+/+ hepatocytes. (C) 3x105 
hepatocyes from WT or KO mice (both fah+/+) were inoculated intraspenically into recipient fah-/- FRG-
NOD mice. 4 days later, NTBC cycling began until body weight stabilized at >100% of the pre-transplant 
weight. No differences were seen in the times needed to achieve NTBC independence and body weight 
stabilization. (D) Gross appearance of recipient FRG-NOD livers 12-14 wks after transplantation of WT or 
KO hepatocytes. Livers have been flushed with PBS to facilitate visualization of regenerating nodules 
(arrows). H&E staining of post-transplant livers showing regenerating nodules of donor cells (arrows). FAH 
immuno-staining of donor-derived fah+/+ nodules (red) in recipient fah-/- FRG-NOD mice. Note the lack of 
staining of adjacent, fah-/- recipient hepatocytes. Tissues were counterstained with DAPI (blue). Myc 
immuno-staining of regenerating hepatic nodules. Numerous representative Myc-positive nuclei in a 
regenerating nodule following transplantation with WT hepatocytes are shown in the top panel. Note the 
absence of Myc in a similar nodule repopulated with KO hepatocytes (lower panel). 
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dropped by >20% and discontinued permanently when weights stabilized at >100% of pre-
transplant values. The time needed to permanently re-establish pre-transplant weights was 
similar in the two groups suggesting that WT and KO hepatocytes possessed equal repopulation 
potential (Fig. 18C). This was supported by the presence of numerous macroscopic and 
microscopic foci of regenerating hepatocytes in both groups of animals (Fig. 18D) and by 
extensive focal FAH immuno-positivity (Fig. 18D, FAH). Additional immuno-histochemical 
staining showed Myc-positive hepatocytes only in regenerating nodules derived from WT donors 
(Fig. 18D, c-Myc). Thus, hepatic parenchyma regeneration by KO hepatocytes could not be 
explained by the selective expansion of cells with non-excised myc loci.  
Quantification of fah+/+ and fah-/- alleles in hepatocytes isolated from repopulated livers 
established that fah+/+ donor cells comprised ~40-50% of the entire hepatocyte population (Fig. 
19A and B). This was confirmed using the PCR-based strategy shown in Suppl. Fig. 31B and C 
(black and blue arrows) to amplify different sized segments of donor and recipient myc loci.  
A more sensitive quantification of proliferative potential was obtained with a competitive 
re-population assay performed ~18 weeks after transplanting a mixed population of WT and KO 
donor hepatocytes (Fig. 19D). PCR of fah alleles (Fig. 19A) again indicated transplant efficiency 
to be ~40% (not shown). PCR for myc alleles (Suppl. Fig. 31A-C) showed that, on average, their 
individual contributions precisely reflected those of the input populations (Fig. 19E). KO 
hepatocytes therefore are not at a proliferative disadvantage even when competing directly with 
their WT counterparts. 
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4.2.6 Abnormal neutral lipid storage following transplantation with KO hepatocytes 
  
Figure 19: WT and KO hepatocytes are equally proficient at re-populating the hepatic parenchyma. 
(A) PCR-based strategy to distinguish fah+/+ donor and fah-/- recipient alleles. (B) Hepatocytes were isolated 
from 11 recipient animals 17-18 wks after transplanting with WT or KO hepatocytes and ~6 wks after NTBC 
discontinuation. PCR of fah alleles showed no difference in the contribution of WT and KO myc alleles to the 
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repopulated liver. (C) The strategy depicted in Suppl. Fig. 30B and C (black and blue arrows) was used to 
amplify the myc alleles from the same hepatocyte samples used in (B). (D) Schematic for competitive 
transplants of Myc WT and KO hepatocytes. (E) 8 FRG-NOD mice were transplanted with a ~1:1 mixture of 
1.5x105 hepatocytes each from WT and KO donors (input) and allowed to achieve NTBC independence. 
Following repopulation, PCR quantification of fah alleles again showed that the donor populations comprised 
~40% of the total hepatocyte mass (not shown). This was confirmed by amplification of the three myc alleles. 
Shown here is the proportion of the donor population in each animal that was comprised of Myc WT and KO 
donor hepatocytes. Note that the average allelic composition of this group was identical to that of the input 
population. Each set of PCR reactions was performed in triplicate for each population of hepatocytes. 
 
The proliferative stress imposed on donor hepatocytes might exaggerate previously identified 
abnormalities or reveal new ones. Consistent with this, ORO staining and triglyceride levels 
were again more pronounced in recipient livers transplanted with KO hepatocytes, with much of 
the stored lipid now being extracellular (Fig. 20A and B). Interestingly, whereas the overall total 
number of lipid droplets/cell fell in transplanted KO hepatocytes, their average size increased, as 
well as  the overall cellular area occupied by lipid. These findings suggested that, following 
transplantation, the lipid droplets of KO hepatocytes increase in size by fusing with pre-existing 
droplets (compare Suppl. Fig. 36A and B to C and D). 
As was the case pre-transplant (Suppl. Fig. 35E), sterol intermediates in recipients 
reconstituted with WT or KO hepatocytes were similar when normalized to protein content (Fig. 
20C) but differed when each analog, including the bile acid intermediate cholestanol, was 
expressed relative to the total sterol content (Fig. 20D). Bile acid levels were also similar in the 
two groups (Fig. 20E). These findings show that abnormalities in sterol biosynthetic pathways, 
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initially identified in pre-transplant hepatocytes only by transcriptional profiling (Fig. 17E) 
become more pronounced following transplantation. 
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4.2.7 Transcriptional profiling of post-transplant hepatocytes 
Post-transplant transcriptional profiling is complicated given that isolated hepatocytes are 
a mixed population of donor and recipient cells (Fig. 19B and C) that could potentially mask 
anything other than the most striking differences between donor hepatocytes. Any differences 
that are observed also cannot necessarily be attributed with certainty to the donor population. 
Nevertheless, with these caveats in mind, we repeated RNAseq on isolated liver cell populations 
from a small number of recipient mice ~18-19 weeks post-transplant. Unlike the limited number 
of transcript differences between pre-transplant hepatocytes (Fig. 17A), we documented 1784 
differences (q<0.05) in the post-transplant setting (Fig. 21A). Gene ontology analysis revealed 
that the 3 groups involving the greatest number of common function transcripts related to energy 
production, metabolism and ribosomal proteins. The first included 19 of the 44 known subunits 
of Complex I and Park7/DJ-1, which plays a role in mitochondrial fission and Complex I 
stabilization [241]. All these transcripts were down-regulated in the livers of mice repopulated 
with KO hepatocytes (Fig. 21B). The second group contained 20 transcripts encoding subunits of 
Figure 20: Hepatic repopulation enhances the defective handling of lipids in KO hepatocytes. (A) 
ORO-stained liver sections showing increased neutral lipid accumulation following transplant of KO 
hepatocytes. The last 2 panels are higher power magnifications that demonstrate not only the overall 
increased lipid content in KO hepatocytes but the larger size of their lipid droplets and extracellular lipid 
deposits. See Suppl. Fig. 36C and D for quantification of lipid droplet numbers and sizes. (B) Quantification 
of total triglyceride levels in mouse livers. Triglyceride assays were performed as described for Suppl. Fig. 
35B. (C) Liver sterol levels adjusted to protein content. Assays were performed as described for Suppl. Fig. 
35E. (D) Data from C expressed as a fraction of total sterol content as described in Suppl. Fig. 35F. (E) No 
differences in the total bile acid of WT and KO transplanted liver, performed as described in Suppl. Fig. 35G. 
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various ATPases, 7 of which encoded components of Complex V (Fig. 21C). These were down-
regulated in the livers of mice repopulated with KO hepatocytes whereas 10 of the remaining 13 
were up-regulated. The third group was comprised of transcripts encoding 61 members of both 
large and small ribosomal subunits, all of which were down-regulated (Fig. 21D). This group 
contained all 6 small ribosomal subunit transcripts previously identified as being down-regulated 
in KO hepatocytes (Fig. 17C). 6 of the 10 most highly altered pathways discovered through 
Ingenuity Pathway Analysis, all of which were up-regulated in recipient livers transplanted with 
KO hepatocytes, pertained to some aspect of acute or chronic inflammation or healing, including 
the induction of fibrosis, leukocyte and IL-8 signaling, phagocytosis and modulation of the 
complement system, (Fig. 21E and Suppl. Table 8). This strongly correlated with increased 
immuno-histochemical staining for the pan-leukocyte cell surface marker CD45 and for 4-
hydroxynonenol, a byproduct of lipid peroxidation (Fig. 21F and Suppl. Fig. 37). 
 The remaining 4 pathways were related by virtue of the central role of mTOR in 
nutrient-sensitive control over protein translation and mitochondrial oxidative function, although 
mTOR also plays a central role immune modulation [242]. The most conservative interpretation 
of these results is that the livers of mice, otherwise equally repopulated with WT or KO 
hepatocytes, nevertheless vary considerably in their gene expression profiles, with the latter 
showing an up-regulation of transcripts involved in pro-inflammatory pathways and a down-
regulation of transcripts regulating mitochondrial function and protein translation.  
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4.3 DISCUSSION 
Previous studies on Myc’s role in hepatic function have produced conflicting or 
inconclusive results. For example, Baena et al. noted increased nuclear pyknosis and apoptosis in 
KO hepatocytes and a disorganized hepatic parenchyma with whereas Sanders et al. found no 
differences [87, 89]. Sanders et al. observed identical liver:body weight ratios in WT and KO 
mice whereas Qu et al. found them to be somewhat reduced in KO mice and Baena found them 
to be increased [87, 89, 225]. Only Sanders et al. reported liver weights following PH and found 
them to be similar in WT and KO mice [87]. Potential explanations for the discrepancies among 
these studies include variable efficiencies of myc gene knockout, excision of myc from cells 
other than hepatocytes and differences in animals’ ages when various phenotypes were assessed. 
Like Qu et al. [225], we found lower liver:body weight ratios in young KO mice (Suppl. 
Fig. 32A). Since WT and KO hepatocytes were of equivalent size (Suppl. Fig. 32C), the most 
likely explanation is that KO livers contained smaller numbers of normal-sized cells as 
Figure 21: Transcriptional profiling of post-transplant hepatocytes. (A) RNAseq results for 
all 1784 differentially expressed transcripts with q values <0.05. (B-D) Gene ontology profiling for 
transcripts involved in common functions identified 20 encoding components of Complex I, 20 
encoding various ATPases and 61 encoding ribosomal components. (E) Ingenuity Pathway Analysis 
depicting the most de-regulated functionally related groups of transcripts shown in A. Green bars 
and red bars indicate transcripts that are up-regulated and down-regulated, respectively in cells 
isolated from animals transplanted with KO hepatocytes. Transcripts levels from these top 10 
pathways are represented in Suppl. Table 8. 
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previously described [78, 84]. The larger livers of older KO mice (Suppl. Fig. 31A) likely 
reflects their age-related lipid accumulation (Suppl. Fig. 35 and 36A and B). 
Increased VO2 by hemizygous (myc+/-) mice has been attributed to a higher surface 
area:body mass ratio and/or to the increased activity and caloric intake of older animals [78]. 
These physical differences, as well as the global nature of the myc+/- state, precluded a more 
definitive explanation for the higher VO2. In our KO mice, increased VO2 and VCO2 were not 
associated with differences in weight, caloric intake or activity compared to WT mice (Fig. 15 
and data not shown). Thus, although the KO metabolic phenotype is solely attributable to the 
loss of Myc in hepatocytes, we cannot state unequivocally that the liver is the actual site of the 
abnormal gas exchange. Indeed, an interesting observation was that despite increased VO2 and 
CO2 in KO animals, there was no difference in RER (calculated as the ratio of VCO2/VO2) 
indicating that fuel utilization was unchanged during fasting and re-feeding in the whole animal. 
The more pronounced metabolic abnormalities of KO mice maintained on a high fat diet 
is likely related to their higher rate of hepatic FAO (Suppl. Fig. 32H) This is reminiscent of 
metabolic changes observed in hearts of obese and/or diabetic mice where reduced glucose 
uptake is offset by an imbalanced increase in fatty acid uptake and utilization, with the former 
exceeding the latter and the difference being stored as neutral lipid [243]. FAO is associated with 
more efficient production of TCA-cycle-derived NADH and FADH2, higher oxygen 
consumption and increased reactive oxygen species (ROS) production, which can cause 
mitochondrial uncoupling [244]. The greater activity of Complex V in KO liver mitochondria 
(Suppl. Fig. 32H and I) may therefore represent a successful compensatory mechanism to 
maintain normal ATP levels in the face of an excess reliance on FAO during a time of excessive 
ETC stress or compromise. 
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The abnormalities in fatty acid metabolism in KO mouse livers also bear similarity to 
those observed in myc-/- fibroblasts [4, 11]. That KO hepatocytes did not activate AMPK 
however, suggests that, while energetically stressed, they maintain normal energy supplies, 
perhaps by optimizing their excessive reliance on FAO. This successful adaptation could be the 
result of less severe mitochondrial structural abnormalities than occur in myc-/- fibroblasts [4] 
(no significant changes in proteomics data [not shown] and Suppl. Fig. 33) and/or the higher 
Complex V activity (Suppl. Fig. 33H and I) [245]. It remains unclear why hepatocytes are so 
much less reliant on Myc than fibroblasts for maintaining mitochondrial integrity. 
Unlike cell lines in which Myc over-expression affects hundreds-thousands of genes [18] 
KO hepatocytes had relatively few transcriptional changes (Fig. 17A). This may reflect the 
relatively low expression levels of Myc in the largely quiescent WT hepatocyte population 
and/or its otherwise normal regulation in the former cells. Transcript differences included those 
encoding some of the same ribosomal proteins reported by others as being affected by Myc over-
expression [87, 234]. However, the most striking differences involved pathways pertaining to 
sterol and bile acid biosynthesis. Cyp450 family members, which also play important roles in 
steroidogenesis and bile acid production, were also highly de-regulated[233, 246] (Fig. 17E). 
Interestingly, 2 of the 7 most de-regulated pathways involved LXRs and FXRs, which are 
activated by oxysterol and bile acid metabolism, respectively [247]. LXRs and FXRs may also 
regulate fatty acid and glucose metabolism, both of which are also Myc-responsive [15, 235]. 
The lipid storage defects of KO livers thus appear to be the result of both increased fatty acid 
uptake [11, 69] and defective steroidogenesis. The ongoing accumulation of these in lipid 
droplets likely accounts for the age-related increase KO liver size (Suppl. Fig. 16A) [248]. 
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Our studies on the repopulation potential of WT and KO hepatocytes capitalized on the 
fact that they expand 50-100-fold following transplantation [227, 240] thus providing a more 
demanding and prolonged proliferative stress than afforded by PH [224, 240]. This model also 
allows a more accurate evaluation of intrinsic hepatocyte proliferative capacity given that it 
assesses re-population rather than regeneration which is more dependent on contributions from 
liver cells other than hepatocytes [224]. That the transplanted fraction remains constant at ~40% 
over time (Fig. 19B and C) probably reflects the ability of donor cells to fully assume the 
disposal of toxic tyrosine catabolites, thus eliminating any further selective pressure. 
Collectively, these studies provide what we feel to be unequivocal proof that Myc is dispensable 
for hepatic repopulation, even under the most challenging circumstances. 
Despite the equivalent repopulation potential of WT and KO hepatocytes (Fig. 19), we 
observed marked differences in the post-transplant setting including an exacerbation of the pre-
existing lipid abnormalities. The lipid accumulation by KO livers is reminiscent of non-alcoholic 
fatty liver disease that commonly evolves to a more severe form termed non-alcoholic 
steatohepatitis [238, 249]. This progression is associated with increased oxidative stress, de-
regulation of cyp450 genes and extracellular lipid accumulation leading to long-term 
inflammation, fibrosis and hepatic failure [90, 249]. The prominence of inflammation- and 
fibrosis-related pathways in the post-transplant setting (Fig. 21E) is consistent with such 
evolution and probably involves transcripts expressed by inflammatory cells that co-purify with 
KO hepatocytes (Fig. 21F and Suppl. Fig. 37). The widespread de-regulation of cyp450 genes in 
KO hepatocytes might further abet this pro-inflammatory environment by affecting arachidonate 
and eicosanoid metabolism [246]. 
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Myc’s dispensability for hepatocyte repopulation is consistent with some reports in other 
organ systems. For example, myc deletion during murine intestinal morphogenesis leads to an 
early but transient decline in the number of small intestinal crypts [85]. Long-term suppression 
of Myc in adult mice with a globally-expressed dominant-negative form of the protein is also 
associated with transient intestinal and hematopoietic phenotypes [86]. In contrast, myc’s 
deletion from hematopoietic stem cells results in impaired hematopoietic renewal and a sustained 
reduction in both myeloid and lymphoid compartments [250]. The long-term survival and 
maintenance of normal tissues thus appears to be under distinct forms of Myc-directed control 
that in many cases are quite different than occur in tumors, which are commonly “addicted” to 
the oncoprotein [86, 221]. Clearly, it will important in future work to define the nature of these 
differences. 
4.4 EXPERIMENTAL PROCEDURES 
4.4.1 Animal studies 
All animal work was conducted in conformity with the Public Health Service Policy on Humane 
Care and Use of Laboratory Animal Research (ILAR) Guide for Care and Use of Laboratory 
Animals. Experimental procedures were approved by the Institutional Animal Care and Use 
Committee at the University of Pittsburgh. C57BL6 c-Mycfl/fl (WT) mice were obtained as a gift 
from I. Moreno de Alboran [89, 222]. They were housed in a pathogen-free facility, maintained 
under standard conditions. Mice were fasted overnight before sacrifice unless otherwise noted. 
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Myc KO mice were generated by breeding a Cre-recombinase heterogeneous mouse with a WT 
control, and then genotyped for Cre-recombinase positivity. FRG-NOD mice (Yecuris, Inc., 
Tualatin, OR) [240, 251] were bred and maintained on 8mg/L NTBC (Yecuris) in the drinking 
water. At the time of sacrifice, mice were euthanized, and their livers were weighed and divided 
into small pieces for further analysis. Genomic DNA was tested for Myc WT and KO PCR 
products, from primers listed in Table 6. 
Table 6: PCR primers used in Chapter 4 
Transcript 
Name: 
Forward Primer Sequence Reverse Primer Sequence Annealing Product 
(5' → 3') (5' → 3') Temp. Length 
(bps) 
  
Myc WT GCCCCTGAATTGCTAGGAAGACTG CCGACCGGGTCCGAGTCCCTATT 65 379 (wt/wt)     
413 (fl/fl) 
Myc KO TCGCGCCCCTGAATTGCTAGGAA TGCCCAGATAGGGAGCTGTGATACTT 65 666 
FAH WT TGAGAGGAGGGTACTGGCAGCTAC TTGCCTCTGAACATAATGCCAAC 57 250 
FAH Δ GATTGGGAAGACAATAGCAGGC TTGCCTCTGAACATAATGCCAAC 57 145 
 
4.4.1.1 Metabolic cage studies 
Mice were maintained on a diet comprised of 45 kcal% fat (D12451, Research Diets Inc., New 
Brunswick, NJ) for 22 weeks prior to performing metabolism studies (high fat diet). Mice were 
weighed every week and body composition was determined every four weeks in awake mice 
using EchoMRI (Echo Medical Systems, Houston, TX). Oxygen consumption (VO2), respiratory 
exchange ratio (RER), and physical activity were determined using a Comprehensive Laboratory 
Animal Monitoring System (CLAMS, Columbus Instruments, Columbus, OH). Mice were fed-
fasted-refed during the CLAMS monitoring. Re-feeding was with 5% glucose solution in 
addition to standard chow diet. The respiratory exchange ratio (RER) was defined as the ratio of 
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VCO2/VO2. Caloric value (CV) was calculated from the formula: CV = 3.815 + (1.232 x RER) 
and heat production was calculated from the formula: Heat = CV x VO2. 
4.4.1.2 Hepatocyte isolation 
Hepatocytes were isolated as previously described using a two-step collagenase perfusion 
method [228]. PCR primers listed in Table 6 allowed us to distinguish fah+/+ donor and fah-/- 
recipient alleles. Similarly, donor and recipient myc alleles could be distinguished by a similar 
PCR-based strategy (Suppl. Fig. 31A-C). 
4.4.2 Histology and immunohistochemistry 
H&E and ORO staining of paraffin-embedded sections were performed using standard 
histopathologic techniques. FAH immuno-staining was performed as previously reported[228]. 
Immuno-staining for Myc, CD45 and 4-HNE were performed under similar conditions (Table 7). 
4.4.3 Assays for pyruvate dehydrogenase, 3H-palmitate oxidation, acetyl CoA and ATP 
PDH activity was quantified using the PDH Enzyme Activity Microplate Assay Kit according to 
the directions provided by the supplier (MitoSciences, Eugene, OR). Liver pieces were 
homogenized in PBS and protein concentrations were determined using a BCA assay (Pierce, 
Inc., Rockford, IL). The homogenate was solubilized in the detergent provided in the kit and 
processed according the manufacturer’s protocol. Typically, 100 µg of extract was assayed 
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kinetically on a BMG LabTech FLUOstar Omega instrument for 30 minutes (Cary, NC). The 
kinetic rates were determined as change in OD over time. 
 For 3H-palmitate oxidation, fresh tissue was finely minced and added to SET buffer 
(0.25 M sucrose, 10 mM Tris, 1 mM EDTA at pH 7.4) containing 1 mM carnitine plus with 0.5 
µCi BSA-bound [9.10-3H(N)]-palmitate (sp. act. = 32 mCi/mmol) (Perkin-Elmer, Waltham, 
MA). The mixture was incubated at 37C for 1 hour, then homogenized and subject to organic 
extraction as previously described [11]. Total protein content was determined using the BCA 
reagent. 
To measure Acetyl CoA, a pulverized piece of flash frozen tissue was solubilized in ice 
cold lysis buffer (20 mM Tris, pH 7.5; 150 mM NaCl; 1 mM EDTA; 1 mM EGTA; 1% Triton 
X-100; 2.5 mM sodium pyrophosphate; 1 mM -glycerolphosphate; 1 mM Na3VO4; 1 μg/ml 
Leupeptin and 1 mM PMSF). The assay was then carried out according to manufacturer’s 
instructions using an Acetyl-Coenzyme A Assay Kit (Sigma-Aldrich cat. # MAK039). 
ATP assays were performed by lysing tissues with 10% trichloroacetic acid to inactivate 
ATPases, and then diluting the samples 1:50 with PBS. 100 µl of this was mixed with 50 µl of 
ATPlite mammalian cell lysis solution in quadruplicate in 96 well plates. The remainder of the 
assay was carried out according to the manufacturer’s instructions using the ATPliteTM 
Luminescence Assay System (Perkin Elmer, Waltham, MA). Results were normalized to total 
protein levels, which were determined on separate sets of identical wells. 
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4.4.4 Immuno-blotting 
Immuno-blotting was performed essentially as described previously using whole liver lysates 
[11, 232]. Antibodies used are listed in Table 7. 
Table 7: Antibodies used in Chapter 4 
Name of antibody Vendor Catalog no. Dilution Secondary 
AMP-dependent protein kinase (AMPK) Cell Signaling  2532S 1:1000 Rabbit 
pAMPK(Thr172) Cell Signaling  4188S 1:1000 Rabbit 
β-actin Cell Signaling  3700S 1:10000 Mouse 
FAH Gift from Markus Grompe 1:500 Rabbit 
c-Myc Epitomics 1472-1 1:500 Rabbit 
Caspase-3 Cell Signaling  9662S 1:2000 Rabbit 
L-Myc (C-20) Santa Cruz sc-790 1:500 Rabbit 
N-Myc Santa Cruz SC-791 1:1000 Rabbit 
ChREBP Abcam ab157155 1:2000 Rabbit 
GAPDH Sigma G8795 1:20,000 Mouse 
4-HNE EMD Millipore 393207 1:2,000 Rabbit 
CD-45 Santa Cruz sc-53665 1:100 Rat 
 
4.4.5 BNGE of mitochondrial proteins and assays for ETC function 
BNGE and enzymatic assays for ETC Complexes I, III, IV and V as well as supercomplexes 
comprised primarily of Complexes I, III and V were performed as previously described [4, 232]. 
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4.4.6 Quantification of oxidative phosphorylation 
These studies were performed on an Oroboros Oxygraph 2k instrument (Oroboros 
Instruments,Innsbruck, Austria). Homogenates were prepared from fresh liver tissue as described 
in the protocol provided by the vendor (MiPNet17.02). Oxygen consumption was measured in 
MiR05 medium (0.5 mM EGTA, 3 mM MgCl2, 60 mM K-lactobionate, 20 mM taurine, 10 mM 
KH2PO4, 20 mM HEPES, 110 mM Sucrose, and 1 g/L bovine serum albumin) at 37
oC Substrates 
added throughout the experiment included those for Complex I (glutamate [10mM], malate 
[1mM], pyruvate [5mM]), complex II (succinate [10mM]), Complex V (ADP [4mM]) and 
cytochrome C (10 µM) to assess outer mitochondrial membrane integrity. O2 consumption rates 
were normalized to total protein content. 
4.4.7 Proteomic Mass Spectrometry 
4.4.7.1 In solution trypsin digestion for mass spectrometry 
For each digestion, 20 µg of mitochondria were re-suspended in 100 µl 50 mM 
NH4HCO3/0.02% ProteaseMAX™ Surfactant (Promega, Madison, WI). The mixture was then 
boiled for 10 min in the presence of 10 mM dithiothreitol and then alkylated by the addition of 
45 mM iodoacetamide for 1 hr in the dark at room temperature). 0.5 µg of trypsin gold 
(Promega, Madison, WI) was then added and digestion was performed overnight at 37°C. The 
resulting tryptic peptides were de-salted using PepClean C-18 Spin Columns (Pierce, Inc., 
Rockford, IL), vacuum-dried, and re-suspended in 40 µl of 0.1% formic acid. 
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4.4.7.2 Targeted mass spectrometry assays for selected peptides 
Selective/multiple reaction monitoring (SRM/MRM)-based targeted mass spectrometry was 
performed on a TSQ Quantum Ultra instrument (Thermo Fisher Scientific) coupled to a Thermo 
Fisher Nanoflow Dionex Ultimate 3000 liquid chromatography system. Nano-LC separations, 
each performed in duplicate, used an analytical C18 PicoChip™ columns packed with 10.5 cm 
Reprosil C18 3µm 120Å chromatography media with a 75 µm ID column and a 15 µm tip (New 
Objective, Inc., Woburn, MA). Mobile phase A consisted of 0.1% formic acid in HPLC water 
and mobile phase B consisted of 0.1% formic acid in 100% acetonitrile. 2 g of tryptic peptides 
were loaded onto the column and washed with mobile phase A for 4min at 6 l/min. The 
peptides were then eluted into the analytical C18 column at a flow rate of 300 nl/min with a 
gradient comprised of 0-5% solvent B for 4.5 min, 5-40% solvent B for 31.5 min, 40-95% 
solvent B for 4 min and 95% solvent B for 8 min. The collision energies were calculated using a 
linear equation CE =0.034 x m/z + 3.314. The full width at half maximum was set to be 0.7 Da 
for Q1 and Q3. The instrument was operated using scheduled SRM mode with 1 sec cycling time 
and 5 min retention time window. The majority of peptides had base peak widths of ~20 sec base 
and ~12 data points were acquired per chromatogram peak. Skyline software [252] was used to 
facilitate targeted SRM assay method development and data analyses. The transitions of the 
targeted peptides were originally selected based on mouse tandem spectrum library downloaded 
from PeptideAtlas (http://www.peptideatlas.org/) and subsequently optimized on the TSQ. All 
selected peptides and their corresponding SRM assay parameters are available upon requrest. 
Peak areas of all transitions for the same peptide were summed and the total peak area was used 
as metric for relative quantitation. Student’s t test was applied to log-transformed total peak area 
to determine the significance of the differences between groups. 
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4.4.7.3 Unbiased label free mass spectrometry assays 
2 µg of tryptic peptides per sample were analyzed with reverse-phased LC-MS/MS using a 
nanoflow LC (EASY-nLC II, Thermo Fisher) coupled online to LTQ/Orbitrap Velos Elite hybrid 
mass spectrometer (Thermo-Fisher). Mobile phases contained 0.1% formic acid in HPLC grade 
water for solvent A and 0.1% formic acid in 100% acetonitrile for solvent B. Peptides were first 
loaded onto a C-18 trap column (Thermo Fisher) and desalted on line for 6 l solvent A. 
Peptides were then eluted onto a capillary column (75 m inner diameter x 360 µm outer 
diameter x 15 cm long (Polymicro Technologies, Phoenix, AZ) slurry-packed-in-house with 5 
µm particle size, 125 Ǻ pore size C-18 silica-bonded stationary phase (Phenomenex, Torrance, 
CA) and resolved using a 100 min gradient at the flow rate of 0.2 µl/min (3-33% B for 90min, 
33-80% B for 2min, constant at 80% B for 6min, and then 80-0% B for 2min). Eluted peptides 
were analyzed via electrospray ionization to the mass spectrometer. Data was collected in 
positive ionization mode, with FT MS1 AGC targets = 100,000, maximum injection time = 200 
ms, spray voltage = 2.5 kV, capillary temperature = 325°C. Acquisition consisted of cycle of a 
full scan FT mass spectrum at a resolution of 60,000 and top 20 MS/MS spectra recorded 
sequentially on the most abundant ions on the ion trap. 
Relative label free quantification of identified peptides/proteins was obtained MaxQuant 
software (version 1.5.1.0). Acquired MS/MS spectra were searched using the MaxQuant build-in 
Andromeda search engine against a mouse proteome downloaded from UniProt 
(http://www.uniprot.org/) together with a sequence database for frequently encountered 
contaminants with the following modifications: trypsin as the proteolytic enzyme, static 
carbamidomethylation of cysteine (+57.0214 Da), variable oxidization of methionine (+15.9949 
Da) and variable acetylation of proteins’ N-termini (+42.0106 Da ). Mass tolerance was set to 20 
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ppm for initial search and 4.5 ppm for the main search for precursor ions, and 0.5 Da for 
fragment ions. Minimum peptide length was set to 7 amino acids and the false discovery rate 
(FDR) based on a target-decoy approach was set to 1%. The match between runs options was 
enabled with 2 min match time window and 20 min alignment window. The intensity values 
from MaxQuant output for identified peptides were used for relative quantitation across samples. 
Only peptides with non-zero intensity values in all samples were included for statistical test. 
Student’s t test was applied to log-transformed intensities to identify peptides with significant 
difference between WT and KO. The linear step-up (LSU) [253] was used to compute FDR-
adjusted p-values (q values) to account for multiple comparisons. Mitochondrial localization was 
confirmed by the David (http://david.abcc.ncifcrf.gov/) Bioinformatics Database and/or mouse 
MitoCarta Inventory (http://www.broadinstitute.org/pubs/MitoCarta/mouse.mitocarta.html). All 
selected peptides and their corresponding SRM assay parameters are available upon request. 
4.4.8 RNAseq and analyses 
Total RNAs were extracted from 107 isolated WT or KO hepatocytes using Qiagen RNeasy 
columns (Valencia, CA). Each RNA sample was assessed for quality and quantity using a Qubit 
2.0 fluorometer and Agilent Bioanalyzer TapeStation 2200. The Sample preparation was 
replicated using Illumina TruSeq Stranded mRNA kit (San Diego, CA). mRNA was used to 
generate poly-A+ libraries using oligo-dT beads following 2 rounds of poly-A selection. 
Following this, RNA was fragmented to an average length of 260 nt by magnesium-catalyzed 
hydrolysis at 940C and then converted into cDNA by random priming. cDNA 3’ ends were 
adenylated, followed by adaptor ligation and a 9-cycle PCR to enrich DNA fragments. cDNA 
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libraries were then validated using KAPA Biosystems (Wilmington, MA) primer premix kit with 
Illumina-compatible DNA primers on the Qubit 2.0 fluorometer and Tapestation 2200 systems 
described above. Libraries were diluted in 0.1% Tween 20 to concentrations of 2 nM for 
stabilization. The cDNA libraries were then pooled to final concentrations of 2.5 pM. Cluster 
generation and 75 bp paired-end single-indexed sequencing were performed with an Illumina 
NextSeq 500 sequencer. Sequence analysis was performed using mRNA-Seq for Differential 
Expression in Eukaryotes (Maverix Biomics, San Mateo, CA). Raw sequencing reads were 
quality checked for potential sequencing issues and contaminants using FastQC (Babraham 
Bioinformatics, Inc, Cambridge, UK.). Adapter sequences, primers, Ns, and reads with quality 
score below 28 were trimmed using fastq-mcf of ea-utils and PRINSEQ 
(http://prinseq.sourceforge. net/manual.html). Reads with a remaining length of less than 20 bp 
after trimming were discarded. Paired end reads were mapped to the mouse genome (m10) using 
TopHat (http://ccb.jhu.edu/software/tophat/index.shtml) in a strand specific manner. Read 
coverage on forward and reverse strands for genome browser visualization was computed using 
SAMtools, BEDtools, and UCSC Genome Browser utilities. Pairwise differential expression was 
quantified using Cuffdiff and DESeq [254, 255]. Cufflinks was used to determine FPKM levels 
for each gene from the TopHat alignment and was used as input for Cuffdiff. Significant 
differentially expressed genes were determined by adjusted P-value with a threshold of 0.05. 
DESeq w a s  utilized for raw read counts, which were calculated by HTSeq based on the TopHat 
alignment (http://www-huber.embl.de/users /anders) /HTSeq/doc/count.html. Read counts were 
then normalized across all samples and significant differentially expressed genes were 
determined by adjusted P-value with a threshold of 0.05 [253]. 
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4.4.9 Hepatic triglyceride, sterol and bile acid quantification 
Triglyceride content was determined on ~25 mg of flash-frozen tissue using the Infinity™ 
Triglycerides reagent (Thermo Scientific, USA) as previously described [256]. 
To determine serum and hepatic sterol levels, we used ion-ratio GC/MS on an Agilent 
6390N/5973 GC/MS system as previously described [9] with modifications to the GC/MS 
method to include ions specific for principal post-squalene cholesterol precursors. Bile acids 
were quantified on frozen total liver tissue using a Mouse Total Bile Acids Assay kit (Crystal 
Chem, Downer’s Grove, IL) using the suppliers’ protocol. 
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5.0  CONCLUSIONS AND FUTURE DIRECTIONS 
5.1 CONCLUSIONS 
We hypothesized that loss of Myc might switch dependence from glucose to fatty acids. One of 
the major findings in the previous chapters is the role of Myc in the regulation of FAO and lipid 
accumulation. We have shown in two models of myc homozygous deletion, a rat myc-/- 
fibroblast cell line and myc-/- mouse liver homogenates, an increase in FAO, indicating that the 
loss of Myc changes the preferential fuel source from glucose and glutamine to fatty acids. That 
both glycolysis and Oxphos are Myc-driven as well is abundantly clear, as Myc over-expressing 
cells can increase both while Myc KO fibroblasts and hepatocytes have reduced capacity [4]. 
Surpassing demand by β-oxidation, the accumulation of intracellular lipids droplets also 
accompanies inhibition of Myc, as demonstrated in cancer cell lines or non-transformed cell lines 
and in vivo tissue (chapters 2 and 4 and [69, 72]). Because all of the Myc KO models 
demonstrated lipid congestion resulting from an imbalance between FAO and uptake, we can 
infer the means for sensing proper balance must be Myc regulated. The loss of Myc typically 
results in decreased respiratory chain capabilities that result in mitochondrial dysfunction, ATP 
deficit, activation of AMPK [4, 11, 72]. That Myc KO hepatocytes do not have activated AMPK 
or reduced ATP and acetyl CoA levels means in vivo loss by hepatocytes does not result in 
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severe energy crisis. Perhaps because the ETC default in mouse hepatocytes is not as severe, 
they are able to better cope metabolically with Myc loss.  
 In chapter 3, we examined the coordination between Myc-directed metabolism and 
AMPK, and how this would affect proliferation. AMPK was found to be unnecessary for the 
induction of Myc-driven proliferation in MEFs, but it does contribute to maintaining 
mitochondrial homeostasis. Crosstalk between Myc and AMPK balances Myc-driven anabolism 
with AMPK-driven catabolism, as illustrated in the dramatic drop of ATP levels in ampk-/- cells 
following the abrupt induction of Myc expression. That Myc activation leads to increased 
glycolysis and ROS production has been documented in many studies [22, 152], but that AMPK 
represses glycolysis and ROS production has been shown in cells with only Myc de-regulation. 
Loss of AMPK function may be more devastating in further progressed tumorigenesis with a 
variety of driver mutations.  
Chapter 4 offered conclusive evidence that Myc is unnecessary for adult hepatic 
proliferation, during the course of a 50-100-fold expansion of transplanted Myc KO hepatocytes. 
The more intense proliferative stress imposed by this method compared to a 2/3rd partial 
hepatectomy is drastic. Interestingly, the fact that our assay was so specific to hepatocytes does 
not allow any conclusions to be made on any of the other liver cell types, such as biliary-specific 
regeneration [257]. Though there was no differential repopulation capacity, there was a huge 
disparity in the amount of stress and damage caused by the KO population, as shown by 
transcriptional differences, lipid droplet accumulation, inflammatory infiltrate, and lipid 
peroxidation. This is analogous to the human disease non-alcoholic fatty liver disease (NAFLD) 
which we hypothesize could worsen to non-alcoholic steatohepatitis (NASH) with increased 
stress common to the aging process.  
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5.2 FUTURE DIRECTIONS 
5.2.1 What is the role of HIF2 and MONDOA/CHREPB in lipid accumulation occurring 
from loss of Myc? 
A paper from Rankin et al. [258] found changes in lipid metabolism very similar to our Myc KO 
hepatocytes, including severe hepatic steatosis, caused by constitutive activation of hypoxia 
inducible factor 2 (HIF2). HIF2 has a stabilizing effect on the Myc-Max heterodimerization 
under normal conditions, by binding with Max and blocking interactions with Mad1, which can 
enhance transcription of target genes [2] and is expressed preferentially in the hepatic 
parenchyma [259]. HIF2 also regulates the Myc family of transcription factors by inducing 
Mxd2 transcription [1]. When Myc is absent or deregulated, the effect on HIF2 is unknown. 
RNA sequencing in proliferating, transplanted hepatocytes (though contaminated with an equal 
proportion of recipient tyrosinemic hepatocytes as described in chapter 4) found HIF2α (also 
known as EPAS1) to be 1.5-fold up-regulated by RNA sequencing in the Myc KO hepatocytes, 
while HIF2β (or ARNT2) was 5.2-fold up-regulated in KO hepatocytes. This implies that loss of 
Myc constitutively up-regulates HIF2 at the transcriptional level in proliferating hepatocytes 
(although we cannot state unequivocally that the transcripts are of donor cell origin).  
 To summarize the Myc family of transcription factors, Myc (and paralogs L-Myc 
and N-Myc) heterodimerize with obligate binding partner Max, another basic helix-loop-helix 
leucine zipper (bHLHLZ) protein (Figure 22A). The Mxd arm of the family include Mxd1-4, 
MNT, MGA, which also bind to Max and oppose Myc signaling, such as prompting cell cycle 
arrest and differentiation  [41]. Mxd1&4 and MNT can also bind to MLX, which coordinates the 
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nutrient sensing arm of the Myc family. The nutrient sensing arm of the family include MondoA 
and MondoB, more commonly referred to as ChREBP. Loss of Myc in these proliferating 
hepatocytes keeps HIF2 from binding to Myc-Max dimers and instead allow Max:Mxd1 
heterodimerization and HIF2 activation of Mxd2. (Figure 22B). De-regulation in the Myc family 
members could tip the balance between normal lipid regulation and increased lipid accumulation 
as regulated by the Myc family member MondoA (as described by [40, 41]). Several interesting 
questions arise from this, such as: 1) What are the proteins levels of HIF2, the Mxd proteins, 
MondoA and ChREBP in Myc-driven proliferation states?; 2) Does ChREBP play a similar role 
in lipid regulation, given that it is the predominant liver isoform and that it has been shown 
previously to preferentially regulate genes involved in carbohydrate and lipid metabolism [260]?; 
3) Is HIF2 necessary for hepatic survival in proliferating myc-/- hepatocytes, and in what manner 
does it contribute to the steatosis found in both models of Myc loss and HIF2 constitutive 
activity?; and 4) Does HIF2 interact with MondoA or ChREBP, or perhaps control Max or Mlx 
dimerization in some way between the Mxd arm, which affects hepatic steatosis? 
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5.2.2 How does lipid biosynthesis affect proliferation in Myc-driven cancers? 
 Lipid synthesis is critical for many tumors, including Myc-driven cancer [40, 261]. This is 
supported by slowed tumor growth after inhibiting key enzymes involved in lipid synthesis such 
Figure 22: Role of HIF2 and Myc in Steatosis (A) Under normal, basal conditions, the Myc:Max 
heterodimer is stabilized by HIF2 [1, 2], which acts in balance with other Myc family members to coordinate 
transcription and appropriate lipid synthesis. (B) When Myc is absent, Max can bind preferentially to the Mxd arm, 
thus allowing Mlx:MondoA heterodimers to increase lipid synthesis. 
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as ACCα, FASN, and stearoyl-CoA desaturase 1 (SCD1) [63, 64, 262]. Transcription factors that 
promote lipid biogenesis are considered good targets for cancer metabolism [263], and many of 
these are down regulated in myc hypomorphic mice, which also exhibit lower cholesterol and 
fibrosis levels than controls [78]. The accumulation of fat in Myc KO models comes from 
increased uptake, rather than increased synthesis (as shown in Chapter 2), and enhanced β-
oxidation further limits synthesis (in an AMPK-dependent manner as described previously). It is 
possible that a therapeutic reduction of Myc might provide health benefits against diseases like 
non-alcoholic fatty liver disease or hepatocellular carcinoma, particularly when combined with 
therapeutic interventions like metformin. Metformin’s mechanism of action involves the 
activation of AMPK, which can then drive FAO and Oxphos while simultaneously inhibiting 
fatty acid synthesis [264, 265]. Faubert et al. [79] found that loss of AMPK signaling cooperates 
with Myc to accelerate tumorigenesis, therefore, reversing both of these trends might 
dramatically reduce tumorigenesis. The reduction of Myc combined with AMPK activation 
would also combat cancers through one of the main mechanisms of Myc-driven cancers – an 
increase in fatty acid synthesis.  
 
5.2.3 What is the effect of AMPK loss in Myc-driven tumors, and how does non-
cannonical ROS activation contribute? 
In chapter 3, we found the primary mechanisms of AMPK activation during Myc over-
expression was the non-canonical activation by ROS, in addition to a reduction in cellular ATP 
(Figure 23A). Potential sources of ROS include the Myc activation of genes that elevate 
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oxidative metabolism thus ROS production, such as p53 [266], ornithine decarboxylase [267], 
TGF-α [268], or the fact that Myc increases Oxphos and thus increases the basal ROS produced 
in the ETC. The sustained phosphorylation of AMPK lasted 8 days after the removal of 4HT and 
4 days beyond a restoration of ATP levels (Figure 23B). We also found ROS levels to remain 
elevated up to 8 days after 4HT removal, as measured by MitoSox staining and flow cytometry. 
Sustained phosphorylation of AMPK ceased after a corresponding reduction in ROS by the 
antioxidant N-acetyl Cysteine (NAC) (Figure 23C). Non-canonical activation by sustained ROS 
explains the delayed phosphorylation of AMPK when 4HT was removed.  
 
Figure 23: Activation of AMPK by Myc. (A) Myc induction promotes AMPK activation through an 
ATP poor and ROS rich environment. (B) When Myc signaling is removed, ATP levels return to normal 
almost immediately, but ROS levels remain high and AMPK stays activated. (C) When ROS signaling is 
perturbed by an antioxidant, N-Acetyl Cysteine (NAC), an ATP-poor conditions persists but AMPK is not 
activated. 
Not as much is known about non-canonical modes of AMPK activation, so it is 
worthwhile to expand this model of Myc-directed activation and see if the ROS activation still 
occurs. A cancer cell line where Myc is a major driver of proliferation could be used to 
determine if tumorigenesis requires AMPK, either during initiation or for sustained proliferation. 
Going one step further, if AMPK is required, is initiation or proliferation inhibited if AMPK 
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activation is inhibited by reducing ROS levels? The activation of AMPK may or may not require 
reduced ATP or increased ROS, as determined by pharmacological inhibition of each. 
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APPENDIX A 
SUPPLEMENTAL FIGURES 
 
 
 
 
 
Figure 24: (A) Immunoblots of endogenous c-Myc and MycER in AMPK WT and KO MEFs before 
and after MycER transduction and β-actin loading control. Both proteins were detected with an anti-Myc 
antibody. (B) Baseline ATP levels in WT and KO cells. The results represent the data obtained in Fig. 15D 
plotted as absolute rather than relative ATP levels. Several repeat experiments showed ATP levels in KO cells 
to be reproducibly lower than WT cells by 30-40%. 
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Figure 25: Seahorse Flux Analysis of Extracellular Acidification Rate (ECAR) and Oxygen 
Consumption Rate (OCR). Cells were plated and analyzed as described in Materials and Methods. (A) ECAR 
normalized to cell number at conclusion of the experiment, which includes the addition of 1 µM oligomycin 
(oligo, an inhibitor of Complex V [ATP synthase]), 0.3 µM carbonyl cyanide-p-
trifluoromethoxyphenylhydrazone (FCCP, an uncoupling agent), 100 mM 2-Deoxy-D-glucose (2-DG, an 
inhibitor of glycolysis), and 1 µM rotenone (rot, a complex I inhibitor). Note that the addition of oligomycin is 
associated with a continued higher level of ECAR by both WT+Myc and KO+Myc cells, which is consistent 
with their overall rates of glycolysis being enhanced following MycER activation (B) Representation of basal 
respiration, glycolytic capacity, non-glycolytic acidification, and glycolytic reserve (differences in respiration 
after addition of oligomycin). (C) OCR normalized to cellular number at the conclusion of the experiment, 
including the same set of injections described in (A). (D) Representation of OCR basal respiration, ATP-
dependent respiration, maximum respiration, non-mitochondrial respiration, and the spare respiratory 
capacity. 
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Figure 26: Quantification of the results shown in Fig. 9. In situ assays for each complex were 
performed on triplicate samples. Results are expressed as the mean ± 1 SEM after normalizing each sample’s 
activity to the amount of protein present in the respective complex. This value in WT cells was arbitrarily set 
to 1 in all cases to allow for relative comparisons. Complex II could not be reliably assayed in situ and was 
therefore assayed in separate reactions and adjusted to total input mitochondrial protein content (see Fig. 
9C). Significance was determined using the Students’ t-test and all values are compared to WT cells. 
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Figure 27: Quantification of real time qRT-PCR data depicted in Fig. 10A. The values presented 
were compared to average gene expression and normalized to β2 microglobulin gene expression. **** P < 
0.0001, *** P < 0.001, ** P < 0.01, * P < 0.05. 
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Figure 28: Quantification of real time qRT-PCR data depicted in Fig. 10D. The values presented 
were compared to average gene expression and normalized to β2 microglobulin gene expression. **** P < 
0.0001, *** P < 0.001, ** P < 0.01, * P < 0.05. 
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Figure 29: Isotope distribution. High-resolution dMS chromatogram (top) and mass spectrum 
(bottom) showing the isotope distribution for the tryptic peptide ATEMVEVGPEDDEVGAERGEATDLLR 
derived from Polymerase I and transcript release factor (Ptrf) with monoisotopic m/z = 930.103 Da and 
retention time 43.5 minutes. Colored lines show the average signal for 4 WT (blue), 4 KO (red), 4 WT+Myc 
(green), 4 KO+Myc (pink), and 6 pooled control (tan) samples. 
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Figure 30: Immuno-blotting for selected pyruvate metabolizing enzymes. Pyruvate dehydrogenase 
(PHDE) and Ser293 (activated) phosphorylated PDHE. Pyruvate dehydrogenase kinase (PDK1), Pyruvate 
dehydrogenase phosphatase (PDP2), Pyruvate kinase M1 and M2 (PKM1/2), and β-actin loading control. 
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Figure 31: Deletion of myc coding exons 2 and 3 from KO hepatocytes. (A) The myc locus in 
“unfloxed” WT (mycwt/wt) animals.  Red arrows indicate the same set of primers as black arrows in B but 
with a smaller product. (B) The myc locus in WT (mycfl/fl) animals. LoxP sites are indicated by red triangles. 
PCR primers used to amplify the WT allele are indicated with black arrows with the size of the expected PCR 
product (in bps) indicated. (C) The myc locus following Cre-recombinase-mediated recombination. PCR 
primers used to amplify KO (myc-/-) alleles are indicated by blue arrows with the size of the PCR product 
indicated. (D) Myc alleles were amplified from WT and KO hepatocyte DNAs of 3 month old mice and 
resolved by agarose gel electrophoresis. Typical genotyping results are shown for two representative animals 
of each group. (E) DNA sequence of the relevant region of the KO PCR product, confirming the deletion and 
showing that the LoxP region (boxed in red) is flanked by intron 1 and intron 3 sequences. Note that the PCR 
primers depicted in A can also be used to distinguish this allele from a normal myc allele without LoxP sites. 
(F) KO hepatocytes show greatly reduced expression of myc coding exons 2 and 3. RNAseq reads across each 
of the 3 myc exons were compiled for both WT and KO hepatocytes. Each set of reads represents the sum of 
sequences generated from hepatocyte RNAs of four animals from each group. 
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Figure 32: Characterization of WT and KO livers and hepatocytes. (A) Liver:body mass ratios. 
Weights were determined on groups of young and old mice (<1 month and >3 months old, respectively). (B) 
Typical histologic appearance of H&E-stained sections of WT and KO livers from young mice. No obvious 
differences were noted in examination of >10 livers from each group. (C) Hepatocyte sizing from ~2 month 
old WT and KO mice. At least 1500 hepatocytes from individual WT and KO mice were examined. Similar 
results were obtained from two additional sets of animals (not shown). (D-F) ATP content, PDH activity and 
acetyl CoA levels, respectively, were quantified on liver lysates. (G) AMPK Immunoblotting. Total liver 
lysates from individual WT or KO mice were immuno-blotted for total AMPK, pAMPK(Thr172) and β-actin 
as a loading control. (H) 3H-palmitate β-oxidation. Liver slices were incubated with 3H-palmitate and the 
amount of tritium incorporated into water-soluble products was quantified. (I) Caspase 3 immunblots. Total 
liver lysates from WT and KO mice were blotted against full length and cleaved Caspase 3 with GAPDH as a 
loading control. 
 144 
 
 145 
 
Figure 33: Comparison of ETCs in WT and KO livers. (A) Representative BNGE of duplicate 
mitochondrial samples, each prepared independently from 5 WT and 5 KO mouse livers. Mitochondria were 
purified as previously described [3, 4]. Arrows indicate each of the complexes as well as higher order 
supercomplexes (SCs) comprised primarily of different stoichiometries of complexes I, III and V [5-8]. (B) 
Examples of typical in situ enzymatic assays for each of the indicated SCs. Relevant regions of gels such as 
those shown in A were excised and assayed in situ. Complex II could not be measured in situ and was instead 
measured separately on isolated mitochondrial lysates as described previously [11, 12]. In situ enzyme 
activities for each of the indicated complexes are depicted here graphically after adjusting for differences in 
the protein content of each complex based on densitometric scanning of BNGE profiles [4]. (C) Complex I 
activity. (D) Complex I activity in SCs. (E) Complex II activity. (F) Complex III activity. (G) Complex IV 
activity. (H) Complex Vm activity. (I) Complex Vd activity. Each bar depicts the results of triplicate assays 
performed on mitochondria isolated from independent liver samples of the same animal. Standard errors and 
p-values were calculated based on the mean of all results. 
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Figure 34: Lack of differential expression of most transcripts encoding Myc homologs, negative 
regulators of Myc function and proteins that can restore some or all Myc phenotypes in myc-/- fibroblasts. 
(A) The results shown here were extracted from RNAseq data discussed in Fig. 17. Note the modest but 
significant down-regulation of Mlxip1/MondoB/ChREBP expression in KO livers. (B) Immuno-blots for N-
Myc, L-Myc, and ChREBP proteins with GAPDH as a loading control. 
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Figure 35: Triglyceride, sterol and bile acid levels in WT and KO livers. (A) Representative ORO-
stained liver sections after fasting or fasting + re-feeding. (B) Quantification of total liver triglycerides in at 
least 6 representative animals from each of the indicated groups. (C) Quantification of total cholesterol levels 
in at least 6 animals from each of the indicated groups. (D) Minimal biosynthetic pathway from squalene to 
cholesterol showing a select sub-set of relevant sterol intermediates and enzymes (red, p-values indicated in 
parenthesis) whose transcripts were up-regulated in KO hepatocytes as indicated by RNAseq. (E) Liver sterol 
levels adjusted to protein content [9, 10]. (F) The data from (E) expressed as a fraction of total sterol content. 
(G) Total bile acids measured in livers of starved mice. 
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Figure 36: Lipid droplets in KO hepatocytes are more numerous and larger. (A) Shown are 
representative images similar to those depicted in Suppl. Fig. 35A on which analyses were performed. (B) 
Lipid droplet number, size and total average percent area occupied within hepatocytes was determined using 
ImageJ software (Analyze Particles function). Analyses were performed on a total of 5 mice from each group 
with a total of 5 independent images being taken from each histologic section. HPF=high power field. 
RU=relative units. (C) Representative images of lipid droplets in hepatocytes of recipient livers following 
transplantation with WT or KO hepatocytes. (D) Quantification was performed as described in (B). 
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Figure 37: Post-transplant immunohistochemical staining of recipient livers for CD45 and 4-
hydroxynonenal (4-HNE). Each image is typical of the remaining section and is taken from individual mice.  
Arrows indicate representative areas of positivity. 
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APPENDIX B 
SUPPLEMENTAL TABLES 
 
Table 8: Transcripts identified by Ingenuity Pathway Analysis from the top 10 deregulated pathways 
in transplanted livers 
Gene 
Symbol 
Fold 
Diff in 
KO 
cells 
Log2 
Diff 
p-value 
Adjusted   
p-value   
(for FDR) 
WT KO 
1 2 1 2 3 4 
EIF4EBP3 0.15 -2.70 0.0001 0.0011         
LEPR 0.19 -2.42 0.0001 0.0011         
DDIT4 0.40 -1.31 0.0001 0.0011         
EGFR 0.41 -1.30 0.0001 0.0011         
RPS27A 0.52 -0.94 0.0001 0.0011         
C5 0.53 -0.93 0.0004 0.0051         
RPS12 0.53 -0.92 0.0001 0.0011         
RPS21 0.53 -0.91 0.0001 0.0011         
SERPINE1 0.55 -0.87 0.0042 0.0340         
IL1R1 0.56 -0.84 0.0001 0.0019         
SDC4 0.57 -0.81 0.0004 0.0051         
RPS24 0.58 -0.80 0.0003 0.0046         
FAU 0.58 -0.78 0.0002 0.0034         
FGFR1 0.59 -0.77 0.0023 0.0216         
RPSA 0.59 -0.77 0.0004 0.0057         
RPS18 0.59 -0.75 0.0004 0.0051         
RPS9 0.60 -0.74 0.0005 0.0062         
RPS14 0.60 -0.73 0.0002 0.0034         
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RPS5 0.62 -0.69 0.0004 0.0051         
ATP5L 0.62 -0.69 0.0002 0.0034         
RPS19 0.62 -0.68 0.0006 0.0073         
RHOD 0.63 -0.67 0.0004 0.0051         
RPS8 0.63 -0.67 0.0007 0.0082         
RPS10 0.64 -0.64 0.0005 0.0062         
RPS13 0.64 -0.64 0.0005 0.0062         
Cxcl9 0.65 -0.63 0.0042 0.0337         
RPS6 0.65 -0.62 0.0023 0.0216         
NDUFA2 0.66 -0.61 0.0004 0.0057         
RPS15A 0.66 -0.61 0.0005 0.0062         
RPS20 0.66 -0.60 0.0008 0.0097         
RPS28 0.66 -0.60 0.0006 0.0078         
RPS16 0.68 -0.56 0.0009 0.0102         
COX4I1 0.68 -0.56 0.0045 0.0353         
Atp5e 0.68 -0.56 0.0014 0.0143         
RPS7 0.68 -0.55 0.0019 0.0183         
UQCR10 0.68 -0.55 0.0011 0.0123         
RPS23 0.69 -0.54 0.0033 0.0283         
GPLD1 0.70 -0.51 0.0054 0.0403         
Ccl9 0.70 -0.51 0.0022 0.0205         
UQCRQ 0.70 -0.51 0.0026 0.0234         
RPS25 0.71 -0.50 0.0033 0.0283         
NDUFA1 0.71 -0.50 0.0017 0.0172         
ATP5G2 0.71 -0.50 0.0029 0.0256         
AGO4 0.71 -0.50 0.0355 0.1513         
SDHD 0.71 -0.49 0.0052 0.0393         
NDUFA4 0.71 -0.49 0.0073 0.0500         
NDUFA11 0.72 -0.48 0.0028 0.0249         
Cox6c 0.72 -0.47 0.0061 0.0441         
NDUFB7 0.72 -0.47 0.0029 0.0256         
CCL27 0.73 -0.46 0.0403 0.1640         
COX5A 0.73 -0.45 0.0066 0.0465         
LBP 0.73 -0.44 0.0080 0.0529         
RPS17 0.74 -0.44 0.0076 0.0512         
UQCR11 0.74 -0.44 0.0051 0.0390         
RPS3 0.74 -0.43 0.0103 0.0635         
NDUFA3 0.76 -0.40 0.0056 0.0415         
NDUFA5 0.76 -0.40 0.0075 0.0507         
NDUFS6 0.76 -0.40 0.0056 0.0415         
RPS26 0.76 -0.40 0.0074 0.0503         
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RPS2 0.76 -0.39 0.0274 0.1274         
RPS4Y1 0.77 -0.38 0.0205 0.1043         
RPS27L 0.77 -0.37 0.0107 0.0653         
IL1RAP 0.78 -0.36 0.0147 0.0816         
ATP5G3 0.78 -0.36 0.0276 0.1279         
COX17 0.78 -0.36 0.0146 0.0814         
NDUFS4 0.78 -0.35 0.0112 0.0672         
NDUFB5 0.78 -0.35 0.0141 0.0794         
RPS29 0.78 -0.35 0.0166 0.0894         
NDUFS2 0.79 -0.34 0.0220 0.1098         
NDUFB3 0.80 -0.33 0.0141 0.0795         
ATP5H 0.80 -0.33 0.0223 0.1108         
COX7A2 0.80 -0.32 0.0159 0.0867         
EIF3I 0.80 -0.32 0.0170 0.0912         
EIF3K 0.80 -0.32 0.0193 0.0998         
NDUFB10 0.80 -0.32 0.0184 0.0966         
COX10 0.80 -0.31 0.0432 0.1719         
COX7A2L 0.80 -0.31 0.0207 0.1051         
F11R 0.81 -0.30 0.0224 0.1109         
RPS11 0.82 -0.29 0.0265 0.1247         
COL5A3 0.82 -0.29 0.0438 0.1734         
RICTOR 0.82 -0.29 0.0496 0.1888         
NDUFB6 0.82 -0.28 0.0216 0.1083         
EIF3F 0.82 -0.28 0.0264 0.1245         
NDUFB8 0.83 -0.27 0.0330 0.1441         
TEC 0.83 -0.27 0.0453 0.1775         
NDUFB4 0.83 -0.26 0.0296 0.1340         
NDUFA7 0.83 -0.26 0.0322 0.1417         
NDUFA12 0.84 -0.26 0.0347 0.1488         
SOS1 0.84 -0.26 0.0366 0.1542         
ATP5J2 0.84 -0.25 0.0448 0.1761         
EIF4EBP1 0.84 -0.25 0.0416 0.1674         
EIF4EBP1 0.84 -0.25 0.0416 0.1674         
NDUFA6 0.84 -0.25 0.0373 0.1560         
HRAS 0.84 -0.24 0.0474 0.1829         
NDUFA8 0.85 -0.24 0.0387 0.1600         
CTNND1 1.63 0.70 0.0436 0.1729         
EIF4EBP2 1.64 0.72 0.0395 0.1620         
STAT1 1.65 0.72 0.0423 0.1694         
TGFBR2 1.66 0.73 0.0494 0.1884         
BCAR1 1.66 0.73 0.0481 0.1850         
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DLC1 1.70 0.76 0.0264 0.1245         
PLD3 1.71 0.78 0.0299 0.1349         
PIK3R1 1.76 0.82 0.0185 0.0970         
VASP 1.85 0.88 0.0156 0.0856         
IFNGR1 1.86 0.90 0.0124 0.0727         
MYH9 1.89 0.92 0.0045 0.0355         
FNBP1 1.92 0.94 0.0462 0.1799         
IGF2 1.99 0.99 0.0352 0.1505         
ACTN1 2.04 1.03 0.0040 0.0325         
ARHGAP5 2.05 1.04 0.0006 0.0078         
RPS6KA2 2.08 1.06 0.0438 0.1734         
GNAI2 2.13 1.09 0.0004 0.0057         
GNAI2 2.13 1.09 0.0004 0.0057         
RPS6KA3 2.16 1.11 0.0483 0.1855         
ARHGAP4 2.19 1.13 0.0305 0.1368         
COL15A1 2.26 1.18 0.0474 0.1830         
MRAS 2.26 1.18 0.0281 0.1296         
ITGA1 2.27 1.18 0.0159 0.0865         
ITGA1 2.27 1.18 0.0159 0.0865         
GLG1 2.45 1.29 0.0007 0.0082         
AGO2 2.45 1.30 0.0025 0.0227         
COL27A1 2.62 1.39 0.0079 0.0527         
CCL19 2.79 1.48 0.0316 0.1401         
COL4A5 2.93 1.55 0.0044 0.0348         
ITGA6 2.94 1.56 0.0003 0.0040         
ITGA6 2.94 1.56 0.0003 0.0040         
CLDN4 3.00 1.59 0.0133 0.0766         
CCL5 3.37 1.75 0.0089 0.0570         
PDGFC 3.38 1.76 0.0002 0.0027         
CXCL2 3.43 1.78 0.1634 0.4068   ##     
GNAI1 3.62 1.85 0.0006 0.0073         
GNAI1 3.62 1.85 0.0006 0.0073         
IL33 3.62 1.86 0.0013 0.0135         
Ccl2 3.67 1.88 0.0195 0.1004         
ITGB3 3.67 1.88 0.0001 0.0019         
ITGB3 3.67 1.88 0.0001 0.0019         
RHOF 3.69 1.89 0.0089 0.0572         
CX3CL1 3.72 1.90 0.0330 0.1441         
COL6A2 3.89 1.96 0.0025 0.0227         
CTGF 3.97 1.99 0.0001 0.0011         
CSF3R 4.20 2.07 0.0024 0.0224         
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SIPA1 4.21 2.07 0.0001 0.0019         
EZR 4.26 2.09 0.0001 0.0019         
EZR 4.26 2.09 0.0001 0.0019         
MMP7 4.42 2.14 0.0037 0.0306         
MMP7 4.42 2.14 0.0037 0.0306         
VAV3 5.24 2.39 0.0075 0.0509         
PDGFB 5.60 2.49 0.0064 0.0457         
CXCL14 5.64 2.50 0.0017 0.0168         
THY1 5.67 2.50 0.0348 0.1491         
CSF1 5.78 2.53 0.0001 0.0011         
NCF4 5.84 2.55 0.0014 0.0143         
COL6A1 6.13 2.62 0.0002 0.0027         
PIK3R5 6.13 2.62 0.0046 0.0359         
RHOJ 6.17 2.63 0.0003 0.0040         
HMOX1 6.43 2.68 0.0001 0.0011         
MAPK12 6.45 2.69 0.0002 0.0034         
MAPK12 6.45 2.69 0.0002 0.0034         
CLDN5 7.00 2.81 0.0001 0.0011         
CXCL16 7.04 2.82 0.0001 0.0011         
CCL22 7.04 2.82 0.0191 0.0990         
PIK3R6 7.10 2.83 0.0095 0.0596         
PRR5L 7.29 2.87 0.0001 0.0019         
ARHGAP9 7.31 2.87 0.0014 0.0143         
PIK3CD 7.60 2.93 0.0001 0.0011         
SELPLG 7.67 2.94 0.0003 0.0040         
CXCL13 7.84 2.97 0.0001 0.0011         
WIPF1 7.84 2.97 0.0001 0.0011         
PLD4 7.85 2.97 0.0001 0.0011         
RAPGEF3 7.97 2.99 0.0001 0.0011         
RAC2 8.13 3.02 0.0001 0.0011         
IL1B 8.20 3.04 0.0003 0.0046         
NCF2 8.22 3.04 0.0001 0.0011         
TNF 8.24 3.04 0.0061 0.0443         
BTK 8.28 3.05 0.0023 0.0212         
C5AR1 8.34 3.06 0.0011 0.0118         
MAPK11 8.39 3.07 0.0021 0.0197         
MAPK11 8.39 3.07 0.0021 0.0197         
PRKCQ 8.40 3.07 0.0017 0.0172         
PLCG2 8.43 3.07 0.0010 0.0115         
CCL4 8.57 3.10 0.0127 0.0739         
CLDN7 8.75 3.13 0.0074 0.0503         
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LHX2 8.77 3.13 0.0003 0.0046         
PRKCH 8.93 3.16 0.0001 0.0011         
FPR2 8.93 3.16 0.0019 0.0183         
IL10RA 8.98 3.17 0.0001 0.0019         
MSN 9.11 3.19 0.0001 0.0011         
MSN 9.11 3.19 0.0001 0.0011         
AKT3 9.19 3.20 0.0001 0.0011         
PDGFRA 9.26 3.21 0.0001 0.0011         
Ccl6 9.35 3.22 0.0001 0.0011         
PRKCB 9.99 3.32 0.0003 0.0040         
NCF1 10.25 3.36 0.0003 0.0040         
CD40 10.47 3.39 0.0026 0.0234         
IGFBP3 10.63 3.41 0.0001 0.0011         
TIMP3 10.65 3.41 0.0001 0.0011         
COL4A1 10.71 3.42 0.0001 0.0011         
CYBA 10.94 3.45 0.0001 0.0011         
VAV1 10.96 3.45 0.0001 0.0019         
Ccl7 11.09 3.47 0.0390 0.1608   ##     
ITGB2 11.49 3.52 0.0001 0.0011         
ITGB2 11.49 3.52 0.0001 0.0011         
ITGAL 11.50 3.52 0.0001 0.0011         
ITGAL 11.50 3.52 0.0001 0.0011         
IL1A 11.68 3.55 0.0001 0.0011         
COL1A2 11.91 3.57 0.0001 0.0011         
JAM2 12.22 3.61 0.0001 0.0011         
ICAM2 12.22 3.61 0.0006 0.0073         
TGFB1 12.32 3.62 0.0001 0.0011         
CCR7 12.55 3.65 0.0101 0.0625         
MMP2 13.19 3.72 0.0111 0.0669         
MMP2 13.19 3.72 0.0111 0.0669         
CD44 13.20 3.72 0.0001 0.0011         
FLT4 13.64 3.77 0.0001 0.0011         
WAS 13.66 3.77 0.0088 0.0565         
CYBB 13.92 3.80 0.0001 0.0011         
PECAM1 14.01 3.81 0.0001 0.0011         
TNFRSF11B 14.61 3.87 0.0002 0.0034         
CCL3L3 14.66 3.87 0.0116 0.0693         
COL4A2 15.09 3.92 0.0001 0.0011         
COL5A1 15.40 3.94 0.0001 0.0019         
NGFR 15.54 3.96 0.0272 0.1270         
PDGFRB 15.97 4.00 0.0001 0.0011         
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TLR4 16.61 4.05 0.0035 0.0296         
CCL24 16.74 4.06 0.0004 0.0051         
EDNRB 17.02 4.09 0.0001 0.0011         
COL3A1 17.10 4.10 0.0001 0.0011         
EDNRA 17.11 4.10 0.0003 0.0046         
JAM3 17.93 4.16 0.0143 0.0802         
VCAM1 18.02 4.17 0.0001 0.0011         
TIMP2 18.70 4.22 0.0001 0.0011         
TIMP2 18.70 4.22 0.0001 0.0011         
COL16A1 19.50 4.29 0.0047 0.0365         
COL13A1 19.81 4.31 0.0001 0.0011         
CDH5 22.66 4.50 0.0001 0.0011         
FLT1 23.71 4.57 0.0002 0.0027         
KDR 24.70 4.63 0.0001 0.0011         
LAMA1 25.22 4.66 0.0024 0.0220         
HGF 26.04 4.70 0.0014 0.0143         
MMP12 26.82 4.75 0.0001 0.0011         
MMP12 26.82 4.75 0.0001 0.0011         
SDC3 27.60 4.79 0.0001 0.0011         
CCR5 27.76 4.80 0.0004 0.0051         
FPR1 29.41 4.88 0.0031 0.0270         
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